metformin has been researched along with Weight Gain in 256 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The rationale for adding metformin in these cases is that it can reduce insulin resistance." | 10.19 | [Combination treatment with insulin and metformin in type 2 diabetes. Improves glycemic control and prevents weight gain]. ( Hermann, LS; Melander, A, 1999) |
| "Our study assesses perinatal outcomes among women with type 2 diabetes, with gestational weight gain (GWG) within and outside of US Institute of Medicine (IOM) guidelines, by conducting a secondary analysis of the Metformin in Type 2 Diabetes in Pregnancy (MiTy) trial." | 9.51 | Gestational weight gain in women with type 2 diabetes and perinatal outcomes: A secondary analysis of the metformin in women with type 2 diabetes in pregnancy (MiTy) trial. ( Feig, DS; Fu, J; Tomlinson, G, 2022) |
| " The TSH level was not affected by metformin, whereas fT4 was significantly higher in the metformin group with less decrease throughout pregnancy compared to placebo, p<0." | 9.51 | Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin. ( Alvarsson, M; Åsvold, BO; Calissendorff, J; Hirschberg, AL; Trouva, A; Vanky, E, 2022) |
| "This study provides evidence that, compared to glimepiride, saxagliptin more effectively achieves a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in T2D patients who are inadequately controlled with metformin monotherapy, especially in overweight patients with moderate hyperglycaemia and a relatively short duration of diabetes." | 9.30 | Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr ( Bi, Y; Cheng, J; Gu, T; Li, D; Ma, J; Shao, J; Shi, B; Sun, Z; Xu, L; Zhang, H; Zhang, Q; Zhong, S; Zhu, D; Zhu, L, 2019) |
| "Metformin prevents weight gain in patients with type 2 diabetes (T2D)." | 9.27 | Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A post hoc analysis of a randomized placebo-controlled 4.3-year trial. ( Jager-Wittenaar, H; Kooy, A; Krijnen, W; Lehert, P; Miedema, I; Out, M; Stehouwer, C; van der Schans, C, 2018) |
| " Although there is evidence for weight loss with metformin for people with obesity who are already taking clozapine, there have been no published trials that have investigated the effect of metformin in attenuating weight gain at the time of clozapine initiation." | 9.27 | CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine. ( Baker, A; Flaws, D; Friend, N; Kisely, S; Lim, C; McGrath, JJ; Moudgil, V; Patterson, S; Russell, A; Sardinha, S; Siskind, D; Stedman, T; Suetani, S; Winckel, K, 2018) |
| "Adjunctive metformin is the most well-studied intervention in the pharmacological management of antipsychotic-induced weight gain (AIWG)." | 9.22 | Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology. ( Crowley, EK; Fitzgerald, I; Hynes, C; Keating, D; McWilliams, S; O'Connell, J, 2022) |
| "In combination with a novel carbohydrate modified diet, metformin enhanced 12-month weight loss and improved body composition in ethnically diverse normoglycemic, hyperinsulinemic women with midlife weight gain." | 9.22 | METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN. ( Freeman, R; Mogul, H; Nguyen, K, 2016) |
| " In this study, data were pooled from two randomized, placebo-controlled trials, which were originally designed to examine the efficacy of metformin in treating antipsychotic-induced weight gain and other metabolic abnormalities." | 9.22 | Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials. ( Chan, PK; Gao, KM; Guo, WB; Jin, H; Ou, JJ; Shao, P; Wu, RR; Zhang, FY; Zhao, JP, 2016) |
| "5% decrease from baseline) with no weight gain and no hypoglycaemic events with alogliptin 12." | 9.22 | Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. ( Chaudhari, P; Del Prato, S; Fleck, P; Wilson, C, 2016) |
| "This 24-week pilot study assessed the efficacy, tolerability, and safety of adjunctive metformin versus placebo for the prevention of olanzapine-associated weight gain in community-dwelling adult patients with schizophrenia, schizoaffective disorder, bipolar disorder, or major depression with psychotic features." | 9.22 | A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population. ( Rado, J; von Ammon Cavanaugh, S, 2016) |
| "To evaluate the efficacy of metformin for weight gain associated with atypical antipsychotic medications in children and adolescents with ASD (defined in the protocol as DSM-IV diagnosis of autistic disorder, Asperger disorder, or pervasive developmental disorder not otherwise specified), aged 6 to 17 years." | 9.22 | Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial. ( Aman, MG; Anagnostou, E; Arnold, LE; Brian, J; Butter, E; Capano, L; Hadjiyannakis, S; Handen, BL; Hellings, JA; Hollway, JA; Kettel, J; Macklin, EA; Mankad, D; Marler, S; McAuliffe-Bellin, S; Newsom, CR; Odrobina, D; Peleg, N; Sanders, KB; Shui, A; Tumuluru, R; Veenstra-VanderWeele, J; Wagner, A; Wong, T; Zakroysky, P, 2016) |
| "Less maternal weight gain was found in the metformin treated groups (9." | 9.20 | Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country: a randomized control trial. ( Ainuddin, J; Hasan, AA; Karim, N; Naqvi, SA, 2015) |
| " This study examined the efficacy and safety of liraglutide monotherapy compared with metformin monotherapy in overweight/obese Japanese patients with type 2 diabetes (T2DM)." | 9.20 | Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes. ( Atsumi, Y; Imai, T; Irie, J; Itoh, H; Kawai, T; Meguro, S; Morimoto, J; Saisho, Y; Shigihara, T; Takei, I; Tanaka, K; Tanaka, M; Yajima, K, 2015) |
| "To assess the effect of metformin and to compare it with insulin treatment in patients with type 2 diabetes in pregnancy in terms of perinatal outcome, maternal complications, additional insulin requirement, and treatment acceptability." | 9.20 | Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy. ( Ainuddin, JA; Ali, SS; Hasan, AA; Karim, N; Zaheer, S, 2015) |
| "Linagliptin as add-on therapy to metformin and pioglitazone produced significant and clinically meaningful improvements in glycaemic control, without an additional risk of hypoglycaemia or weight gain (Clinical Trials Registry No: NCT 00996658)." | 9.19 | Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study. ( Bajaj, M; Gilman, R; Kempthorne-Rawson, J; Lewis-D'Agostino, D; Patel, S; Woerle, HJ, 2014) |
| "To evaluate the effects of vildagliptin compared to glimepiride on glycemic control, insulin resistance and post-prandial lipemia." | 9.19 | Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D, 2014) |
| "0 mmol/mol) without hypoglycaemia and weight gain was higher with vildagliptin than glimepiride after 2 years in type 2 diabetes patients inadequately controlled on metformin monotherapy, regardless of age and duration of diabetes." | 9.17 | Vildagliptin more effectively achieves a composite endpoint of HbA₁c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. ( Bader, G; Geransar, P; Schweizer, A, 2013) |
| "The purpose of this study was to determine whether metformin promotes weight loss in overweight outpatients with chronic schizophrenia or schizoaffective disorder." | 9.17 | Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. ( Catellier, DJ; Golden, LH; Hamer, RM; Jarskog, LF; Lavange, L; Lieberman, JA; Ray, N; Stewart, DD; Stroup, TS, 2013) |
| "Outpatients with schizophrenia or schizoaffective disorder (DSM-IV-TR criteria) were randomly assigned to olanzapine alone (n = 50), olanzapine plus algorithm A (olanzapine + A [amantadine 200 mg/d with possible switches to metformin 1,000-1,500 mg/d and then to zonisamide 100-400 mg/d; n = 76]), or olanzapine plus algorithm B (olanzapine + B [metformin 1,000-1,500 mg/d with possible switches to amantadine 200 mg/d and then to zonisamide 100-400 mg/d; n = 73])." | 9.16 | Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. ( Case, M; Hoffmann, VP; Jacobson, JG, 2012) |
| "We tested genetic associations with weight loss and weight regain in the Diabetes Prevention Program, a randomized controlled trial of weight loss-inducing interventions (lifestyle and metformin) versus placebo." | 9.16 | Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program. ( Delahanty, LM; Florez, JC; Franks, PW; Jablonski, KA; Kahn, SE; Knowler, WC; McCaffery, JM; Pan, Q; Shuldiner, A; Watson, KE, 2012) |
| " The body weight, body mass index, fasting insulin and insulin resistance index decreased significantly in the metformin group, but increased in the placebo group during the 12-week follow-up period." | 9.16 | Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. ( Liang, GM; Tong, JH; Wang, M; Wang, XZ; Yan, HF; Zhu, G, 2012) |
| "Eighty-four women (ages 18-40 years) with first-episode schizophrenia who suffered from amenorrhea during antipsychotic treatment were randomly assigned, in a double-blind study design, to receive 1000 mg/day of metformin or placebo in addition to their antipsychotic treatment for 6 months." | 9.16 | Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. ( Chan, PK; Davis, JM; Gao, K; Guo, XF; Jin, H; Ou, JJ; Shao, P; Twamley, EW; Wang, J; Wu, RR; Zhao, JP, 2012) |
| "The impact of metformin medication in pregnant women with polycystic ovary syndrome on weight gain during pregnancy and after delivery and the impact on growth of the offspring are essentially unexplored." | 9.16 | Metformin's effect on first-year weight gain: a follow-up study. ( Carlsen, SM; Martinussen, MP; Vanky, E, 2012) |
| "To test whether a portion control diet could prevent weight gain during treatment with pioglitazone in patients with type 2 diabetes mellitus (T2DM)." | 9.14 | Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. ( Bray, GA; Greenway, FL; Gupta, AK; Smith, SR, 2009) |
| "The aim of this randomized, placebo-controlled study was to explore the effect of metformin in children with a neurogenic or myogenic motor deficit, who are therefore prone to develop overweight, adiposity, and insulin resistance." | 9.14 | Metformin therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit. ( Casteels, K; Coudyzer, W; de Zegher, F; Fieuws, S; Goemans, N; Loeckx, D; van Helvoirt, M; Verpoorten, C, 2010) |
| "Combination therapy of nitrendipine and atenolol may significantly increase BW and fasting BG in overweight or obese patients with hypertension." | 9.14 | Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients. ( Qin, YW; Qiu, JL; Zhang, JL; Zhao, XX; Zheng, X; Zou, DJ, 2009) |
| "Rosiglitazone treatment was associated with durable reductions in CRP independent of changes in insulin sensitivity, A1C, and weight gain." | 9.14 | Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). ( Haffner, SM; Herman, WH; Holman, RR; Kahn, SE; Kravitz, BG; Lachin, JM; Paul, G; Viberti, G; Yu, D; Zinman, B, 2010) |
| "Study the effects of exenatide (EXE) plus rosiglitazone (ROSI) on beta-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type 2 diabetes on metformin." | 9.14 | Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. ( DeFronzo, RA; Glass, LC; Lewis, MS; Maggs, D; Qu, Y; Triplitt, C, 2010) |
| "Vildagliptin add-on has similar efficacy to glimepiride after 2 years' treatment, with markedly reduced hypoglycaemia risk and no weight gain." | 9.14 | Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. ( Ahren, B; Couturier, A; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, V; Matthews, DR; Zinman, B, 2010) |
| "We investigated whether or not "low dose" metformin could prevent weight gain induced by pioglitazone." | 9.13 | Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes. ( Atsumi, Y; Funae, O; Hirata, T; Itoh, H; Kawai, T; Shimada, A; Tabata, M, 2008) |
| "To evaluate the effect of metformin treatment on the risperidone-induced body weight gain in patients." | 9.13 | A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. ( Arman, S; Koleini, N; Nadi, M; Sadramely, MR, 2008) |
| "To test the efficacy of lifestyle intervention and metformin alone and in combination for antipsychotic-induced weight gain and abnormalities in insulin sensitivity." | 9.13 | Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. ( Chen, JD; Fang, MS; Guo, XF; He, YQ; Jin, H; Li, LH; Liu, YJ; Shao, P; Wu, RR; Zhao, JP, 2008) |
| "Forty patients with schizophrenia were randomly assigned to treatment for 12 weeks with olanzapine, 15 mg/day, plus metformin, 750 mg/day (N=20), or olanzapine, 15 mg/day, plus placebo (N=20)." | 9.13 | Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. ( Chen, JD; Fang, MS; Guo, WB; Guo, XF; He, YQ; Li, LH; Wu, RR; Zhao, JP, 2008) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 9.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "To assess whether metformin prevents body weight gain (BWG) and metabolic dysfunction in patients with schizophrenia who are treated with olanzapine." | 9.12 | Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. ( Arapé, Y; Baptista, T; Beaulieu, S; de Mendoza, S; Hernández, L; Lacruz, A; Martínez, J; Martinez, M; Rangel, N; Serrano, A; Teneud, L, 2006) |
| "Metformin therapy is safe and effective in abrogating weight gain, decreased insulin sensitivity, and abnormal glucose metabolism resulting from treatment of children and adolescents with atypicals." | 9.12 | A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. ( Barton, BA; Cottingham, EM; Klein, DJ; Morrison, JA; Sorter, M, 2006) |
| "To evaluate whether, in adolescents with type 1 diabetes, the addition of metformin to insulin and standard diabetes management results in 1) higher insulin sensitivity and 2) lower HbA1c, fasting glucose, insulin dosage (units per kilogram per day) and BMI." | 9.10 | Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. ( Cummings, E; Daneman, D; Finegood, D; Hamilton, J; Zdravkovic, V, 2003) |
| "To determine causes of weight gain during insulin therapy with and without metformin in Type II (non-insulin-dependent) diabetes mellitus." | 9.09 | Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. ( Mäkimattila, S; Nikkilä, K; Yki-Järvinen, H, 1999) |
| " This meta-analysis examined the efficacy and tolerability of combining metformin and lifestyle intervention for AP-related weight gain in schizophrenia." | 9.01 | Combination of Metformin and Lifestyle Intervention for Antipsychotic-Related Weight Gain: A Meta-Analysis of Randomized Controlled Trials. ( Cai, DB; Ng, CH; Ungvari, GS; Wu, RR; Xiang, YT; Yang, XH; Zhang, QE; Zheng, W, 2019) |
| "To perform meta-analyses of studies evaluating the risk of pre-eclampsia in high-risk insulin-resistant women taking metformin prior to, or during pregnancy." | 8.98 | Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis. ( Alqudah, A; Graham, U; Lyons, TJ; McClements, L; McKinley, MC; McNally, R; Watson, CJ, 2018) |
| "The objective of this study was to perform the first systematic review and meta-analysis of randomized controlled trials (RCTs) assessing the effects of metformin on weight gain in children and adolescents treated with SGAs." | 8.98 | Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis. ( Cortese, S; Delorme, R; Ellul, P, 2018) |
| "We conducted a systematic-review and meta-analysis of metformin versus placebo for change in weight and metabolic syndrome for people on clozapine without diabetes mellitus." | 8.93 | Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis. ( Kisely, S; Leung, J; Russell, AW; Siskind, DJ; Wysoczanski, D, 2016) |
| "This meta-analysis confirms that metformin is effective in treating antipsychotic induced weight gain in patients with schizophrenia or schizoaffective disorder." | 8.93 | Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. ( Dayabandara, M; de Silva, VA; Hanwella, R; Ratnatunga, SS; Suraweera, C; Wanniarachchi, N, 2016) |
| "This meta-analysis examined the effectiveness and safety of metformin to prevent or treat weight gain and metabolic abnormalities associated with antipsychotic drugs." | 8.91 | Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials. ( de Leon, J; Li, XB; Tang, YL; Wang, CY; Xiang, YQ; Zheng, W, 2015) |
| "Metformin have been reported to counteract effectively antipsychotic-induced body weight gain and has been demonstrated to improve glycaemic control and promote a moderate weight loss in both diabetic and non-diabetic subjects." | 8.91 | A review of the evidence for the use of metformin in the treatment of metabolic syndrome caused by antipsychotics. ( Agius, M; Jesus, C; Jesus, I, 2015) |
| "There is uncertainty with regard to the appropriate use of metformin for the prevention and management of second-generation antipsychotic-induced weight gain and metabolic abnormalities." | 8.88 | Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. ( Curtis, J; Myles, N; Newall, H; Samaras, K; Shiers, D; Ward, PB, 2012) |
| "Olanzapine is an atypical antipsychotic that is useful in schizophrenia and bipolar affective disorder, but its use is associated with troublesome weight gain and metabolic syndrome." | 8.87 | Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. ( Goyal, N; Jana, AK; Praharaj, SK; Sinha, VK, 2011) |
| " However, the antihyperglycaemic agent metformin appears promising in some recent studies and we review the literature that evaluates metformin for limiting or reversing atypical antipsychotic drug-induced weight gain and glucose metabolism dysregulation." | 8.86 | Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions. ( Fredrickson, SK; Hasnain, M; Vieweg, WV, 2010) |
| "Articles were identified by searching the MEDLINE database (from 1949 through January 2010) using the key words metformin, topiramate, antipsychotic, weight, weight gain, and obesity." | 8.86 | Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain. ( Ellinger, LK; Ipema, HJ; Stachnik, JM, 2010) |
| "To determine the comparative efficacy, risk of weight gain, and hypoglycemia associated with noninsulin antidiabetic drugs in patients with type 2 DM not controlled by metformin alone." | 8.86 | Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. ( Coleman, CI; Phung, OJ; Scholle, JM; Talwar, M, 2010) |
| "Pioglitazone monotherapy and combinations were assessed in patients with type 2 diabetes and metabolic syndrome (Adult Treatment Panel III criteria) from four worldwide randomised, multicentre, double-blind studies." | 8.82 | Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome. ( Fernandes, AW; Lester, JW, 2005) |
| "Metformin has been associated with modest weight reduction in the non-pregnant population." | 8.12 | Weight gain in pregnancy: can metformin steady the scales? ( Adams, JH; Antony, KM; Eddy, A; Hoppe, KK; Iruretagoyena, JI; Poehlmann, J; Racine, JL; Rhoades, J; Stewart, K, 2022) |
| "In this large retrospective naturalistic cohort study, co-prescription of clozapine and metformin was associated with less weight gain and related metabolic dysfunction at 6 and 12 months after initiation versus clozapine alone." | 8.12 | Metformin for the prevention of clozapine-induced weight gain: A retrospective naturalistic cohort study. ( Agarwal, SM; Chintoh, AF; Foussias, G; Gerretsen, P; Graff-Guerrero, A; Hahn, MK; Maksyutynska, K; Navagnanavel, J; Powell, V; Remington, G; Sanches, M; Stogios, N, 2022) |
| "The present study aimed to investigate the possible effects of metformin on the olanzapine-induced insulin resistance in rats." | 8.02 | Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats. ( Guo, C; Li, H; Liu, J, 2021) |
| "There is considerable evidence that metformin reduces weight gain associated with antipsychotic medication." | 7.85 | Developing a metformin prescribing tool for use in adults with mental illness to reduce medication-related weight gain and cardiovascular risk. ( Galletly, C; Myles, H; Smith, C, 2017) |
| "Sixty six adult patients with schizophrenia or schizoaffective disorder treated, with atypical antipsychotics, and who had increased by more than 10% their pre treatment body weight, were randomly assigned to receive metformin or placebo in a double-blind study." | 7.81 | Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study. ( Dayabandara, M; de Silva, VA; Gunewardena, H; Hanwella, R; Henegama, T; Suraweera, C; Wijesundara, H, 2015) |
| "Olanzapine is a first line medication for the treatment of schizophrenia, but it is also one of the atypical antipsychotics carrying the highest risk of weight gain." | 7.80 | Metformin and berberine prevent olanzapine-induced weight gain in rats. ( Davies, GE; Davies, PS; Droke, EA; Ehli, EA; Hu, Y; Nowotny, D; Soundy, TJ; Young, AJ, 2014) |
| "(1) High-fat diet induces insulin resistance in SD rats; this was associated with an increase in visceral fat and a decrease in the level of adiponectin; (2) Metformin treatment improved insulin sensitivity accompanied by a decrease in body weight and TG level; (3) Rosiglitazone treatment ameliorates IR in a greater extent and is accompanied by a reduction of FFA, TG and an increase of adiponectin levels." | 7.72 | [Effects of rosiglitazone and metformin on insulin resistance in high-fat diet rats]. ( Bu, S; Chen, XP; Liu, XL; Wang, N; Xiao, JZ; Yang, WY; Zhao, WH, 2004) |
| "Metformin was generally well-tolerated." | 7.01 | Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled Trial of Metformin for Antipsychotic-Induced Weight Gain in Patients with First-Episode Psychosis: A Pilot Study. ( Abdin, E; Chua, YC; Subramaniam, M; Tang, C; Verma, S, 2021) |
| "Weight gain is a clinically important side effect of antipsychotic drug therapy." | 6.47 | Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. ( Asplund, AB; Björkhem-Bergman, L; Lindh, JD, 2011) |
| "Metformin is an antidiabetic drug that has been shown to cause weight loss in patients with diabetes mellitus, as well as in some individuals without diabetes." | 6.45 | Management of atypical antipsychotic drug-induced weight gain: focus on metformin. ( Miller, LJ, 2009) |
| " The rationale for adding metformin in these cases is that it can reduce insulin resistance." | 6.19 | [Combination treatment with insulin and metformin in type 2 diabetes. Improves glycemic control and prevents weight gain]. ( Hermann, LS; Melander, A, 1999) |
| "Our study assesses perinatal outcomes among women with type 2 diabetes, with gestational weight gain (GWG) within and outside of US Institute of Medicine (IOM) guidelines, by conducting a secondary analysis of the Metformin in Type 2 Diabetes in Pregnancy (MiTy) trial." | 5.51 | Gestational weight gain in women with type 2 diabetes and perinatal outcomes: A secondary analysis of the metformin in women with type 2 diabetes in pregnancy (MiTy) trial. ( Feig, DS; Fu, J; Tomlinson, G, 2022) |
| " The TSH level was not affected by metformin, whereas fT4 was significantly higher in the metformin group with less decrease throughout pregnancy compared to placebo, p<0." | 5.51 | Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin. ( Alvarsson, M; Åsvold, BO; Calissendorff, J; Hirschberg, AL; Trouva, A; Vanky, E, 2022) |
| "Unlike insulin, metformin lowered neonatal birth weights (mean difference - 122." | 5.41 | Short-term neonatal outcomes in women with gestational diabetes treated using metformin versus insulin: a systematic review and meta-analysis of randomized controlled trials. ( Jiang, G; Li, H; Lin, X; Lv, B; Ni, J; Sheng, B, 2023) |
| "Metformin is the most investigated pharmacological treatment of antipsychotics-induced weight gain (AIWG)." | 5.41 | [Prevention and treatment of antipsychotic induced weight gain]. ( Cohen, D; Veerman, SRT, 2023) |
| "sulphonylurea (SU) compounds." | 5.38 | Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea. ( Knop, FK; Lund, A, 2012) |
| "Metformin treatment also improved hyperleptinemia, whereas pioglitazone was ineffective." | 5.36 | Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice. ( Hirasawa, Y; Ito, M; Kyuki, K; Matsui, Y; Sugiura, T; Toyoshi, T, 2010) |
| "This study provides evidence that, compared to glimepiride, saxagliptin more effectively achieves a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in T2D patients who are inadequately controlled with metformin monotherapy, especially in overweight patients with moderate hyperglycaemia and a relatively short duration of diabetes." | 5.30 | Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr ( Bi, Y; Cheng, J; Gu, T; Li, D; Ma, J; Shao, J; Shi, B; Sun, Z; Xu, L; Zhang, H; Zhang, Q; Zhong, S; Zhu, D; Zhu, L, 2019) |
| "Metformin prevents weight gain in patients with type 2 diabetes (T2D)." | 5.27 | Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A post hoc analysis of a randomized placebo-controlled 4.3-year trial. ( Jager-Wittenaar, H; Kooy, A; Krijnen, W; Lehert, P; Miedema, I; Out, M; Stehouwer, C; van der Schans, C, 2018) |
| " Although there is evidence for weight loss with metformin for people with obesity who are already taking clozapine, there have been no published trials that have investigated the effect of metformin in attenuating weight gain at the time of clozapine initiation." | 5.27 | CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine. ( Baker, A; Flaws, D; Friend, N; Kisely, S; Lim, C; McGrath, JJ; Moudgil, V; Patterson, S; Russell, A; Sardinha, S; Siskind, D; Stedman, T; Suetani, S; Winckel, K, 2018) |
| "Adjunctive metformin is the most well-studied intervention in the pharmacological management of antipsychotic-induced weight gain (AIWG)." | 5.22 | Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology. ( Crowley, EK; Fitzgerald, I; Hynes, C; Keating, D; McWilliams, S; O'Connell, J, 2022) |
| "There is low-certainty evidence to suggest that metformin may be effective in preventing weight gain." | 5.22 | Pharmacological interventions for prevention of weight gain in people with schizophrenia. ( Agarwal, SM; Ahsan, ZA; Cohn, T; Duncan, MJ; Faulkner, GEJ; Hahn, M; Lockwood, JT; Remington, G; Stogios, N; Takeuchi, H; Taylor, VH, 2022) |
| "In combination with a novel carbohydrate modified diet, metformin enhanced 12-month weight loss and improved body composition in ethnically diverse normoglycemic, hyperinsulinemic women with midlife weight gain." | 5.22 | METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN. ( Freeman, R; Mogul, H; Nguyen, K, 2016) |
| " In this study, data were pooled from two randomized, placebo-controlled trials, which were originally designed to examine the efficacy of metformin in treating antipsychotic-induced weight gain and other metabolic abnormalities." | 5.22 | Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials. ( Chan, PK; Gao, KM; Guo, WB; Jin, H; Ou, JJ; Shao, P; Wu, RR; Zhang, FY; Zhao, JP, 2016) |
| "Among women without diabetes who had a BMI of more than 35, the antenatal administration of metformin reduced maternal weight gain but not neonatal birth weight." | 5.22 | Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. ( Akolekar, R; Balani, J; Hyer, S; Kotecha, R; Nicolaides, KH; Pastides, A; Shehata, H; Syngelaki, A, 2016) |
| "5% decrease from baseline) with no weight gain and no hypoglycaemic events with alogliptin 12." | 5.22 | Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. ( Chaudhari, P; Del Prato, S; Fleck, P; Wilson, C, 2016) |
| "This 24-week pilot study assessed the efficacy, tolerability, and safety of adjunctive metformin versus placebo for the prevention of olanzapine-associated weight gain in community-dwelling adult patients with schizophrenia, schizoaffective disorder, bipolar disorder, or major depression with psychotic features." | 5.22 | A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population. ( Rado, J; von Ammon Cavanaugh, S, 2016) |
| "To evaluate the efficacy of metformin for weight gain associated with atypical antipsychotic medications in children and adolescents with ASD (defined in the protocol as DSM-IV diagnosis of autistic disorder, Asperger disorder, or pervasive developmental disorder not otherwise specified), aged 6 to 17 years." | 5.22 | Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial. ( Aman, MG; Anagnostou, E; Arnold, LE; Brian, J; Butter, E; Capano, L; Hadjiyannakis, S; Handen, BL; Hellings, JA; Hollway, JA; Kettel, J; Macklin, EA; Mankad, D; Marler, S; McAuliffe-Bellin, S; Newsom, CR; Odrobina, D; Peleg, N; Sanders, KB; Shui, A; Tumuluru, R; Veenstra-VanderWeele, J; Wagner, A; Wong, T; Zakroysky, P, 2016) |
| "Less maternal weight gain was found in the metformin treated groups (9." | 5.20 | Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country: a randomized control trial. ( Ainuddin, J; Hasan, AA; Karim, N; Naqvi, SA, 2015) |
| " This study examined the efficacy and safety of liraglutide monotherapy compared with metformin monotherapy in overweight/obese Japanese patients with type 2 diabetes (T2DM)." | 5.20 | Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes. ( Atsumi, Y; Imai, T; Irie, J; Itoh, H; Kawai, T; Meguro, S; Morimoto, J; Saisho, Y; Shigihara, T; Takei, I; Tanaka, K; Tanaka, M; Yajima, K, 2015) |
| "To assess the effect of metformin and to compare it with insulin treatment in patients with type 2 diabetes in pregnancy in terms of perinatal outcome, maternal complications, additional insulin requirement, and treatment acceptability." | 5.20 | Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy. ( Ainuddin, JA; Ali, SS; Hasan, AA; Karim, N; Zaheer, S, 2015) |
| "INT131 demonstrated dose-dependent reductions in HbA1c, equivalent to 45 mg pioglitazone, but with less fluid accumulation and weight gain, consistent with its SPPARM design." | 5.19 | Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? ( DePaoli, AM; Dunn, FL; Henry, RR; Higgins, LS; Mantzoros, C, 2014) |
| "Linagliptin as add-on therapy to metformin and pioglitazone produced significant and clinically meaningful improvements in glycaemic control, without an additional risk of hypoglycaemia or weight gain (Clinical Trials Registry No: NCT 00996658)." | 5.19 | Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study. ( Bajaj, M; Gilman, R; Kempthorne-Rawson, J; Lewis-D'Agostino, D; Patel, S; Woerle, HJ, 2014) |
| "To evaluate the effects of vildagliptin compared to glimepiride on glycemic control, insulin resistance and post-prandial lipemia." | 5.19 | Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D, 2014) |
| "Metformin was found to provide adequate glycemic control with lower mean glucose levels throughout the day, less weight gain and a lower frequency of neonatal hypoglycemia." | 5.17 | Randomized trial of metformin vs insulin in the management of gestational diabetes. ( Bernardes, LS; Francisco, RP; Spaulonci, CP; Trindade, TC; Zugaib, M, 2013) |
| "Alogliptin monotherapy maintained glycaemic control comparable to that of glipizide in elderly patients with T2DM over 1 year of treatment, with substantially lower risk of hypoglycaemia and without weight gain." | 5.17 | Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. ( Fleck, P; Rosenstock, J; Wilson, C, 2013) |
| "0 mmol/mol) without hypoglycaemia and weight gain was higher with vildagliptin than glimepiride after 2 years in type 2 diabetes patients inadequately controlled on metformin monotherapy, regardless of age and duration of diabetes." | 5.17 | Vildagliptin more effectively achieves a composite endpoint of HbA₁c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. ( Bader, G; Geransar, P; Schweizer, A, 2013) |
| "The purpose of this study was to determine whether metformin promotes weight loss in overweight outpatients with chronic schizophrenia or schizoaffective disorder." | 5.17 | Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. ( Catellier, DJ; Golden, LH; Hamer, RM; Jarskog, LF; Lavange, L; Lieberman, JA; Ray, N; Stewart, DD; Stroup, TS, 2013) |
| "The aim of this study was to evaluate the effectiveness of sitagliptin, alone or in combination with metformin, in kidney transplant patients with newly diagnosed new-onset diabetes mellitus after transplant who had inadequate glycemic control, compared with a group of patients receiving insulin glargine with special emphasis on weight gain." | 5.17 | Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant. ( Fathy, A; Khashab, S; Shaheen, N; Soliman, AR; Soliman, MA, 2013) |
| "Outpatients with schizophrenia or schizoaffective disorder (DSM-IV-TR criteria) were randomly assigned to olanzapine alone (n = 50), olanzapine plus algorithm A (olanzapine + A [amantadine 200 mg/d with possible switches to metformin 1,000-1,500 mg/d and then to zonisamide 100-400 mg/d; n = 76]), or olanzapine plus algorithm B (olanzapine + B [metformin 1,000-1,500 mg/d with possible switches to amantadine 200 mg/d and then to zonisamide 100-400 mg/d; n = 73])." | 5.16 | Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. ( Case, M; Hoffmann, VP; Jacobson, JG, 2012) |
| "We tested genetic associations with weight loss and weight regain in the Diabetes Prevention Program, a randomized controlled trial of weight loss-inducing interventions (lifestyle and metformin) versus placebo." | 5.16 | Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program. ( Delahanty, LM; Florez, JC; Franks, PW; Jablonski, KA; Kahn, SE; Knowler, WC; McCaffery, JM; Pan, Q; Shuldiner, A; Watson, KE, 2012) |
| " The body weight, body mass index, fasting insulin and insulin resistance index decreased significantly in the metformin group, but increased in the placebo group during the 12-week follow-up period." | 5.16 | Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. ( Liang, GM; Tong, JH; Wang, M; Wang, XZ; Yan, HF; Zhu, G, 2012) |
| "Eighty-four women (ages 18-40 years) with first-episode schizophrenia who suffered from amenorrhea during antipsychotic treatment were randomly assigned, in a double-blind study design, to receive 1000 mg/day of metformin or placebo in addition to their antipsychotic treatment for 6 months." | 5.16 | Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. ( Chan, PK; Davis, JM; Gao, K; Guo, XF; Jin, H; Ou, JJ; Shao, P; Twamley, EW; Wang, J; Wu, RR; Zhao, JP, 2012) |
| " The neonates of metformin group had less rate of birth weight centile >90 than insulin group (RR: 0." | 5.16 | Metformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial. ( Akbari, S; Alavi, A; Amjadi, N; Moosavi, S; Niromanesh, S; Sharbaf, FR, 2012) |
| "The impact of metformin medication in pregnant women with polycystic ovary syndrome on weight gain during pregnancy and after delivery and the impact on growth of the offspring are essentially unexplored." | 5.16 | Metformin's effect on first-year weight gain: a follow-up study. ( Carlsen, SM; Martinussen, MP; Vanky, E, 2012) |
| "To test whether a portion control diet could prevent weight gain during treatment with pioglitazone in patients with type 2 diabetes mellitus (T2DM)." | 5.14 | Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. ( Bray, GA; Greenway, FL; Gupta, AK; Smith, SR, 2009) |
| "Metformin treatment prevented weight gain (mean weight gain, -3." | 5.14 | Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. ( Bets, D; de Jager, J; Donker, AJ; Kooy, A; Lehert, P; Stehouwer, CD; Wulffelé, MG, 2009) |
| "The aim of this randomized, placebo-controlled study was to explore the effect of metformin in children with a neurogenic or myogenic motor deficit, who are therefore prone to develop overweight, adiposity, and insulin resistance." | 5.14 | Metformin therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit. ( Casteels, K; Coudyzer, W; de Zegher, F; Fieuws, S; Goemans, N; Loeckx, D; van Helvoirt, M; Verpoorten, C, 2010) |
| " Vildagliptin provided additional HbA(1c) lowering to that achieved with metformin alone and comparable to that achieved with pioglitazone, with only pioglitazone causing weight gain." | 5.14 | Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. ( Bolli, G; Colin, L; Dotta, F; Goodman, M; Minic, B, 2009) |
| "Metformin was assessed as an interventional medication for weight gain in children and adolescents taking atypical antipsychotic agents." | 5.14 | Metformin for weight control in pediatric patients on atypical antipsychotic medication. ( Breeze, JL; Bregman, H; Frazier, JA; Noyes, N; Shin, L, 2009) |
| "Combination therapy of nitrendipine and atenolol may significantly increase BW and fasting BG in overweight or obese patients with hypertension." | 5.14 | Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients. ( Qin, YW; Qiu, JL; Zhang, JL; Zhao, XX; Zheng, X; Zou, DJ, 2009) |
| "Rosiglitazone treatment was associated with durable reductions in CRP independent of changes in insulin sensitivity, A1C, and weight gain." | 5.14 | Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). ( Haffner, SM; Herman, WH; Holman, RR; Kahn, SE; Kravitz, BG; Lachin, JM; Paul, G; Viberti, G; Yu, D; Zinman, B, 2010) |
| "Study the effects of exenatide (EXE) plus rosiglitazone (ROSI) on beta-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type 2 diabetes on metformin." | 5.14 | Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. ( DeFronzo, RA; Glass, LC; Lewis, MS; Maggs, D; Qu, Y; Triplitt, C, 2010) |
| "Vildagliptin add-on has similar efficacy to glimepiride after 2 years' treatment, with markedly reduced hypoglycaemia risk and no weight gain." | 5.14 | Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. ( Ahren, B; Couturier, A; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, V; Matthews, DR; Zinman, B, 2010) |
| "We investigated whether or not "low dose" metformin could prevent weight gain induced by pioglitazone." | 5.13 | Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes. ( Atsumi, Y; Funae, O; Hirata, T; Itoh, H; Kawai, T; Shimada, A; Tabata, M, 2008) |
| "To evaluate the effect of metformin treatment on the risperidone-induced body weight gain in patients." | 5.13 | A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. ( Arman, S; Koleini, N; Nadi, M; Sadramely, MR, 2008) |
| "7), 439 patients (40%) who received treatment with diet alone, diet followed by metformin or metformin alone demonstrated a maintained weight reduction in addition to improved glycaemic control." | 5.13 | Weight changes in type 2 diabetes and the impact of gender. ( McKenna, MJ; McKenna, TJ; O'Shea, D; Tuthill, A, 2008) |
| "To test the efficacy of lifestyle intervention and metformin alone and in combination for antipsychotic-induced weight gain and abnormalities in insulin sensitivity." | 5.13 | Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. ( Chen, JD; Fang, MS; Guo, XF; He, YQ; Jin, H; Li, LH; Liu, YJ; Shao, P; Wu, RR; Zhao, JP, 2008) |
| "While exenatide treatment provided similarly effective glycemic control compared with insulin analogue therapy, it was also associated with weight reduction in the majority of subjects (73." | 5.13 | Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. ( Bergenstal, RM; Brodows, R; Gates, JR; Glass, LC; Kim, D; Lenox, S; Qu, Y; Trautmann, M, 2008) |
| "Forty patients with schizophrenia were randomly assigned to treatment for 12 weeks with olanzapine, 15 mg/day, plus metformin, 750 mg/day (N=20), or olanzapine, 15 mg/day, plus placebo (N=20)." | 5.13 | Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. ( Chen, JD; Fang, MS; Guo, WB; Guo, XF; He, YQ; Li, LH; Wu, RR; Zhao, JP, 2008) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 5.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "To assess whether metformin prevents body weight gain (BWG) and metabolic dysfunction in patients with schizophrenia who are treated with olanzapine." | 5.12 | Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. ( Arapé, Y; Baptista, T; Beaulieu, S; de Mendoza, S; Hernández, L; Lacruz, A; Martínez, J; Martinez, M; Rangel, N; Serrano, A; Teneud, L, 2006) |
| "Metformin therapy is safe and effective in abrogating weight gain, decreased insulin sensitivity, and abnormal glucose metabolism resulting from treatment of children and adolescents with atypicals." | 5.12 | A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. ( Barton, BA; Cottingham, EM; Klein, DJ; Morrison, JA; Sorter, M, 2006) |
| "Glimepiride reduced A1C similarly to metformin with greater weight gain, and there was comparable safety over 24 weeks in the treatment of pediatric subjects with type 2 diabetes." | 5.12 | Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. ( Cara, JF; Danne, T; Gottschalk, M; Vlajnic, A, 2007) |
| " The addition of biphasic or prandial insulin aspart reduced levels more than the addition of basal insulin detemir but was associated with greater risks of hypoglycemia and weight gain." | 5.12 | Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. ( Davies, MJ; Farmer, AJ; Holman, RR; Keenan, JF; Levy, JC; Paul, S; Thorne, KI, 2007) |
| "To test the effect of continuing metformin on weight gain and glycaemic control in patients with poorly controlled Type 2 diabetes who need to start insulin." | 5.11 | Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial. ( Allen, SE; Bingley, PJ; Douek, IF; Ewings, P; Gale, EA, 2005) |
| "To evaluate whether, in adolescents with type 1 diabetes, the addition of metformin to insulin and standard diabetes management results in 1) higher insulin sensitivity and 2) lower HbA1c, fasting glucose, insulin dosage (units per kilogram per day) and BMI." | 5.10 | Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. ( Cummings, E; Daneman, D; Finegood, D; Hamilton, J; Zdravkovic, V, 2003) |
| "Over 13 weeks, both repaglinide and gliclazide, when combined with bedtime NPH insulin produce similar significant improvements in glycaemic control (-1%) and similar weight gain." | 5.10 | Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents. ( Furlong, NJ; Hardy, KJ; Hulme, SA; O'Brien, SV, 2003) |
| "Combination therapy with bedtime insulin plus metformin prevents weight gain." | 5.09 | Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. ( Heikkilä, M; Nikkilä, K; Ryysy, L; Tulokas, T; Vanamo, R; Yki-Järvinen, H, 1999) |
| "To determine causes of weight gain during insulin therapy with and without metformin in Type II (non-insulin-dependent) diabetes mellitus." | 5.09 | Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. ( Mäkimattila, S; Nikkilä, K; Yki-Järvinen, H, 1999) |
| "The present study firstly provided quantitative information for metformin effects on weight in different disease states, including patients with type 2 diabetes mellitus, patients with antipsychotic induced weight gain, patients with obesity." | 5.05 | Time course and dose effect of metformin on weight in patients with different disease states. ( Chen, X; Li, ZP; Wang, DD, 2020) |
| " This meta-analysis examined the efficacy and tolerability of combining metformin and lifestyle intervention for AP-related weight gain in schizophrenia." | 5.01 | Combination of Metformin and Lifestyle Intervention for Antipsychotic-Related Weight Gain: A Meta-Analysis of Randomized Controlled Trials. ( Cai, DB; Ng, CH; Ungvari, GS; Wu, RR; Xiang, YT; Yang, XH; Zhang, QE; Zheng, W, 2019) |
| "" On the 1-year anniversary of his death in 2018, we challenge three myths associated with insulin resistance: metformin improves insulin resistance; measurement of waist circumference predicts insulin resistance better than body mass index; and insulin resistance causes weight gain." | 5.01 | Myths about Insulin Resistance: Tribute to Gerald Reaven. ( Abbasi, F; Kim, SH, 2019) |
| "To perform meta-analyses of studies evaluating the risk of pre-eclampsia in high-risk insulin-resistant women taking metformin prior to, or during pregnancy." | 4.98 | Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis. ( Alqudah, A; Graham, U; Lyons, TJ; McClements, L; McKinley, MC; McNally, R; Watson, CJ, 2018) |
| "The objective of this study was to perform the first systematic review and meta-analysis of randomized controlled trials (RCTs) assessing the effects of metformin on weight gain in children and adolescents treated with SGAs." | 4.98 | Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis. ( Cortese, S; Delorme, R; Ellul, P, 2018) |
| "We conducted a systematic-review and meta-analysis of metformin versus placebo for change in weight and metabolic syndrome for people on clozapine without diabetes mellitus." | 4.93 | Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis. ( Kisely, S; Leung, J; Russell, AW; Siskind, DJ; Wysoczanski, D, 2016) |
| "This meta-analysis confirms that metformin is effective in treating antipsychotic induced weight gain in patients with schizophrenia or schizoaffective disorder." | 4.93 | Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. ( Dayabandara, M; de Silva, VA; Hanwella, R; Ratnatunga, SS; Suraweera, C; Wanniarachchi, N, 2016) |
| "26); whereas, significantly reduced results were found in the metformin group in pregnancy-induced hypertension (PIH) rate (RR = 0." | 4.91 | Effect comparison of metformin with insulin treatment for gestational diabetes: a meta-analysis based on RCTs. ( Cui, S; Li, G; Li, L; Li, Y; Xu, Y; Zhao, S, 2015) |
| "This meta-analysis examined the effectiveness and safety of metformin to prevent or treat weight gain and metabolic abnormalities associated with antipsychotic drugs." | 4.91 | Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials. ( de Leon, J; Li, XB; Tang, YL; Wang, CY; Xiang, YQ; Zheng, W, 2015) |
| "Metformin have been reported to counteract effectively antipsychotic-induced body weight gain and has been demonstrated to improve glycaemic control and promote a moderate weight loss in both diabetic and non-diabetic subjects." | 4.91 | A review of the evidence for the use of metformin in the treatment of metabolic syndrome caused by antipsychotics. ( Agius, M; Jesus, C; Jesus, I, 2015) |
| " The use of pioglitazone has been associated with an increased risk of bladder cancer, edema, heart failure, weight gain, and distal bone fractures in postmenopausal women." | 4.89 | [Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus]. ( de Pablos-Velasco, PL; Valerón, PF, 2013) |
| "There is uncertainty with regard to the appropriate use of metformin for the prevention and management of second-generation antipsychotic-induced weight gain and metabolic abnormalities." | 4.88 | Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. ( Curtis, J; Myles, N; Newall, H; Samaras, K; Shiers, D; Ward, PB, 2012) |
| " Direct comparisons with active glucose-lowering comparators in drug-naive patients have demonstrated that DPP-4 inhibitors exert slightly less pronounced HbA(1c) reduction than metformin (with the advantage of better gastrointestinal tolerability) and similar glucose-lowering effects as with a thiazolidinedione (TZD; with the advantage of no weight gain)." | 4.88 | DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. ( Scheen, AJ, 2012) |
| "Olanzapine is an atypical antipsychotic that is useful in schizophrenia and bipolar affective disorder, but its use is associated with troublesome weight gain and metabolic syndrome." | 4.87 | Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. ( Goyal, N; Jana, AK; Praharaj, SK; Sinha, VK, 2011) |
| " However, the antihyperglycaemic agent metformin appears promising in some recent studies and we review the literature that evaluates metformin for limiting or reversing atypical antipsychotic drug-induced weight gain and glucose metabolism dysregulation." | 4.86 | Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions. ( Fredrickson, SK; Hasnain, M; Vieweg, WV, 2010) |
| "Articles were identified by searching the MEDLINE database (from 1949 through January 2010) using the key words metformin, topiramate, antipsychotic, weight, weight gain, and obesity." | 4.86 | Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain. ( Ellinger, LK; Ipema, HJ; Stachnik, JM, 2010) |
| "To determine the comparative efficacy, risk of weight gain, and hypoglycemia associated with noninsulin antidiabetic drugs in patients with type 2 DM not controlled by metformin alone." | 4.86 | Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. ( Coleman, CI; Phung, OJ; Scholle, JM; Talwar, M, 2010) |
| " Metformin has been evaluated in clinical studies to prevent or reduce weight gain and changes in metabolic parameters in non-diabetic subjects." | 4.85 | Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies. ( Bradley, AJ; Bushe, CJ; Doshi, S; Karagianis, J, 2009) |
| " One such combination regimen is repaglinide (a prandial glucose regulator that increases insulin release) plus metformin (an insulin sensitizer that inhibits hepatic glucose output, increases peripheral glucose uptake and utilization and minimizes weight gain)." | 4.84 | Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes. ( Raskin, P, 2008) |
| "Pioglitazone monotherapy and combinations were assessed in patients with type 2 diabetes and metabolic syndrome (Adult Treatment Panel III criteria) from four worldwide randomised, multicentre, double-blind studies." | 4.82 | Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome. ( Fernandes, AW; Lester, JW, 2005) |
| " The sulfonyluereas, repaglinide, metformin, acarbose and the thiazolidinediones are effective in decreasing fasting plasma glucose levels, but their limitations may include adverse effects, such as weight gain and hypoglycemia, and an inability to modify some of the important comorbidities of diabetes." | 4.80 | Advances in oral therapy for type 2 diabetes. ( Davis, SN, 2000) |
| "Metformin has been associated with modest weight reduction in the non-pregnant population." | 4.12 | Weight gain in pregnancy: can metformin steady the scales? ( Adams, JH; Antony, KM; Eddy, A; Hoppe, KK; Iruretagoyena, JI; Poehlmann, J; Racine, JL; Rhoades, J; Stewart, K, 2022) |
| "In this large retrospective naturalistic cohort study, co-prescription of clozapine and metformin was associated with less weight gain and related metabolic dysfunction at 6 and 12 months after initiation versus clozapine alone." | 4.12 | Metformin for the prevention of clozapine-induced weight gain: A retrospective naturalistic cohort study. ( Agarwal, SM; Chintoh, AF; Foussias, G; Gerretsen, P; Graff-Guerrero, A; Hahn, MK; Maksyutynska, K; Navagnanavel, J; Powell, V; Remington, G; Sanches, M; Stogios, N, 2022) |
| "The present study aimed to investigate the possible effects of metformin on the olanzapine-induced insulin resistance in rats." | 4.02 | Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats. ( Guo, C; Li, H; Liu, J, 2021) |
| "Women with GDM treated with insulin plus metformin had similar obstetric and neonatal complications, weight gained and insulin dose compared to those only treated with insulin." | 4.02 | Metformin combined with insulin in women with gestational diabetes mellitus: a propensity score-matched study. ( Almeida, M; Almeida, MC; Chaves, C; Cunha, F; Estevinho, C; Figueiredo, O; Garrido, S; Martinho, M; Melo, A; Morgado, A; Silva-Vieira, M, 2021) |
| "What is the central question of this study? Studies reported the efficacy of metformin as a promising drug for preventing or treating of metabolic diseases." | 3.96 | Early metformin treatment improves pancreatic function and prevents metabolic dysfunction in early overfeeding male rats at adulthood. ( Alves, VS; de Moraes, AMP; de Oliveira, JC; Francisco, FA; Franco, CCDS; Malta, A; Martins, IP; Mathias, PCF; Matiusso, CCI; Miranda, RA; Moreira, VM; Pavanello, A; Prates, KV; Previate, C, 2020) |
| "Patients dispensed a second-generation antipsychotic and antipsychotics with high risk of weight gain appear to be at increased risk of being secondarily dispensed metformin." | 3.91 | Comparative risk of new-onset diabetes following commencement of antipsychotics in New Zealand: a population-based clustered multiple baseline time series design. ( Bridgford, P; Currie, O; Mangin, D; McKinnon-Gee, B; Williman, J, 2019) |
| " for their interest in our article on metformin and children with autism spectrum disorders (ASD) and for providing information about the MOBILITY study (a Patient-Centered Outcomes Research Institute (PCORI)-funded pragmatic clinical trial to examine the relative effectiveness of metformin plus healthy lifestyle instruction versus healthy lifestyle instruction alone)." | 3.88 | Dr. Handen et al. Reply. ( Aman, MG; Anagnostou, E; Handen, BL; Veenstra-VanderWeele, J, 2018) |
| "There is considerable evidence that metformin reduces weight gain associated with antipsychotic medication." | 3.85 | Developing a metformin prescribing tool for use in adults with mental illness to reduce medication-related weight gain and cardiovascular risk. ( Galletly, C; Myles, H; Smith, C, 2017) |
| "Linagliptin added to basal insulin and metformin improved glycaemic control, without increasing the risk of hypoglycaemia or body weight gain." | 3.83 | Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes. ( Durán-Garcia, S; Hehnke, U; Lee, J; Patel, S; Rosenstock, J; Thiemann, S; Woerle, HJ; Yki-Järvinen, H, 2016) |
| "Metformin, a biguanide drug, is emerging as an important treatment option for the prevention or treatment of weight gain, type 2 diabetes mellitus, and the metabolic syndrome in psychiatric patients, especially those who require or receive antipsychotic drugs." | 3.83 | Use of Metformin for Cardiometabolic Risks in Psychiatric Practice: Need-to-Know Safety Issues. ( Andrade, C, 2016) |
| "Sixty six adult patients with schizophrenia or schizoaffective disorder treated, with atypical antipsychotics, and who had increased by more than 10% their pre treatment body weight, were randomly assigned to receive metformin or placebo in a double-blind study." | 3.81 | Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study. ( Dayabandara, M; de Silva, VA; Gunewardena, H; Hanwella, R; Henegama, T; Suraweera, C; Wijesundara, H, 2015) |
| "Pioglitazone was associated with a significant increase in body weight and edema." | 3.75 | Adverse effect of pioglitazone in military personnel and their families: a preliminary report. ( Benjasuratwong, Y; Patarakitvanit, S; Satyapan, N; Temboonkiat, S; Vudhironarit, T, 2009) |
| "The objective of this study was to quantify 1-year weight gain associated with the initiation of sulphonylurea (SU), metformin, insulin and thiazolidinedione (TZD) therapy in a representative real world population of type 2 diabetic patients." | 3.74 | Weight changes following the initiation of new anti-hyperglycaemic therapies. ( Gomez-Caminero, A; Nichols, GA, 2007) |
| "Prominent weight gain (mostly subcutaneous fat area) was observed in the pioglitazone-treated OLETF (O-P) rats versus significant weight loss was observed in the metformin-treated OLETF (O-M) rats." | 3.74 | The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats. ( Ahn, CW; Cha, BS; Choi, SH; Kim, DJ; Kim, SK; Lee, HC; Lee, YJ; Lim, SK; Zhao, ZS, 2007) |
| "We investigated the effects of metformin on the growth of lewis lung LLC1 carcinoma in C57BL/6J mice provided with either a control diet or a high-energy diet, previously reported to lead to weight gain and systemic insulin resistance with hyperinsulinemia." | 3.74 | Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. ( Algire, C; Blouin, MJ; Pollak, M; Shuai, JH; Zakikhani, M, 2008) |
| "(1) High-fat diet induces insulin resistance in SD rats; this was associated with an increase in visceral fat and a decrease in the level of adiponectin; (2) Metformin treatment improved insulin sensitivity accompanied by a decrease in body weight and TG level; (3) Rosiglitazone treatment ameliorates IR in a greater extent and is accompanied by a reduction of FFA, TG and an increase of adiponectin levels." | 3.72 | [Effects of rosiglitazone and metformin on insulin resistance in high-fat diet rats]. ( Bu, S; Chen, XP; Liu, XL; Wang, N; Xiao, JZ; Yang, WY; Zhao, WH, 2004) |
| " We hypothesized that correction of insulin resistance with metformin might also restore anabolic effects of GH." | 3.71 | Metformin restores responses to insulin but not to growth hormone in Sprague-Dawley rats. ( Borst, SE; Kim, YW; Ross, H; Scarpace, PJ; Snellen, HG, 2002) |
| "When oral agents alone can no longer provide adequate glycemic control, the combination of a single bedtime injection of insulin with two daily doses of metformin will often normalize blood glucoses levels without the weight gain and hypoglycemia that may occur with other combined regimens." | 3.70 | A simple therapeutic combination for type 2 diabetes. ( Yki-Järvinen, H, 2000) |
| "Seventy drug-naïve patients with type 2 diabetes (mean age, 52." | 3.30 | Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study. ( Ahn, J; Florez, JC; Lim, S; Nauck, MA; Sohn, M, 2023) |
| "iGlarLixi achieved significant HbA1c reductions, to near-normoglycaemic levels, compared with iGlar or Lixi, with no meaningful additional risk of hypoglycaemia and mitigated body weight gain versus iGlar, with fewer gastrointestinal adverse events versus Lixi." | 3.11 | Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial. ( Chen, L; Cheng, Z; Dong, X; Gu, S; Li, Q; Liu, M; Niemoeller, E; Ping, L; Souhami, E; Xiao, J; Yang, W; Yuan, G, 2022) |
| "Pregnancies affected by gestational diabetes mellitus (GDM) are associated with an increased risk of adverse maternal and foetal outcomes." | 3.11 | A randomised placebo-controlled trial of the effectiveness of early metformin in addition to usual care in the reduction of gestational diabetes mellitus effects (EMERGE): study protocol. ( Alvarez-Iglesias, A; Browne, M; Devane, D; Dunne, F; Gillespie, P; Newman, C; O'Donnell, M; Smyth, A, 2022) |
| "Metformin was generally well-tolerated." | 3.01 | Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled Trial of Metformin for Antipsychotic-Induced Weight Gain in Patients with First-Episode Psychosis: A Pilot Study. ( Abdin, E; Chua, YC; Subramaniam, M; Tang, C; Verma, S, 2021) |
| " The incidence of overall adverse events and the number of hypoglycaemic adverse events were similar between the study groups." | 2.94 | Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study). ( Benjachareonwong, S; Chamnan, P; Cho, YM; Choi, S; Deerochanawong, C; Kang, ES; Kim, S; Kosachunhanun, N; Kwon, S; Lee, MK; Lee, WJ; Oh, T; Pratipanawatr, T; Sattanon, S; Seekaew, S; Sirirak, T; Suraamornkul, S; Suwanwalaikorn, S, 2020) |
| "Weight gain is an ongoing challenge when initiating insulin therapy in patients with type 2 diabetes mellitus (T2DM)." | 2.84 | Prediction of excessive weight gain in insulin treated patients with type 2 diabetes. ( Almdal, TP; Cichosz, SL; Hejlesen, OK; Johansen, MD; Lundby-Christensen, L; Tarnow, L, 2017) |
| "Among patients with uncontrolled type 2 diabetes taking glargine and metformin, treatment with degludec/liraglutide compared with up-titration of glargine resulted in noninferior HbA1c levels, with secondary analyses indicating greater HbA1c level reduction after 26 weeks of treatment." | 2.82 | Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. ( Buse, JB; García-Hernández, P; Lehmann, L; Lingvay, I; Norwood, P; Pérez Manghi, F; Tarp-Johansen, MJ, 2016) |
| " The rate of adverse events was comparable in both groups." | 2.78 | [Efficacy and safety of vildagliptin as a second-line therapy vs other oral antidiabetic agents in patients with type 2 diabetes: Czech results within the worldwide prospective cohort EDGE study]. ( Brada, M; Dohnalová, L; Edelsberger, T; Gerle, J; Haluzík, M; Houdová, J; Veselá, V, 2013) |
| "TODAY (Treatment Options for type 2 Diabetes in Adolescents and Youth) is a federally funded multicenter randomized clinical trial comparing three treatments of youth onset type 2 diabetes." | 2.77 | Metformin monotherapy in youth with recent onset type 2 diabetes: experience from the prerandomization run-in phase of the TODAY study. ( Chang, N; Grey, M; Hale, D; Higgins, L; Hirst, K; Izquierdo, R; Laffel, L; Larkin, M; Macha, C; Pham, T; Wauters, A; Weinstock, RS, 2012) |
| "The mean weight gain was higher in the prandial group than in either the biphasic group or the basal group." | 2.74 | Three-year efficacy of complex insulin regimens in type 2 diabetes. ( Darbyshire, JL; Davies, MJ; Farmer, AJ; Holman, RR; Keenan, JF; Levy, JC; Paul, SK, 2009) |
| "Weight gain was less with metformin plus biphasic insulin aspart 70/30 than with repaglinide plus biphasic insulin aspart 70/30 (difference in mean body weight between treatments -2." | 2.74 | Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. ( Frandsen, M; Hansen, BV; Lund, SS; Nielsen, BB; Parving, HH; Pedersen, O; Tarnow, L; Vaag, AA, 2009) |
| "Hypoglycemia was similar in the 2 groups, but sample size limited the ability to make a definite safety assessment." | 2.73 | Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. ( Beneduce, F; Ceriello, A; Ciotola, M; Esposito, K; Feola, G; Giugliano, D; Gualdiero, R; Maiorino, MI; Schisano, B, 2008) |
" Insulin dosage in each group was titrated to target fasting blood glucose (FBG) of 100 mg/dL or less (| 2.73 | Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. ( Busch, K; Janka, HU; Plewe, G, 2007) | |
| "Weight gain was probably not due to an increase in food intake, while REE per lean body mass decreased, suggesting a role for increased efficiency in fuel usage due to improved glycaemic control." | 2.73 | Weight gain in type 2 diabetes mellitus. ( Adams-Huet, B; Jacob, AN; Raskin, P; Salinas, K, 2007) |
| "The combination of repaglinide, metformin and bedtime NPH is safe and effective and it provides better postprandial blood glucose control." | 2.73 | Safety and efficacy of repaglinide in combination with metformin and bedtime NPH insulin as an insulin treatment regimen in type 2 diabetes. ( Civera, M; Martínez, I; Merchante, A; Salvador, M; Sanz, J, 2008) |
| "In these patients with type 2 diabetes that was poorly controlled by OADs, BIAsp 30 TID and BIAsp 30 BID plus MET were associated with significantly greater reductions in HbA(1c) and postprandial BG compared with OADs alone." | 2.73 | Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial ( Al-Tayar, B; Kazakova, E; Morozova, A; Saifullina, M; Sazonova, O; Shapiro, I; Sokolovskaya, V; Starceva, M; Starkova, N; Tarasov, A; Ushakova, O; Valeeva, F; Zanozina, O; Zhadanova, E, 2007) |
| "Glyburide was associated with a lower risk of cardiovascular events (including congestive heart failure) than was rosiglitazone (P<0." | 2.72 | Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. ( Haffner, SM; Heise, MA; Herman, WH; Holman, RR; Jones, NP; Kahn, SE; Kravitz, BG; Lachin, JM; O'Neill, MC; Viberti, G; Zinman, B, 2006) |
| "Weight gain was avoided when MET therapy preceded the addition of TGZ therapy." | 2.71 | Improved glycemic control without weight gain using triple therapy in type 2 diabetes. ( Avilés-Santa, ML; Raskin, P; Strowig, SM, 2004) |
| " Insulin dosage was titrated to target FBG | 2.71 | Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. ( Janka, HU; Kliebe-Frisch, C; Plewe, G; Riddle, MC; Schweitzer, MA; Yki-Järvinen, H, 2005) |
| "In patients with Type 2 diabetes and inadequate glucose control while on insulin or insulin and oral agent(s) combination therapy, treatment with a twice-daily insulin lispro mixture plus metformin, which targets both post-prandial and pre-meal BG, provided clinically significant improvements in A1c, significantly reduced post-prandial BG after each meal, and reduced nocturnal hypoglycaemia as compared with once-daily glargine plus metformin, a treatment that targets fasting BG." | 2.71 | Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. ( Augendre-Ferrante, B; Bai, S; Campaigne, BN; Malone, JK; Reviriego, J, 2005) |
| "Metformin has been gradually used in the management of gestational diabetes mellitus (GDM)." | 2.55 | Metformin - a potentially effective drug for gestational diabetes mellitus: a systematic review and meta-analysis. ( Feng, Y; Yang, H, 2017) |
| "Iatrogenic and compensatory hyperinsulinemia are metabolic disruptors of β-cells, liver, muscle, kidney, brain, heart and vasculature, inflammation, and lipid homeostasis, among other systems." | 2.53 | Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile. ( Herman, ME; Jellinger, PS; Schwartz, SS, 2016) |
| "Maternal obesity is associated with adverse perinatal outcome." | 2.52 | Placental dysfunction in obese women and antenatal surveillance strategies. ( Doshani, A; Jeve, YB; Konje, JC, 2015) |
| "Metformin has the potential effect of inducing hippocampal neurogenesis, and additional studies of this drug are warranted in patients with mood or cognitive disorders." | 2.49 | A "glucose eater" drug as a therapeutic agent in psychiatry. ( Howland, RH, 2013) |
| "Weight gain is a clinically important side effect of antipsychotic drug therapy." | 2.47 | Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. ( Asplund, AB; Björkhem-Bergman, L; Lindh, JD, 2011) |
| "Although drugs for type 2 diabetes are studied in heterogeneous samples of patients, their efficacy can be predicted by some clinical parameters." | 2.47 | Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. ( Cremasco, F; Lamanna, C; Mannucci, E; Marchionni, N; Monami, M, 2011) |
| "Metformin was well tolerated." | 2.47 | A systematic review of metformin to limit weight-gain with atypical antipsychotics. ( Jeong, JH; Lee, YJ, 2011) |
| "Metabolic syndrome is prevalent in older adults and increases the risk of cardiovascular disease." | 2.45 | Metabolic risks in older adults receiving second-generation antipsychotic medication. ( Brooks, JO; Chang, HS; Krasnykh, O, 2009) |
| "Metformin is an antidiabetic drug that has been shown to cause weight loss in patients with diabetes mellitus, as well as in some individuals without diabetes." | 2.45 | Management of atypical antipsychotic drug-induced weight gain: focus on metformin. ( Miller, LJ, 2009) |
| "Type 2 diabetes is a progressive syndrome that evolves toward complete insulin deficiency during the patient's life." | 2.44 | Treatment of type 2 diabetes with combined therapy: what are the pros and cons? ( Massi-Benedetti, M; Orsini-Federici, M, 2008) |
| "Children with psychiatric illness are at greater risk for obesity than those in the general population." | 2.44 | An overview of obesity in children with psychiatric disorders taking atypical antipsychotics. ( Bregman, H; Frazier, J; Noyes, N; Shin, L, 2008) |
| "The aim of this study was to quantify the effect of a sulphonylurea on glycaemic control and the risk adverse events when incorporated into the treatment regimen of patients with type 2 diabetes inadequately controlled on metformin." | 2.44 | Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis. ( Belsey, J; Krishnarajah, G, 2008) |
| "Obesity is associated with considerable morbidity and decreased life expectancy." | 2.41 | Options for pharmacological management of obesity in patients treated with atypical antipsychotics. ( Sanders, TA; Taylor, D; Werneke, U, 2002) |
| "Patients with type 2 diabetes mellitus who initiated BI treatment due to uncontrolled hyperglycemia (HbA1c≥7 %) by oral antidiabetic drugs (OADs) were recruited in Chinese real-world settings between 2011 and 2013." | 1.72 | Effectiveness and safety of basal insulin therapy in type 2 diabetes mellitus patients with or without metformin observed in a national cohort in China. ( Chen, M; Duolikun, N; Ji, J; Ji, L; Li, X; Luo, Y; Wang, D; Zhang, H; Zhang, P; Zhu, D, 2022) |
| "Metformin treatment significantly ameliorated the abnormal metabolic profile, decreasing piglets' weight, weight gain from birth, abdominal circumference and fructosamine (all p < 0." | 1.72 | Metabolic programming in the offspring after gestational overfeeding in the mother: toward neonatal rescuing with metformin in a swine model. ( Bassols, J; Carreras-Badosa, G; De Zegher, F; Ibáñez, L; Lizárraga-Mollinedo, E; López-Bermejo, A; Mas-Parés, B; Platero-Gutierrez, E; Prats-Puig, A; Reixach, J; Tibau, J; Xargay-Torrent, S, 2022) |
| "Patients with type 2 diabetes mellitus (T2DM) often experience hypoglycaemia and weight gain due to treatment side effects." | 1.56 | Real-world Evaluation of glycemic control and hypoglycemic Events among type 2 Diabetes mellitus study (REEDS): a multicentre, cross-sectional study in Thailand. ( Benjasuratwong, Y; Nitiyanant, W; Ongphiphadhanakul, B; Pratipanawatr, T; Satirapoj, B; Suwanwalaikorn, S, 2020) |
| "Bringing patients with type 2 diabetes to recommended glycated hemoglobin (HbA1c) treatment targets can reduce the risk of developing diabetes-related complications." | 1.46 | Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States. ( Dang-Tan, T; Gamble, C; Hunt, B; McConnachie, CC, 2017) |
| "Metformin was orally administered to control mice or mice with streptozotocin-induced diabetes." | 1.46 | Metformin protects against retinal cell death in diabetic mice. ( Cho, GJ; Choi, MY; Choi, WS; Kang, SS; Kim, HJ; Kim, M; Kim, SJ; Kim, YS; Lee, DH; Roh, GS; Yoo, JM, 2017) |
| "Many patients with type 2 diabetes mellitus (T2DM) do not achieve glycaemic control targets on basal insulin regimens." | 1.43 | How much is too much? Outcomes in patients using high-dose insulin glargine. ( Gao, L; Gill, J; Reid, T; Rhinehart, A; Stuhr, A; Traylor, L; Vlajnic, A, 2016) |
| "Metformin, which has demonstrated efficacy for these adverse treatment outcomes in adult samples, has been examined in pediatric samples, as well." | 1.43 | Metformin as a Possible Intervention for Cardiometabolic Risks in Pediatric Subjects Exposed to Antipsychotic Drugs. ( Andrade, C, 2016) |
| "Bariatric surgery rapidly improves Type 2 diabetes mellitus (T2DM)." | 1.42 | Effect of bariatric surgery combined with medical therapy versus intensive medical therapy or calorie restriction and weight loss on glycemic control in Zucker diabetic fatty rats. ( Abegg, K; Boza, C; Corteville, C; Docherty, NG; le Roux, CW; Lutz, TA; Muñoz, R, 2015) |
| "Metformin treatments would have positive effects on growth patterns, adiposity and metabolic features of young females from ethnicities with thrifty genotype or developing leptin resistance, but a negative effect by advancing the attainment of puberty." | 1.40 | Advanced onset of puberty after metformin therapy in swine with thrifty genotype. ( Astiz, I; Astiz, S; Barbero, A; Garcia-Real, I; Gonzalez-Bulnes, A; Perez-Solana, ML, 2014) |
| "Weight gain was associated with a significant increase in all-cause costs of $3400 per year compared with the weight-neutral cohort; however, differences in T2DM-specific costs and discontinuation rates did not reach significance levels." | 1.40 | Economic implications of weight change in patients with type 2 diabetes mellitus. ( Bell, K; D'Souza, A; Graham, J; Lamerato, L; Parasuraman, S; Raju, A; Shah, M, 2014) |
| "A total of 660 insulin-naive type 2 diabetes patients with poor glycemic control (glycosylated hemoglobin [HbA1c] ≥7." | 1.38 | The impact of initiating biphasic human insulin 30 therapy in type 2 diabetes patients after failure of oral antidiabetes drugs. ( Bao, Y; Cai, Q; Gu, Y; Hou, X; Jia, W; Pan, J; Zhang, L, 2012) |
| "sulphonylurea (SU) compounds." | 1.38 | Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea. ( Knop, FK; Lund, A, 2012) |
| "Metformin was combined with MPI in 81 patients." | 1.37 | Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes. ( Levit, S; Toledano, Y; Wainstein, J, 2011) |
| "Metformin treatment also improved hyperleptinemia, whereas pioglitazone was ineffective." | 1.36 | Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice. ( Hirasawa, Y; Ito, M; Kyuki, K; Matsui, Y; Sugiura, T; Toyoshi, T, 2010) |
| "(1) When type 2 diabetes is inadequately controlled with oral antidiabetic therapy, one option is to add subcutaneous insulin injections (or to accept less stringent glycaemic control)." | 1.34 | Exenatide: new drug. Type 2 diabetes for some overweight patients. ( , 2007) |
| "When used late in the course of type 2 diabetes, TZDs result in improved and prolonged glycaemic control which persisted for a median time of 6 years." | 1.33 | Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes. ( Bell, DS; Ovalle, F, 2006) |
| "In 224 subjects with type 2 diabetes we assessed the association between baseline IGF-II levels and risk of weight gain (>2." | 1.33 | Low insulin-like growth factor-II levels predict weight gain in normal weight subjects with type 2 diabetes. ( Anderson, SG; Brismar, K; Cruickshank, JK; Gibson, JM; Grill, V; Heald, AH; Kärvestedt, L; Knowles, A; McLaughlin, J; White, A; Wong, L, 2006) |
| "Metformin treatment resulted in a modest loss of weight." | 1.33 | Stability of body weight in type 2 diabetes. ( Chaudhry, ZW; Gannon, MC; Nuttall, FQ, 2006) |
| "Patients with type 2 diabetes who are failing on oral agents will generally gain a large amount of body fat when switched to insulin treatment." | 1.32 | Prevention of weight gain in type 2 diabetes requiring insulin treatment. ( de Boer, H; Jansen, M; Koerts, J; Verschoor, L, 2004) |
| "Obesity has been associated with alterations in glucocorticoid metabolism in both man and rodents, but the underlying mechanisms remain undefined." | 1.31 | Mechanisms of dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in obese Zucker rats. ( Kenyon, CJ; Livingstone, DE; Walker, BR, 2000) |
| "The weight gains were identically reduced in the metformin- and pair-fed control group compared to the ad libitum--fed rats." | 1.29 | Metformin and brown adipose tissue thermogenetic activity in genetically obese Zucker rats. ( Huupponen, R; Isaksson, K; Koulu, M; Rouru, J; Santti, E, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (3.52) | 18.2507 |
| 2000's | 73 (28.52) | 29.6817 |
| 2010's | 141 (55.08) | 24.3611 |
| 2020's | 33 (12.89) | 2.80 |
| Authors | Studies |
|---|---|
| Fitzgerald, I | 1 |
| O'Connell, J | 1 |
| Keating, D | 1 |
| Hynes, C | 1 |
| McWilliams, S | 1 |
| Crowley, EK | 1 |
| Calco, GN | 1 |
| Proskocil, BJ | 1 |
| Jacoby, DB | 1 |
| Fryer, AD | 1 |
| Nie, Z | 1 |
| Stojnić, B | 1 |
| Serrano, A | 2 |
| Sušak, L | 1 |
| Palou, A | 1 |
| Bonet, ML | 1 |
| Ribot, J | 1 |
| Molina-Vega, M | 1 |
| Picón-César, MJ | 1 |
| Gutiérrez-Repiso, C | 1 |
| Fernández-Valero, A | 1 |
| Lima-Rubio, F | 1 |
| González-Romero, S | 1 |
| Moreno-Indias, I | 1 |
| Tinahones, FJ | 1 |
| Tang, C | 1 |
| Chua, YC | 1 |
| Abdin, E | 1 |
| Subramaniam, M | 1 |
| Verma, S | 1 |
| Zhang, P | 1 |
| Chen, M | 1 |
| Zhang, H | 2 |
| Luo, Y | 1 |
| Zhu, D | 2 |
| Li, X | 1 |
| Ji, J | 1 |
| Wang, D | 1 |
| Duolikun, N | 1 |
| Ji, L | 1 |
| Xargay-Torrent, S | 1 |
| Mas-Parés, B | 1 |
| Carreras-Badosa, G | 2 |
| Lizárraga-Mollinedo, E | 1 |
| Tibau, J | 1 |
| Reixach, J | 1 |
| Platero-Gutierrez, E | 1 |
| Prats-Puig, A | 1 |
| De Zegher, F | 3 |
| Ibáñez, L | 2 |
| Bassols, J | 2 |
| López-Bermejo, A | 2 |
| Nagy, LR | 1 |
| Rice, T | 1 |
| Coffey, BJ | 3 |
| Fu, J | 1 |
| Tomlinson, G | 1 |
| Feig, DS | 1 |
| Trouva, A | 1 |
| Alvarsson, M | 1 |
| Calissendorff, J | 1 |
| Åsvold, BO | 1 |
| Vanky, E | 3 |
| Hirschberg, AL | 1 |
| Adams, JH | 1 |
| Poehlmann, J | 1 |
| Racine, JL | 1 |
| Iruretagoyena, JI | 1 |
| Eddy, A | 1 |
| Hoppe, KK | 1 |
| Stewart, K | 1 |
| Rhoades, J | 1 |
| Antony, KM | 1 |
| Yang, W | 1 |
| Dong, X | 1 |
| Li, Q | 1 |
| Cheng, Z | 1 |
| Yuan, G | 1 |
| Liu, M | 1 |
| Xiao, J | 1 |
| Gu, S | 1 |
| Niemoeller, E | 1 |
| Chen, L | 2 |
| Ping, L | 1 |
| Souhami, E | 1 |
| Stogios, N | 2 |
| Maksyutynska, K | 1 |
| Navagnanavel, J | 1 |
| Sanches, M | 1 |
| Powell, V | 1 |
| Gerretsen, P | 1 |
| Graff-Guerrero, A | 1 |
| Chintoh, AF | 1 |
| Foussias, G | 1 |
| Remington, G | 2 |
| Hahn, MK | 2 |
| Agarwal, SM | 2 |
| Dunne, F | 1 |
| Newman, C | 1 |
| Devane, D | 1 |
| Smyth, A | 1 |
| Alvarez-Iglesias, A | 1 |
| Gillespie, P | 1 |
| Browne, M | 1 |
| O'Donnell, M | 1 |
| Mc Namara, KP | 1 |
| Alzubaidi, H | 1 |
| Murray, M | 1 |
| Samorinha, C | 1 |
| Dunbar, JA | 1 |
| Versace, VL | 1 |
| Castle, D | 1 |
| Ahsan, ZA | 1 |
| Lockwood, JT | 1 |
| Duncan, MJ | 1 |
| Takeuchi, H | 1 |
| Cohn, T | 1 |
| Taylor, VH | 1 |
| Faulkner, GEJ | 1 |
| Hahn, M | 1 |
| Brand, KM | 3 |
| Thoren, R | 3 |
| Sõnajalg, J | 3 |
| Boutmy, E | 3 |
| Foch, C | 3 |
| Schlachter, J | 3 |
| Hakkarainen, KM | 3 |
| Saarelainen, L | 3 |
| Sheng, B | 1 |
| Ni, J | 1 |
| Lv, B | 1 |
| Jiang, G | 1 |
| Lin, X | 1 |
| Li, H | 2 |
| Lim, S | 1 |
| Sohn, M | 1 |
| Florez, JC | 2 |
| Nauck, MA | 1 |
| Ahn, J | 1 |
| Elton, AC | 1 |
| Cedarstrom, V | 1 |
| Quraishi, A | 1 |
| Wuertz, B | 1 |
| Murray, K | 1 |
| Markowski, TW | 1 |
| Seabloom, D | 1 |
| Ondrey, FG | 1 |
| Diaz, M | 1 |
| Garcia-Beltran, C | 1 |
| Puerto-Carranza, E | 1 |
| Oliver-Vila, C | 1 |
| Casano, P | 1 |
| Franco, CA | 1 |
| Malpique, R | 1 |
| Molin, J | 1 |
| Bixo, M | 1 |
| Veerman, SRT | 1 |
| Cohen, D | 1 |
| Shamshoum, H | 1 |
| Medak, KD | 1 |
| McKie, GL | 1 |
| Jeromson, S | 1 |
| Wright, DC | 1 |
| Ryan, PM | 1 |
| Patterson, E | 1 |
| Carafa, I | 1 |
| Mandal, R | 1 |
| Wishart, DS | 1 |
| Dinan, TG | 1 |
| Cryan, JF | 1 |
| Tuohy, KM | 1 |
| Stanton, C | 1 |
| Ross, RP | 1 |
| Cho, YM | 1 |
| Deerochanawong, C | 1 |
| Seekaew, S | 1 |
| Suraamornkul, S | 1 |
| Benjachareonwong, S | 1 |
| Sattanon, S | 1 |
| Chamnan, P | 1 |
| Sirirak, T | 1 |
| Kosachunhanun, N | 1 |
| Pratipanawatr, T | 2 |
| Suwanwalaikorn, S | 2 |
| Lee, WJ | 1 |
| Kim, S | 1 |
| Choi, S | 1 |
| Kang, ES | 1 |
| Oh, T | 1 |
| Kwon, S | 1 |
| Lee, MK | 1 |
| Ding, Y | 1 |
| Xu, M | 1 |
| Lu, Q | 1 |
| Wei, P | 1 |
| Tan, J | 1 |
| Liu, R | 1 |
| Satirapoj, B | 1 |
| Ongphiphadhanakul, B | 1 |
| Benjasuratwong, Y | 2 |
| Nitiyanant, W | 1 |
| De Diego, MV | 1 |
| Gómez-Pardo, O | 1 |
| Groar, JK | 1 |
| López-Escobar, A | 1 |
| Martín-Estal, I | 1 |
| Castilla-Cortázar, I | 1 |
| Rodríguez-Zambrano, MÁ | 1 |
| Chen, X | 1 |
| Wang, DD | 1 |
| Li, ZP | 1 |
| Previate, C | 1 |
| Malta, A | 1 |
| Miranda, RA | 1 |
| Martins, IP | 1 |
| Pavanello, A | 1 |
| de Oliveira, JC | 1 |
| Prates, KV | 1 |
| Alves, VS | 1 |
| Francisco, FA | 1 |
| Moreira, VM | 1 |
| Matiusso, CCI | 1 |
| de Moraes, AMP | 1 |
| Mathias, PCF | 1 |
| Franco, CCDS | 1 |
| Guo, C | 1 |
| Liu, J | 1 |
| de Boer, N | 1 |
| Guloksuz, S | 1 |
| van Baal, C | 1 |
| Willebrands, L | 1 |
| Deenik, J | 1 |
| Vinkers, CH | 1 |
| Rossum, IW | 1 |
| Zinkstok, J | 1 |
| Wilting, I | 1 |
| Zantvoord, JB | 1 |
| Backx, F | 1 |
| Swildens, WE | 1 |
| Schouw, M | 1 |
| Bogers, J | 1 |
| Hulshof, F | 1 |
| de Knijff, R | 1 |
| Duindam, P | 1 |
| Veereschild, M | 1 |
| Bak, M | 1 |
| Frederix, G | 1 |
| de Haan, L | 1 |
| van Os, J | 1 |
| Cahn, W | 1 |
| Luykx, JJ | 1 |
| Chaves, C | 1 |
| Cunha, F | 1 |
| Martinho, M | 1 |
| Garrido, S | 1 |
| Silva-Vieira, M | 1 |
| Estevinho, C | 1 |
| Melo, A | 1 |
| Figueiredo, O | 1 |
| Morgado, A | 1 |
| Almeida, MC | 1 |
| Almeida, M | 1 |
| Ertefaie, A | 1 |
| Flory, JH | 2 |
| Hennessy, S | 1 |
| Small, DS | 1 |
| Pinto, EF | 1 |
| George, B | 1 |
| Karia, S | 1 |
| Andrade, C | 4 |
| Wink, LK | 1 |
| Adams, R | 1 |
| Pedapati, EV | 1 |
| Dominick, KC | 1 |
| Fox, E | 1 |
| Buck, C | 1 |
| Erickson, CA | 1 |
| Hendrick, V | 1 |
| Dasher, R | 1 |
| Gitlin, M | 1 |
| Parsi, M | 1 |
| Lingvay, I | 2 |
| Harris, S | 1 |
| Jaeckel, E | 1 |
| Chandarana, K | 1 |
| Ranthe, MF | 1 |
| Jódar, E | 1 |
| Hunt, B | 1 |
| McConnachie, CC | 1 |
| Gamble, C | 1 |
| Dang-Tan, T | 1 |
| Out, M | 1 |
| Miedema, I | 1 |
| Jager-Wittenaar, H | 1 |
| van der Schans, C | 1 |
| Krijnen, W | 1 |
| Lehert, P | 2 |
| Stehouwer, C | 1 |
| Kooy, A | 2 |
| Smith, C | 1 |
| Myles, H | 1 |
| Galletly, C | 1 |
| Kim, YS | 1 |
| Kim, M | 1 |
| Choi, MY | 1 |
| Lee, DH | 1 |
| Roh, GS | 1 |
| Kim, HJ | 1 |
| Kang, SS | 1 |
| Cho, GJ | 1 |
| Kim, SJ | 1 |
| Yoo, JM | 1 |
| Choi, WS | 1 |
| Walkup, JT | 2 |
| Cottingham, E | 2 |
| Alqudah, A | 1 |
| McKinley, MC | 1 |
| McNally, R | 1 |
| Graham, U | 1 |
| Watson, CJ | 1 |
| Lyons, TJ | 1 |
| McClements, L | 1 |
| Suetani, SC | 1 |
| Parker, S | 1 |
| Korman, N | 1 |
| Crompton, D | 1 |
| Dark, F | 1 |
| Siskind, D | 2 |
| Zheng, W | 2 |
| Zhang, QE | 1 |
| Cai, DB | 1 |
| Yang, XH | 1 |
| Ungvari, GS | 1 |
| Ng, CH | 1 |
| Wu, RR | 5 |
| Xiang, YT | 1 |
| Friend, N | 1 |
| Russell, A | 1 |
| McGrath, JJ | 1 |
| Lim, C | 1 |
| Patterson, S | 1 |
| Flaws, D | 1 |
| Stedman, T | 1 |
| Moudgil, V | 1 |
| Sardinha, S | 1 |
| Suetani, S | 1 |
| Kisely, S | 2 |
| Winckel, K | 1 |
| Baker, A | 1 |
| Chang, HH | 1 |
| Moro, A | 1 |
| Chou, CEN | 1 |
| Dawson, DW | 1 |
| French, S | 1 |
| Schmidt, AI | 1 |
| Sinnett-Smith, J | 1 |
| Hao, F | 1 |
| Hines, OJ | 1 |
| Eibl, G | 1 |
| Rozengurt, E | 1 |
| Nicodemus, NA | 1 |
| Naguy, A | 1 |
| El-Sori, D | 1 |
| Guo, L | 1 |
| Chang, B | 1 |
| Yang, L | 1 |
| Liu, Y | 1 |
| Feng, B | 1 |
| López, M | 1 |
| Ellul, P | 1 |
| Delorme, R | 1 |
| Cortese, S | 1 |
| Higdon, C | 1 |
| Correll, CU | 2 |
| Crystal, S | 1 |
| Patel, N | 1 |
| DelBello, MP | 1 |
| Handen, BL | 3 |
| Veenstra-VanderWeele, J | 3 |
| Anagnostou, E | 2 |
| Aman, MG | 3 |
| Gu, T | 1 |
| Ma, J | 1 |
| Zhang, Q | 1 |
| Zhu, L | 1 |
| Xu, L | 1 |
| Cheng, J | 1 |
| Shi, B | 1 |
| Li, D | 1 |
| Shao, J | 1 |
| Sun, Z | 1 |
| Zhong, S | 1 |
| Bi, Y | 1 |
| Currie, O | 1 |
| Williman, J | 1 |
| Mangin, D | 1 |
| McKinnon-Gee, B | 1 |
| Bridgford, P | 1 |
| Kim, SH | 1 |
| Abbasi, F | 1 |
| Garfunkel, D | 1 |
| Anagnostou, EA | 1 |
| Sanders, KB | 2 |
| Macklin, EA | 2 |
| Chan, J | 1 |
| Fonseca, V | 3 |
| McDuffie, R | 1 |
| Calles, J | 1 |
| Cohen, RM | 1 |
| Feeney, P | 1 |
| Feinglos, M | 1 |
| Gerstein, HC | 1 |
| Ismail-Beigi, F | 1 |
| Morgan, TM | 1 |
| Pop-Busui, R | 1 |
| Riddle, MC | 2 |
| Spaulonci, CP | 1 |
| Bernardes, LS | 1 |
| Trindade, TC | 1 |
| Zugaib, M | 1 |
| Francisco, RP | 1 |
| Rosenstock, J | 2 |
| Wilson, C | 2 |
| Fleck, P | 2 |
| Bader, G | 1 |
| Geransar, P | 1 |
| Schweizer, A | 1 |
| Jarskog, LF | 2 |
| Hamer, RM | 1 |
| Catellier, DJ | 1 |
| Stewart, DD | 1 |
| Lavange, L | 1 |
| Ray, N | 1 |
| Golden, LH | 1 |
| Lieberman, JA | 1 |
| Stroup, TS | 2 |
| Howland, RH | 1 |
| Sikich, L | 1 |
| Reeves, G | 1 |
| Riddle, M | 1 |
| Gadéa, É | 1 |
| Thivat, É | 1 |
| Wang-Lopez, Q | 1 |
| Viala, M | 1 |
| Paulon, R | 1 |
| Planchat, É | 1 |
| Chadeyras, JB | 1 |
| Merlin, C | 1 |
| Coudert, B | 1 |
| Bignon, YJ | 1 |
| Morio, B | 1 |
| Durando, X | 1 |
| Soliman, AR | 1 |
| Fathy, A | 1 |
| Khashab, S | 1 |
| Shaheen, N | 1 |
| Soliman, MA | 1 |
| Haluzík, M | 1 |
| Veselá, V | 1 |
| Gerle, J | 1 |
| Brada, M | 1 |
| Dohnalová, L | 1 |
| Edelsberger, T | 1 |
| Houdová, J | 1 |
| Rosenfeld, JE | 1 |
| Valerón, PF | 1 |
| de Pablos-Velasco, PL | 1 |
| Hu, Y | 1 |
| Young, AJ | 1 |
| Ehli, EA | 1 |
| Nowotny, D | 1 |
| Davies, PS | 1 |
| Droke, EA | 1 |
| Soundy, TJ | 1 |
| Davies, GE | 1 |
| Tek, C | 1 |
| Chwastiak, L | 1 |
| DePaoli, AM | 1 |
| Higgins, LS | 1 |
| Henry, RR | 1 |
| Mantzoros, C | 1 |
| Dunn, FL | 1 |
| Bajaj, M | 1 |
| Gilman, R | 1 |
| Patel, S | 2 |
| Kempthorne-Rawson, J | 1 |
| Lewis-D'Agostino, D | 1 |
| Woerle, HJ | 2 |
| Derosa, G | 1 |
| Bonaventura, A | 1 |
| Bianchi, L | 1 |
| Romano, D | 1 |
| Fogari, E | 1 |
| D'Angelo, A | 1 |
| Maffioli, P | 1 |
| Glintborg, D | 1 |
| Mumm, H | 1 |
| Altinok, ML | 1 |
| Richelsen, B | 1 |
| Bruun, JM | 1 |
| Andersen, M | 1 |
| Astiz, S | 1 |
| Gonzalez-Bulnes, A | 1 |
| Astiz, I | 1 |
| Barbero, A | 1 |
| Perez-Solana, ML | 1 |
| Garcia-Real, I | 1 |
| Bell, K | 1 |
| Parasuraman, S | 1 |
| Shah, M | 1 |
| Raju, A | 1 |
| Graham, J | 1 |
| Lamerato, L | 1 |
| D'Souza, A | 1 |
| Kurzthaler, D | 1 |
| Hadziomerovic-Pekic, D | 1 |
| Wildt, L | 1 |
| Seeber, BE | 1 |
| Linneke, JL | 1 |
| Jørgensen, GK | 1 |
| Csillag, C | 1 |
| Abdul-Ghani, MA | 1 |
| Puckett, C | 1 |
| Triplitt, C | 2 |
| Maggs, D | 2 |
| Adams, J | 1 |
| Cersosimo, E | 1 |
| DeFronzo, RA | 2 |
| Mushlin, AI | 1 |
| Jeve, YB | 1 |
| Konje, JC | 1 |
| Doshani, A | 1 |
| Ainuddin, J | 1 |
| Karim, N | 2 |
| Hasan, AA | 2 |
| Naqvi, SA | 1 |
| Abegg, K | 1 |
| Corteville, C | 1 |
| Docherty, NG | 1 |
| Boza, C | 1 |
| Lutz, TA | 1 |
| Muñoz, R | 1 |
| le Roux, CW | 1 |
| Li, G | 1 |
| Zhao, S | 1 |
| Cui, S | 1 |
| Li, L | 1 |
| Xu, Y | 1 |
| Li, Y | 2 |
| Tanaka, K | 1 |
| Saisho, Y | 1 |
| Kawai, T | 2 |
| Tanaka, M | 1 |
| Meguro, S | 1 |
| Irie, J | 1 |
| Imai, T | 1 |
| Shigihara, T | 1 |
| Morimoto, J | 1 |
| Yajima, K | 1 |
| Atsumi, Y | 2 |
| Takei, I | 1 |
| Itoh, H | 2 |
| Spritzer, PM | 1 |
| Motta, AB | 1 |
| Sir-Petermann, T | 1 |
| Diamanti-Kandarakis, E | 1 |
| Ainuddin, JA | 1 |
| Zaheer, S | 1 |
| Ali, SS | 1 |
| Li, XB | 1 |
| Tang, YL | 1 |
| Xiang, YQ | 1 |
| Wang, CY | 1 |
| de Leon, J | 1 |
| Dungan, KM | 1 |
| Raz, I | 1 |
| Skrivanek, Z | 1 |
| Sealls, W | 1 |
| Fahrbach, JL | 1 |
| Salau, M | 1 |
| Adam, B | 1 |
| Jesus, C | 1 |
| Jesus, I | 1 |
| Agius, M | 1 |
| de Silva, VA | 2 |
| Dayabandara, M | 2 |
| Wijesundara, H | 1 |
| Henegama, T | 1 |
| Gunewardena, H | 1 |
| Suraweera, C | 2 |
| Hanwella, R | 2 |
| Reid, T | 1 |
| Gao, L | 1 |
| Gill, J | 1 |
| Stuhr, A | 1 |
| Traylor, L | 1 |
| Vlajnic, A | 2 |
| Rhinehart, A | 1 |
| Durán-Garcia, S | 1 |
| Lee, J | 1 |
| Yki-Järvinen, H | 6 |
| Hehnke, U | 1 |
| Thiemann, S | 1 |
| Mogul, H | 1 |
| Freeman, R | 1 |
| Nguyen, K | 1 |
| Zhang, FY | 1 |
| Gao, KM | 1 |
| Ou, JJ | 2 |
| Shao, P | 3 |
| Jin, H | 3 |
| Guo, WB | 2 |
| Chan, PK | 2 |
| Zhao, JP | 4 |
| Syngelaki, A | 1 |
| Nicolaides, KH | 1 |
| Balani, J | 2 |
| Hyer, S | 2 |
| Akolekar, R | 1 |
| Kotecha, R | 1 |
| Pastides, A | 1 |
| Shehata, H | 2 |
| Del Prato, S | 1 |
| Chaudhari, P | 1 |
| Rado, J | 1 |
| von Ammon Cavanaugh, S | 1 |
| McFadden, M | 1 |
| Gordon, A | 1 |
| Leong, G | 1 |
| Ward, D | 1 |
| Scott, JG | 1 |
| Pérez Manghi, F | 1 |
| García-Hernández, P | 1 |
| Norwood, P | 1 |
| Lehmann, L | 1 |
| Tarp-Johansen, MJ | 1 |
| Buse, JB | 1 |
| Cichosz, SL | 1 |
| Lundby-Christensen, L | 1 |
| Johansen, MD | 1 |
| Tarnow, L | 2 |
| Almdal, TP | 1 |
| Hejlesen, OK | 1 |
| Galligan, A | 1 |
| Greenaway, TM | 1 |
| Schwartz, SS | 1 |
| Jellinger, PS | 2 |
| Herman, ME | 1 |
| Siskind, DJ | 1 |
| Leung, J | 1 |
| Russell, AW | 1 |
| Wysoczanski, D | 1 |
| Smith, JD | 1 |
| Mills, E | 1 |
| Carlisle, SE | 1 |
| Sahin, M | 1 |
| Corapcioglu, D | 1 |
| Stanford, FC | 1 |
| Alfaris, N | 1 |
| Misra, M | 1 |
| Mennella, C | 1 |
| Dickstein, DP | 1 |
| Feng, Y | 1 |
| Yang, H | 1 |
| Sharma, AM | 1 |
| Shui, A | 1 |
| Hollway, JA | 1 |
| Brian, J | 1 |
| Arnold, LE | 1 |
| Capano, L | 1 |
| Hellings, JA | 1 |
| Butter, E | 1 |
| Mankad, D | 1 |
| Tumuluru, R | 1 |
| Kettel, J | 1 |
| Newsom, CR | 1 |
| Hadjiyannakis, S | 1 |
| Peleg, N | 1 |
| Odrobina, D | 1 |
| McAuliffe-Bellin, S | 1 |
| Zakroysky, P | 1 |
| Marler, S | 1 |
| Wagner, A | 1 |
| Wong, T | 1 |
| Ratnatunga, SS | 1 |
| Wanniarachchi, N | 1 |
| Chen, YH | 1 |
| Tarng, DC | 1 |
| Chen, HS | 1 |
| Funae, O | 1 |
| Shimada, A | 1 |
| Tabata, M | 1 |
| Hirata, T | 1 |
| Kapoor, S | 1 |
| Arman, S | 1 |
| Sadramely, MR | 1 |
| Nadi, M | 1 |
| Koleini, N | 1 |
| Esposito, K | 1 |
| Ciotola, M | 1 |
| Maiorino, MI | 1 |
| Gualdiero, R | 1 |
| Schisano, B | 1 |
| Ceriello, A | 1 |
| Beneduce, F | 1 |
| Feola, G | 1 |
| Giugliano, D | 1 |
| Brooks, JO | 1 |
| Chang, HS | 1 |
| Krasnykh, O | 1 |
| Gupta, AK | 1 |
| Smith, SR | 1 |
| Greenway, FL | 1 |
| Bray, GA | 1 |
| de Jager, J | 1 |
| Bets, D | 1 |
| Wulffelé, MG | 1 |
| Donker, AJ | 1 |
| Stehouwer, CD | 1 |
| Miller, LJ | 1 |
| Casteels, K | 1 |
| Fieuws, S | 1 |
| van Helvoirt, M | 1 |
| Verpoorten, C | 1 |
| Goemans, N | 1 |
| Coudyzer, W | 1 |
| Loeckx, D | 1 |
| Bolli, G | 1 |
| Dotta, F | 1 |
| Colin, L | 1 |
| Minic, B | 1 |
| Goodman, M | 1 |
| Shin, L | 2 |
| Bregman, H | 2 |
| Breeze, JL | 1 |
| Noyes, N | 2 |
| Frazier, JA | 1 |
| Mitri, J | 1 |
| Hamdy, O | 1 |
| Zhang, JL | 1 |
| Zheng, X | 1 |
| Zou, DJ | 1 |
| Qiu, JL | 1 |
| Zhao, XX | 1 |
| Qin, YW | 1 |
| Blonde, L | 1 |
| Dagogo-Jack, S | 1 |
| Banerji, MA | 1 |
| Pratley, RE | 1 |
| Marcellari, A | 1 |
| Braceras, R | 1 |
| Purkayastha, D | 1 |
| Baron, M | 1 |
| Davis, SN | 1 |
| Kahn, SE | 3 |
| Haffner, SM | 2 |
| Viberti, G | 2 |
| Herman, WH | 2 |
| Lachin, JM | 2 |
| Kravitz, BG | 2 |
| Yu, D | 1 |
| Paul, G | 1 |
| Holman, RR | 5 |
| Zinman, B | 3 |
| Bushe, CJ | 1 |
| Bradley, AJ | 1 |
| Doshi, S | 1 |
| Karagianis, J | 1 |
| Farmer, AJ | 2 |
| Davies, MJ | 3 |
| Levy, JC | 2 |
| Darbyshire, JL | 1 |
| Keenan, JF | 2 |
| Paul, SK | 1 |
| Lund, SS | 2 |
| Frandsen, M | 1 |
| Nielsen, BB | 1 |
| Hansen, BV | 1 |
| Pedersen, O | 1 |
| Parving, HH | 1 |
| Vaag, AA | 1 |
| Housel, AK | 1 |
| Waterbury, N | 1 |
| Argo, TR | 1 |
| Björkhem-Bergman, L | 1 |
| Asplund, AB | 1 |
| Lindh, JD | 1 |
| Qu, Y | 2 |
| Lewis, MS | 1 |
| Glass, LC | 2 |
| Hasnain, M | 1 |
| Vieweg, WV | 1 |
| Fredrickson, SK | 1 |
| Ellinger, LK | 1 |
| Ipema, HJ | 1 |
| Stachnik, JM | 1 |
| Phung, OJ | 1 |
| Scholle, JM | 1 |
| Talwar, M | 1 |
| Coleman, CI | 1 |
| Weaver, LA | 1 |
| De León, DD | 1 |
| Borgmann-Winter, K | 1 |
| Winsberg, B | 1 |
| Yeager, C | 1 |
| Hobbs, B | 1 |
| Wei, R | 1 |
| Elangovan, N | 1 |
| Matsui, Y | 1 |
| Hirasawa, Y | 1 |
| Sugiura, T | 1 |
| Toyoshi, T | 1 |
| Kyuki, K | 1 |
| Ito, M | 1 |
| Hou, M | 1 |
| Venier, N | 1 |
| Sugar, L | 1 |
| Musquera, M | 1 |
| Pollak, M | 2 |
| Kiss, A | 1 |
| Fleshner, N | 1 |
| Klotz, L | 1 |
| Venkateswaran, V | 1 |
| Matthews, DR | 1 |
| Dejager, S | 1 |
| Ahren, B | 1 |
| Ferrannini, E | 1 |
| Couturier, A | 1 |
| Foley, JE | 1 |
| Rodbard, HW | 1 |
| Pramyothin, P | 1 |
| Khaodhiar, L | 1 |
| Lee, HH | 1 |
| Yeh, CH | 1 |
| Chen, YT | 1 |
| Chi, TC | 1 |
| Cheng, JT | 1 |
| Lo, SH | 1 |
| Oldham, J | 1 |
| Swinnen, SG | 1 |
| Dain, MP | 1 |
| Mauricio, D | 1 |
| DeVries, JH | 1 |
| Hoekstra, JB | 1 |
| Holleman, F | 1 |
| Jansen, HJ | 1 |
| Vervoort, G | 1 |
| van der Graaf, M | 1 |
| Tack, CJ | 1 |
| Petrie, JR | 1 |
| Adler, A | 1 |
| Vella, S | 1 |
| Levit, S | 1 |
| Toledano, Y | 1 |
| Wainstein, J | 1 |
| Robinson, LA | 1 |
| Penzner, JB | 1 |
| Arkow, S | 1 |
| Kahn, DA | 1 |
| Berman, JA | 1 |
| Praharaj, SK | 1 |
| Jana, AK | 1 |
| Goyal, N | 1 |
| Sinha, VK | 1 |
| Vudhironarit, T | 1 |
| Patarakitvanit, S | 1 |
| Temboonkiat, S | 1 |
| Satyapan, N | 1 |
| Monami, M | 1 |
| Cremasco, F | 1 |
| Lamanna, C | 1 |
| Marchionni, N | 1 |
| Mannucci, E | 1 |
| Bannon, M | 1 |
| Lee, YJ | 2 |
| Jeong, JH | 1 |
| Seck, TL | 1 |
| Engel, SS | 1 |
| Williams-Herman, DE | 1 |
| Sisk, CM | 1 |
| Golm, GT | 1 |
| Wang, H | 1 |
| Kaufman, KD | 1 |
| Goldstein, BJ | 1 |
| Gross, JL | 1 |
| Kramer, CK | 1 |
| Leitão, CB | 1 |
| Hawkins, N | 1 |
| Viana, LV | 1 |
| Schaan, BD | 1 |
| Pinto, LC | 1 |
| Rodrigues, TC | 1 |
| Azevedo, MJ | 1 |
| Adeneye, AA | 1 |
| Agbaje, EO | 1 |
| Olagunju, JA | 1 |
| Hoffmann, VP | 1 |
| Case, M | 1 |
| Jacobson, JG | 1 |
| Petznick, A | 1 |
| Reid, TS | 1 |
| Newall, H | 2 |
| Myles, N | 2 |
| Ward, PB | 1 |
| Samaras, K | 2 |
| Shiers, D | 2 |
| Curtis, J | 2 |
| Gu, Y | 1 |
| Hou, X | 1 |
| Zhang, L | 1 |
| Pan, J | 1 |
| Cai, Q | 1 |
| Bao, Y | 1 |
| Jia, W | 1 |
| Mathiesen, ER | 1 |
| Ringholm, L | 1 |
| Damm, P | 1 |
| Delahanty, LM | 1 |
| Pan, Q | 1 |
| Jablonski, KA | 1 |
| Watson, KE | 1 |
| McCaffery, JM | 1 |
| Shuldiner, A | 1 |
| Knowler, WC | 1 |
| Franks, PW | 1 |
| Reyes-Morales, H | 1 |
| Mino-León, D | 1 |
| Doubova, SV | 1 |
| Flores-Hernández, S | 1 |
| Scheen, AJ | 1 |
| Laffel, L | 1 |
| Chang, N | 1 |
| Grey, M | 1 |
| Hale, D | 1 |
| Higgins, L | 1 |
| Hirst, K | 1 |
| Izquierdo, R | 1 |
| Larkin, M | 1 |
| Macha, C | 1 |
| Pham, T | 1 |
| Wauters, A | 1 |
| Weinstock, RS | 1 |
| Wang, M | 1 |
| Tong, JH | 1 |
| Zhu, G | 1 |
| Liang, GM | 1 |
| Yan, HF | 1 |
| Wang, XZ | 1 |
| Lund, A | 1 |
| Knop, FK | 1 |
| Silva, JC | 1 |
| Fachin, DR | 1 |
| Coral, ML | 1 |
| Bertini, AM | 1 |
| Hemmingsen, B | 1 |
| Christensen, LL | 1 |
| Wetterslev, J | 1 |
| Vaag, A | 1 |
| Gluud, C | 1 |
| Almdal, T | 1 |
| Gao, K | 1 |
| Twamley, EW | 1 |
| Wang, J | 1 |
| Guo, XF | 3 |
| Davis, JM | 1 |
| Smith, RC | 1 |
| Singh-Franco, D | 1 |
| Elrod, S | 1 |
| Harrington, C | 1 |
| McLaughlin-Middlekauff, J | 1 |
| Niromanesh, S | 1 |
| Alavi, A | 1 |
| Sharbaf, FR | 1 |
| Amjadi, N | 1 |
| Moosavi, S | 1 |
| Akbari, S | 1 |
| Carlsen, SM | 1 |
| Martinussen, MP | 1 |
| Bergenstal, RM | 2 |
| Porter, TK | 1 |
| Weaver, C | 1 |
| Han, J | 1 |
| Werneke, U | 1 |
| Taylor, D | 1 |
| Sanders, TA | 1 |
| Hamilton, J | 1 |
| Cummings, E | 1 |
| Zdravkovic, V | 1 |
| Finegood, D | 1 |
| Daneman, D | 1 |
| Gunton, JE | 1 |
| Twigg, SM | 1 |
| Furlong, NJ | 1 |
| Hulme, SA | 1 |
| O'Brien, SV | 1 |
| Hardy, KJ | 1 |
| Nesto, RW | 1 |
| Bell, D | 1 |
| Bonow, RO | 1 |
| Grundy, SM | 1 |
| Horton, ES | 1 |
| Le Winter, M | 1 |
| Porte, D | 1 |
| Semenkovich, CF | 1 |
| Smith, S | 1 |
| Young, LH | 1 |
| Kahn, R | 1 |
| de Boer, H | 2 |
| Jansen, M | 2 |
| Koerts, J | 1 |
| Verschoor, L | 2 |
| Yasuda, N | 1 |
| Inoue, T | 1 |
| Nagakura, T | 1 |
| Yamazaki, K | 1 |
| Kira, K | 1 |
| Saeki, T | 1 |
| Tanaka, I | 1 |
| Chen, XP | 1 |
| Yang, WY | 1 |
| Bu, S | 1 |
| Xiao, JZ | 1 |
| Liu, XL | 1 |
| Wang, N | 1 |
| Zhao, WH | 1 |
| Strowig, SM | 1 |
| Avilés-Santa, ML | 1 |
| Raskin, P | 3 |
| Janka, HU | 2 |
| Plewe, G | 2 |
| Kliebe-Frisch, C | 1 |
| Schweitzer, MA | 1 |
| Malone, JK | 1 |
| Bai, S | 1 |
| Campaigne, BN | 1 |
| Reviriego, J | 1 |
| Augendre-Ferrante, B | 1 |
| Douek, IF | 1 |
| Allen, SE | 1 |
| Ewings, P | 1 |
| Gale, EA | 1 |
| Bingley, PJ | 1 |
| Lester, JW | 1 |
| Fernandes, AW | 1 |
| Dhahbi, JM | 1 |
| Mote, PL | 1 |
| Fahy, GM | 1 |
| Spindler, SR | 1 |
| Bell, DS | 1 |
| Ovalle, F | 1 |
| Heald, AH | 1 |
| Kärvestedt, L | 1 |
| Anderson, SG | 1 |
| McLaughlin, J | 1 |
| Knowles, A | 1 |
| Wong, L | 1 |
| Grill, V | 1 |
| Cruickshank, JK | 1 |
| White, A | 1 |
| Gibson, JM | 1 |
| Brismar, K | 1 |
| Chaudhry, ZW | 1 |
| Gannon, MC | 1 |
| Nuttall, FQ | 1 |
| Baptista, T | 2 |
| Martínez, J | 1 |
| Lacruz, A | 1 |
| Rangel, N | 2 |
| Beaulieu, S | 2 |
| Arapé, Y | 1 |
| Martinez, M | 1 |
| de Mendoza, S | 1 |
| Teneud, L | 1 |
| Hernández, L | 1 |
| Keizers, R | 1 |
| Ruineman-Koerts, J | 1 |
| Alisky, JM | 1 |
| Biesenbach, G | 1 |
| Raml, A | 1 |
| Alsaraji, N | 1 |
| Hamann, A | 1 |
| Heise, MA | 1 |
| Jones, NP | 1 |
| O'Neill, MC | 1 |
| Nathan, DM | 1 |
| Towbin, KE | 1 |
| Klein, DJ | 1 |
| Cottingham, EM | 1 |
| Sorter, M | 1 |
| Barton, BA | 1 |
| Morrison, JA | 1 |
| Nichols, GA | 1 |
| Gomez-Caminero, A | 1 |
| Busch, K | 1 |
| Jacob, AN | 1 |
| Salinas, K | 1 |
| Adams-Huet, B | 1 |
| Gottschalk, M | 1 |
| Danne, T | 1 |
| Cara, JF | 1 |
| Thaware, PK | 1 |
| Tringham, JR | 1 |
| Howe, J | 1 |
| Jarvis, J | 1 |
| Johnston, V | 1 |
| Kitchener, DL | 1 |
| Skinner, TC | 1 |
| McNally, PG | 1 |
| Lawrence, IG | 1 |
| Choi, SH | 1 |
| Zhao, ZS | 1 |
| Kim, SK | 1 |
| Kim, DJ | 1 |
| Ahn, CW | 1 |
| Lim, SK | 1 |
| Lee, HC | 1 |
| Cha, BS | 1 |
| Civera, M | 1 |
| Merchante, A | 1 |
| Salvador, M | 1 |
| Sanz, J | 1 |
| Martínez, I | 1 |
| Thorne, KI | 1 |
| Paul, S | 1 |
| Tuthill, A | 1 |
| McKenna, MJ | 1 |
| O'Shea, D | 1 |
| McKenna, TJ | 1 |
| Ushakova, O | 1 |
| Sokolovskaya, V | 1 |
| Morozova, A | 1 |
| Valeeva, F | 1 |
| Zanozina, O | 1 |
| Sazonova, O | 1 |
| Zhadanova, E | 1 |
| Starceva, M | 1 |
| Kazakova, E | 1 |
| Saifullina, M | 1 |
| Shapiro, I | 1 |
| Tarasov, A | 1 |
| Al-Tayar, B | 1 |
| Starkova, N | 1 |
| Fang, MS | 2 |
| He, YQ | 2 |
| Liu, YJ | 1 |
| Chen, JD | 2 |
| Li, LH | 2 |
| Lenox, S | 1 |
| Kim, D | 1 |
| Gates, JR | 1 |
| Brodows, R | 1 |
| Trautmann, M | 1 |
| Massi-Benedetti, M | 1 |
| Orsini-Federici, M | 1 |
| Uzcátegui, E | 1 |
| El Fakih, Y | 1 |
| Galeazzi, T | 1 |
| de Baptista, EA | 1 |
| Frazier, J | 1 |
| Venkatasubramanian, G | 1 |
| Belsey, J | 1 |
| Krishnarajah, G | 1 |
| Algire, C | 1 |
| Zakikhani, M | 1 |
| Blouin, MJ | 1 |
| Shuai, JH | 1 |
| Rouru, J | 2 |
| Isaksson, K | 1 |
| Santti, E | 1 |
| Huupponen, R | 2 |
| Koulu, M | 2 |
| Turner, RC | 1 |
| Savontaus, E | 1 |
| Boss, O | 1 |
| Relimpio, F | 1 |
| Pumar, A | 1 |
| Losada, F | 1 |
| Mangas, MA | 1 |
| Acosta, D | 1 |
| Astorga, R | 1 |
| Ryysy, L | 1 |
| Nikkilä, K | 3 |
| Tulokas, T | 1 |
| Vanamo, R | 1 |
| Heikkilä, M | 1 |
| Mäkimattila, S | 2 |
| Hermann, LS | 1 |
| Melander, A | 1 |
| Bailey, CJ | 1 |
| Livingstone, DE | 1 |
| Kenyon, CJ | 1 |
| Walker, BR | 1 |
| Kumar, VB | 1 |
| Bernardo, AE | 1 |
| Vyas, K | 1 |
| Franko, M | 1 |
| Farr, S | 1 |
| Lakshmanan, L | 1 |
| Buddhiraju, C | 1 |
| Morley, JE | 1 |
| Borst, SE | 1 |
| Snellen, HG | 1 |
| Ross, H | 1 |
| Scarpace, PJ | 1 |
| Kim, YW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome (PCOS)[NCT00159536] | Phase 3 | 257 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome: a Pilot Study[NCT03259919] | Phase 2 | 40 participants (Actual) | Interventional | 2000-10-31 | Completed | ||
| A Randomized, 24 Week, Active-controlled, Open-label, 3-arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to Insulin Glargine and Lixisenatide in Type 2 Diabetes Mellitus Patients Insufficiently Controlled With Oral Anti[NCT03798054] | Phase 3 | 878 participants (Actual) | Interventional | 2019-02-15 | Completed | ||
| A Randomised Placebo Controlled Trial of the Effectiveness of Early MEtformin in Addition to Usual Care in the Reduction of Gestational Diabetes Mellitus Effects (EMERGE)[NCT02980276] | Phase 3 | 535 participants (Actual) | Interventional | 2017-06-06 | Completed | ||
| A Comparison of Bupropion SR and Placebo for Smoking Cessation[NCT00176449] | Phase 4 | 52 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V - Basal Insulin Switch)[NCT01952145] | Phase 3 | 557 participants (Actual) | Interventional | 2013-09-20 | Completed | ||
| Study of Metformin HCL in Patients With Type 2 Diabetes Intensively Treated With Insulin: a Treatment Strategy for Insulin Resistance in Type 2 Diabetes Mellitus: a Randomized Controlled Trial[NCT00375388] | Phase 3 | 400 participants | Interventional | 1998-01-31 | Completed | ||
| Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513] | 414 participants (Anticipated) | Interventional | 2022-03-24 | Not yet recruiting | |||
| Efficacy and Safety of Saxagliptin and Glimepiride in Chinese Patients With Type 2 Diabetes Controlled Inadequately With Metformin Monotherapy (SPECIFY Study) : a 48-week, Multi-center, Randomized, Open-label Trial[NCT02280486] | Phase 4 | 388 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| Action to Control Cardiovascular Risk in Diabetes (ACCORD)[NCT00000620] | Phase 3 | 10,251 participants (Actual) | Interventional | 1999-09-30 | Completed | ||
| Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS) - Pilot Study[NCT00816907] | Phase 4 | 146 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Metformin and Lorcaserin for Weight Loss in Schizophrenia[NCT02796144] | Phase 4 | 71 participants (Actual) | Interventional | 2016-09-30 | Terminated (stopped due to The FDA advised of a possible health risk associated with lorcaserin and the drug is being withdrawn.) | ||
| Effect of Empagliflozin Versus Linagliptin on Glycemic Outcomes, Renal Outcomes and Body Composition in Renal Transplant Recipients With Diabetes Mellitus: Randomized Controlled Trial[NCT06098625] | 200 participants (Anticipated) | Interventional | 2023-11-10 | Not yet recruiting | |||
| Effect of Empagliflozin Versus Linagliptin on Glycemic Outcomes, Renal Outcomes and Body Composition in Renal Transplant Recipients With Diabetes Mellitus: Randomized Controlled Trial (EmLina Renal Trial)[NCT06095492] | 200 participants (Anticipated) | Interventional | 2023-10-30 | Recruiting | |||
| A Double-blind, Randomized, Placebo-controlled Trial of Berberine as an Adjuvant to Treat Antipsychotic-induced Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders[NCT02983188] | Phase 2/Phase 3 | 113 participants (Actual) | Interventional | 2018-04-25 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of INT131 Besylate Compared to Pioglitazone in Subjects With Type 2 Diabetes[NCT00631007] | Phase 2 | 367 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metfor[NCT00996658] | Phase 3 | 278 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Metformin and Oral Contraceptives in PCOS[NCT00451568] | Phase 4 | 90 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes[NCT02946632] | Phase 3 | 104 participants (Anticipated) | Interventional | 2016-12-31 | Not yet recruiting | ||
| A 16-wk, Uni-center, Randomized, Double-blind, Parallel, Phase 3b Trial to Evaluate Efficacy of Saxagliptin + Dapagliflozin vs.Dapagliflozin With Regard to EGP in T2DM With Insufficient Glycemic Control on Metformin+/-Sulfonylurea Therapy[NCT02613897] | 56 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction[NCT03658031] | Phase 3 | 576 participants (Anticipated) | Interventional | 2019-03-01 | Not yet recruiting | ||
| Metformin in Gestational Diabetes and type2 Diabetes in Pregnancy in a Developing Country[NCT01855763] | Phase 2/Phase 3 | 300 participants (Actual) | Interventional | 2008-12-31 | Active, not recruiting | ||
| Effect of Adding Metformin to Insulin in Uncontrolled Diabetic Patients During the 3rd Trimester of Pregnancy on Glycemic Control, Fetal and Neonatal Outcomes ,Randomized Controlled Trial[NCT05479214] | Phase 4 | 150 participants (Actual) | Interventional | 2022-07-29 | Completed | ||
| Efficacy and Safety of Add-on Topiramate vs Metformin on Cardio-Metabolic Profile in Patients With Schizophrenia on Atypical Antipsychotics With Metabolic Syndrome: a Randomized Controlled Trial[NCT05663749] | Phase 4 | 60 participants (Actual) | Interventional | 2022-09-20 | Completed | ||
| EMPOWIR: Enhance the Metabolic Profile of Women With Insulin Resistance: Carbohydrate Modified Diet Alone and in Combination With Metformin or Metformin Plus Avandia in Non-diabetic Women With Midlife Weight Gain and Documented Insulin Elevations (Syndrom[NCT00618072] | Phase 2 | 46 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Does Metformin Improve Pregnancy Outcomes (Incidence of LGA (≥90% Birth Weight Centile) Babies, Onset of Maternal GDM, Hypertension, PET, Macrosomia, Shoulder Dystocia, Admission to SCBU) in Obese Non-diabetic Women?[NCT01273584] | Phase 2/Phase 3 | 450 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Aspirin Versus Metformin in Pregnancies at High Risk of Preterm Preeclampsia: a 3-arm Randomized Controlled Trial[NCT05580523] | 3,000 participants (Anticipated) | Interventional | 2023-07-03 | Recruiting | |||
| Use of Metformin in Prevention and Treatment of Cardiac Fibrosis in PAI-1 Deficient Population[NCT05317806] | Phase 4 | 15 participants (Anticipated) | Interventional | 2022-10-10 | Active, not recruiting | ||
| A Feasibility and Acceptability Study of Elevated Protein Dietary Intake for Children Diagnosed With Autism Spectrum Disorder (ASD) While on Atypical Antipsychotic Medication[NCT03708614] | 10 participants (Anticipated) | Interventional | 2018-12-07 | Recruiting | |||
| Efficacy of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder[NCT05916339] | Phase 4 | 500 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)[NCT01825798] | Phase 3 | 60 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy[NCT01175486] | Phase 4 | 200 participants (Anticipated) | Interventional | 2010-07-31 | Recruiting | ||
| A Portion-controlled Diet Will Prevent Weight Gain in Diabetics Treated With ACTOS[NCT00219440] | Phase 4 | 60 participants (Anticipated) | Interventional | 2003-02-28 | Completed | ||
| Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes[NCT04943692] | Phase 3 | 500 participants (Anticipated) | Interventional | 2021-08-31 | Suspended (stopped due to Administrative decision of the investigation direction) | ||
| A Multi-center, Randomized, Open-label, Active Controlled, Parallel Arm Study to Compare the Efficacy of 12 Weeks of Treatment With Vildagliptin 100 mg, qd to Thiazolidinedione (TZD) as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controll[NCT00396227] | Phase 3 | 2,665 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed [NCT00279045] | Phase 3 | 4,426 participants (Actual) | Interventional | 2000-01-03 | Completed | ||
| A 36-month, Multi-centre, Open-label, Randomised, Parallel-group Trial Comparing the Safety, Efficacy and Durability of Adding a Basal Insulin Versus a Twice Daily Insulin Mixture Versus a Meal-time Rapid-Acting Insulin in Subjects With Type 2 Diabetes In[NCT00184600] | Phase 3 | 708 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Effect of Repaglinide Versus Metformin Treatment in Combination With Insulin Biasp30 (Novologmix 70/30) Predinner on Glycemic and Non-Glycemic Cardiovascular Risk-Factors in Non-Obese Patients With Type-2-Diabetes With Unsatisfactory Glycaemic Control Wit[NCT00118963] | Phase 4 | 102 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| An Evaluation of the Metabolic Effects of Exenatide, Rosiglitazone, and Exenatide Plus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin[NCT00135330] | Phase 3 | 137 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| The Effects of Saxagliptin 5mg, Once Daily for 52 Weeks on 24 Hour Urine Albumin Creatinine Rate(ACR) , in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin or/and Acarbose[NCT02462369] | Phase 4 | 88 participants (Anticipated) | Interventional | 2015-06-30 | Enrolling by invitation | ||
| Safety and Efficacy of Metformin Glycinate vs Metformin Hydrochloride on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes Patients[NCT01386671] | Phase 3 | 203 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function[NCT02377388] | Phase 3 | 74 participants (Actual) | Interventional | 2017-02-07 | Completed | ||
| Open-label, Flexible-dose Adjunctive Bromocriptine for Patients With Schizophrenia and Impaired Glucose Tolerance[NCT03575000] | Phase 4 | 20 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy[NCT00094770] | Phase 3 | 1,172 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| The Assessment of the Safety, Efficacy, and Practicality of an Algorithm Including Amantadine, Metformin and Zonisamide for the Prevention of Olanzapine-Associated Weight Gain in Outpatients With Schizophrenia[NCT00401973] | Phase 3 | 199 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A 12 Week, Parallel, Open-label, Randomized, Multi-center Study Evaluating Use, Safety and Effectiveness of a Web Based Tool vs. Enhanced Usual Therapy of Glargine Titration in T2DM Patients With a 4 Week Safety Extension[NCT02540486] | 139 participants (Actual) | Interventional | 2013-12-31 | Completed | |||
| [NCT00004992] | Phase 3 | 3,234 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial[NCT00081328] | Phase 3 | 699 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Glyburide and Metformin for the Treatment of Gestational Diabetes Mellitus. A Systematic Review and Meta-analysis of Randomized Controlled Trials Comparing These Drugs Either vs Insulin or vs Each Other.[NCT01998113] | 2,509 participants (Actual) | Observational | 2013-03-31 | Completed | |||
| A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes[NCT01881828] | Phase 3 | 164 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| The Influence of Rosiglitazone on the Diuretic Effect of Furosemide and Amiloride. A Double-blind Placebo Controlled Cross Over Study.[NCT00285805] | 13 participants (Actual) | Interventional | 2006-02-28 | Completed | |||
| New Approach to Treat Type II Diabetes Failing on Maximal Oral Treatment[NCT00151697] | Phase 3 | 150 participants (Anticipated) | Interventional | 2005-05-31 | Completed | ||
| Phase 4 Study of Comparison of Combination Therapy of Gliclazide MR and Basal Insulin With Pre-mix Insulin Monotherapy for the Patients With Type 2 Diabetes Mellitus[NCT00736515] | Phase 4 | 160 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Prospective, Parallel Goups Study, Aimed to Evaluating Possible Benefits of the Treatment of New Generation Hypoglycaemic Drugs Compared to Sulphonylureas for the Tratment of Type 2 Diabetes Mellitus[NCT04272359] | 138 participants (Anticipated) | Observational [Patient Registry] | 2019-05-06 | Recruiting | |||
| Impact of Rheumatoid Arthritis on Type 2 Diabetes Mellitus[NCT02639988] | 1,000 participants (Anticipated) | Observational | 2016-04-13 | Suspended | |||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Adaptive Study for Efficacy and Safety of Metformin Glycinate for the Treatment of Patients With MS and DM2, Hospitalized With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb.[NCT04626089] | Phase 2 | 0 participants (Actual) | Interventional | 2021-02-28 | Withdrawn (stopped due to Administrative decision of the company) | ||
| Glimepiride Versus Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus: A Single Blind Comparison Study[NCT00353691] | Phase 3 | 100 participants | Interventional | 2002-10-31 | Completed | ||
| Effect of Biphasic Insulin Aspart 30 on Glycaemic Control in Subjects With Type 2 Diabetes[NCT00280046] | Phase 3 | 307 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain: a Randomized Double-Blind Placebo- Controlled Comparison[NCT00451399] | Phase 4 | 128 participants | Interventional | 2004-10-31 | Completed | ||
| Efficacy and Safety of Metformin in Preventing Patients With Risperidone From Weight Gain and Amenorrhea:a 24-week, Randomized, Placebo-controlled, Double-blind, Fixed-dose Study[NCT01423487] | 0 participants (Actual) | Interventional | 2011-08-31 | Withdrawn (stopped due to Difficult to obtain informed consent) | |||
| Efficacy/Safety Study of Adding Glimepiride to Type 2 Diabetes Patients With Inadequate Glycemic Control Based on Combination With Metformin And Basal Insulin[NCT02026310] | 40 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from baseline in body weight after 26 weeks of treatment (NCT01952145)
Timeframe: Week 0, week 26
| Intervention | Kg (Mean) |
|---|---|
| Insulin Degludec/Liraglutide (IDegLira) | -1.4 |
| Insulin Glargine (IGlar) | 1.8 |
Change from baseline in HbA1c after 26 weeks of treatment (NCT01952145)
Timeframe: Week 0, week 26
| Intervention | Percentage (%) (Mean) |
|---|---|
| Insulin Degludec/Liraglutide (IDegLira) | -1.81 |
| Insulin Glargine (IGlar) | -1.13 |
Confirmed hypoglycaemic episodes were defined as either: Severe (i.e., an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions) or an episode biochemically confirmed by a plasma glucose value of <3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia. (NCT01952145)
Timeframe: During 26 weeks of treatment
| Intervention | Number of episodes (Number) |
|---|---|
| Insulin Degludec/Liraglutide (IDegLira) | 289 |
| Insulin Glargine (IGlar) | 683 |
"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 391 |
| Glycemia Trial: Standard Control | 327 |
"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 503 |
| Glycemia Trial: Standard Control | 543 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 208 |
| BP Trial: Standard Control | 237 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 291 |
| Lipid Trial: Placebo | 310 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 641 |
| Lipid Trial: Placebo | 667 |
Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 36 |
| BP Trial: Standard Control | 62 |
fasting blood glucose (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -1.6 |
| Metformin | -2.3 |
Fasting insulin (NCT00816907)
Timeframe: 16 weeks
| Intervention | mU/L (Mean) |
|---|---|
| Placebo | 5.5 |
| Metformin | 1.6 |
high-density lipoprotein (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -0.4 |
| Metformin | -0.6 |
glycosylated hemoglobin (NCT00816907)
Timeframe: 16 weeks
| Intervention | percent (Least Squares Mean) |
|---|---|
| Placebo | 0.01 |
| Metformin | -0.06 |
low-density lipoprotein (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -2.0 |
| Metformin | -7.1 |
Total cholesterol (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo | 0.2 |
| Metformin | -8.9 |
serum triglycerides (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 13.2 |
| Metformin | -7.0 |
Mean difference in body weight change between participants assigned to metformin and participants assigned to placebo from baseline to last study visit (up to 16 weeks) (NCT00816907)
Timeframe: Measured at the last study visit
| Intervention | kilograms (Mean) |
|---|---|
| Placebo | -1.0 |
| Metformin | -3.0 |
Change in body weight in participants assigned to lorcaserin monotherapy treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin | -5.18 |
| Placebo | -3.02 |
Change in body weight in participants assigned to lorcaserin/metformin combination treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin and Metformin | -13.05 |
| Placebo | -3.02 |
fasting blood glucose (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -4.30 |
| Lorcaserin | -3.27 |
| Placebo | 3.53 |
high-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | 3.8 |
| Lorcaserin | 1.45 |
| Placebo | -0.78 |
glycosylated hemoglobin (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | percentage of glycosylated hemoglobin (Mean) |
|---|---|
| Lorcaserin and Metformin | -0.03 |
| Lorcaserin | 0.07 |
| Placebo | 0.05 |
low-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -7.60 |
| Lorcaserin | -10.86 |
| Placebo | -6.83 |
Total Cholesterol (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -9.05 |
| Lorcaserin | -13.45 |
| Placebo | -9.21 |
serum triglycerides (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -18.60 |
| Lorcaserin | -19.68 |
| Placebo | -3.11 |
The change from baseline reflects the Week 24 FPG minus the Week 0 FPG with last observation carried forward. (NCT00631007)
Timeframe: Weeks 0-24
| Intervention | mg/dL (Mean) |
|---|---|
| INT131 Besylate 0.5 mg | -0.3 |
| INT131 Besylate 1 mg | -14.6 |
| INT131 Besylate 2 mg | -28.9 |
| INT131 Besylate 3 mg | -26.9 |
| Pioglitazone HCl 45 mg | -33.2 |
| Placebo | 4.6 |
HbA1c is measured as percent. Thus this change from baseline reflects the week 24 HbA1c percent minus the Week 0 HbA1c percent (NCT00631007)
Timeframe: Weeks 0-24
| Intervention | Percernt (Mean) |
|---|---|
| INT131 Besylate 0.5 mg | -0.3 |
| INT131 Besylate 1 mg | -0.6 |
| INT131 Besylate 2 mg | -0.9 |
| INT131 Besylate 3 mg | -1.0 |
| Pioglitazone HCl 45 mg | -0.9 |
| Placebo | -0.1 |
Adjusted mean change in fasting plasma glucose (FPG) from baseline at week 12 (NCT00996658)
Timeframe: baseline, 12 weeks
| Intervention | mg/dL (milligrams per deciliter) (Least Squares Mean) |
|---|---|
| Placebo Tablet | 3.8 |
| Linagliptin 5 mg Tablet | -7.1 |
Adjusted mean change in fasting plasma glucose (FPG) from baseline at week 18 (NCT00996658)
Timeframe: baseline, 18 weeks
| Intervention | mg/dL (milligrams per deciliter) (Least Squares Mean) |
|---|---|
| Placebo Tablet | -2.4 |
| Linagliptin 5 mg Tablet | -8.6 |
Adjusted mean change in fasting plasma glucose (FPG) from baseline at week 24 (NCT00996658)
Timeframe: baseline, 24 weeks
| Intervention | mg/dL (milligrams per deciliter) (Least Squares Mean) |
|---|---|
| Placebo Tablet | 0.1 |
| Linagliptin 5 mg Tablet | -10.3 |
Adjusted mean change in fasting plasma glucose (FPG) from baseline at week 6 (NCT00996658)
Timeframe: baseline, 6 weeks
| Intervention | mg/dL (milligrams per deciliter) (Least Squares Mean) |
|---|---|
| Placebo Tablet | 12.4 |
| Linagliptin 5 mg Tablet | -3.3 |
Glycosylated hemoglobin is reported as a percentage of the total hemoglobin (NCT00996658)
Timeframe: baseline, 12 weeks
| Intervention | Percentage (Least Squares Mean) |
|---|---|
| Placebo Tablet | -0.28 |
| Linagliptin 5 mg Tablet | -0.82 |
Glycosylated hemoglobin is reported as a percentage of the total hemoglobin (NCT00996658)
Timeframe: baseline, 18 weeks
| Intervention | Percentage (Least Squares Mean) |
|---|---|
| Placebo Tablet | -0.37 |
| Linagliptin 5 mg Tablet | -0.91 |
Glycosylated hemoglobin is reported as a percentage of the total hemoglobin (NCT00996658)
Timeframe: baseline, 24 weeks
| Intervention | Percentage (Least Squares Mean) |
|---|---|
| Placebo Tablet | -0.27 |
| Linagliptin 5 mg Tablet | -0.84 |
Glycosylated hemoglobin is reported as a percentage of the total hemoglobin (NCT00996658)
Timeframe: baseline, 6 weeks
| Intervention | Percentage (Least Squares Mean) |
|---|---|
| Placebo Tablet | -0.19 |
| Linagliptin 5 mg Tablet | -0.60 |
Glycosylated hemoglobin is reported as a percentage of the total hemoglobin (NCT00996658)
Timeframe: 24 weeks
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Responder (HbA1c < 6.5%) | Non-responder (HbA1c >= 6.5%) | Missing | |
| Linagliptin 5 mg Tablet | 34 | 143 | 1 |
| Placebo Tablet | 5 | 84 | 0 |
Glycosylated hemoglobin is reported as a percentage of the total hemoglobin (NCT00996658)
Timeframe: 24 weeks
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Responder (HbA1c < 7.0%) | Non-responder (HbA1c >= 7.0%) | Missing | |
| Linagliptin 5 mg Tablet | 57 | 118 | 1 |
| Placebo Tablet | 12 | 75 | 0 |
Glycosylated hemoglobin is reported as a percentage of the total hemoglobin (NCT00996658)
Timeframe: 24 weeks
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Responder (reduction in HbA1c >= 0.5%) | Non-responder (reduction in HbA1c < 0.5%) | Missing | |
| Linagliptin 5 mg Tablet | 117 | 61 | 1 |
| Placebo Tablet | 44 | 45 | 0 |
Change in BMI (body mass index) from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | Kg/m^2 (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -0.8 |
| DAPA (Dapagliflozin Plus Placebo) | -0.66 |
| PCB (Placebo Plus Placebo) | 0.16 |
Change in body weight from baseline to 16 weeks (NCT02613897)
Timeframe: Baseline to 16 weeks
| Intervention | Kg (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -2.28 |
| DAPA (Dapagliflozin Plus Placebo) | -1.76 |
| PCB (Placebo Plus Placebo) | 0.26 |
A measure of the change in fasting plasma glucagon from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -28.52 |
| DAPA (Dapagliflozin Plus Placebo) | 26.89 |
| PCB (Placebo Plus Placebo) | 6.88 |
Measure of change in Free Fatty Acids from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mEq/L (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -0.06 |
| DAPA (Dapagliflozin Plus Placebo) | -0.01 |
| PCB (Placebo Plus Placebo) | 0.00 |
Change in percentage of glucose oxidation from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage of oxidation (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -22.07 |
| DAPA (Dapagliflozin Plus Placebo) | -46.54 |
| PCB (Placebo Plus Placebo) | 4.65 |
Change in lipid oxidation percentage from baseline to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage of oxidation (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -11.87 |
| DAPA (Dapagliflozin Plus Placebo) | 22.02 |
| PCB (Placebo Plus Placebo) | -6.69 |
Change in blood glucose level measured over a 3 month period from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage change in blood glucose level (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -1.67 |
| DAPA (Dapagliflozin Plus Placebo) | -1.46 |
| PCB (Placebo Plus Placebo) | 0.44 |
Measure of change in OGTT from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -49.62 |
| DAPA (Dapagliflozin Plus Placebo) | -44.24 |
| PCB (Placebo Plus Placebo) | 20.26 |
All subjects received a Double-Tracer Oral Glucose Tolerance Test (OGTT) with 75g of glucose containing 14C-glucose together with intravenous primed-continuous infusion of 3(3H)-glucose for 240 minutes, at baseline (prior to) and after 16 weeks of therapy. Blood and urine samples were obtained during the OGTT to determine EGP. (NCT02613897)
Timeframe: Baseline and 16 weeks
| Intervention | mg/kg*min (Mean) | |
|---|---|---|
| Baseline Measurement | 16 weeks | |
| DAPA (Dapagliflozin Plus Placebo) | 2.56 | 2.8 |
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | 2.45 | 2.4 |
| PCB (Placebo Plus Placebo) | 1.95 | 2.15 |
Total adiponectin was measured with a commercial ELISA kit (Millipore/Linco Research, St. Charles, MO) in the laboratory of Dr. Philipp Scherer. (NCT00618072)
Timeframe: 6 months
| Intervention | ug/mL (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 10.6 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 10.9 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 18.5 |
Body weight measurement was performed three times and averaged by a single study coordinator. (NCT00618072)
Timeframe: 6 months
| Intervention | kg (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 80.0 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 80.4 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 77.5 |
Blood pressure was assessed using NCEP guidelines. (NCT00618072)
Timeframe: 6 months
| Intervention | mmHg (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 71.7 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 72.7 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 74.3 |
Insulin was determined with a Siemens Immulite assay with respective intra-and inter-CV's 5.7 and 5.9%, and no cross reactivity to pro-insulin. (NCT00618072)
Timeframe: 6 months
| Intervention | uIU/mL (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 8.1 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 8.0 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 6.3 |
HDL was measured using two reagents homogeneous systems with selective detergents to homogenize the lipoprotein of interest. (NCT00618072)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 56.5 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 70.1 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 68.3 |
HOMA-IR was calculated by the formula: fasting insulin (uU/mL) times fasting glucose (mg/L) divided by 22.5. (NCT00618072)
Timeframe: 6 months
| Intervention | HOMA-IR score (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 1.5 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 1.6 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 1.3 |
Blood pressure was assessed using NCEP guidelines. (NCT00618072)
Timeframe: 6 months
| Intervention | mmHg (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 113.8 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 107.2 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 114.2 |
Triglycerides were measured by enzymatic immunoassay on an AU400 chemistry auto-analyzer with commercially available enzymatic reagents. (NCT00618072)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 95.2 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 103.1 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 109.2 |
(NCT00618072)
Timeframe: 6 months
| Intervention | cm (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 93.1 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 90.4 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 87.5 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-wk change in BMI z-score (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 0.02 |
| Metformin | -0.08 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | centimetres (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 1.45 |
| Metformin | -0.21 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-wk change in BMI (kg/m2) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 0.52 |
| Metformin | -0.43 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-wk change in weight (kg) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 2.80 |
| Metformin | 0.07 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | centimetres (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 1.06 |
| Metformin | -0.63 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-wk change in weight (z-score) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 0.04 |
| Metformin | -0.10 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-week change in gluclose (mg/dL) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | -2.41 |
| Metformin | -3.06 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-week change in HDL (mg/dL) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | -0.98 |
| Metformin | 3.27 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-week change insulin fasting (µIU/mL) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 2.95 |
| Metformin | 1.97 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-week change in LDL (mg/dL) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | -0.41 |
| Metformin | -4.41 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-week change total cholesterol (mg/dL) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | -3.29 |
| Metformin | -1.05 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-week change in triglycerides (mg/dL) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 6.18 |
| Metformin | 5.74 |
(NCT00184600)
Timeframe: Week 0 (baseline), month 12
| Intervention | kilogram (Mean) |
|---|---|
| Insulin Detemir (Basal Insulin) | 1.9 |
| Insulin Aspart (Prandial Insulin) | 5.7 |
| Biphasic Insulin Aspart 30 (Biphasic Insulin) | 4.7 |
(NCT00184600)
Timeframe: Week 0 (baseline), month 36
| Intervention | kilograms (Mean) |
|---|---|
| Insulin Detemir (Basal Insulin) | 3.6 |
| Insulin Aspart (Prandial Insulin) | 6.4 |
| Biphasic Insulin Aspart 30 (Biphasic Insulin) | 5.7 |
(NCT00184600)
Timeframe: Up to month 37 (36 months of treatment plus 1 month follow-up)
| Intervention | participants (Number) |
|---|---|
| Insulin Detemir (Basal Insulin) | 227 |
| Insulin Aspart (Prandial Insulin) | 235 |
| Biphasic Insulin Aspart 30 (Biphasic Insulin) | 228 |
Percentage of participants who achieved the target (HbA1c below or equal to 6.5%) at Month 36 (NCT00184600)
Timeframe: Month 36
| Intervention | percentage of participants (Number) |
|---|---|
| Insulin Detemir (Basal Insulin) | 43.2 |
| Insulin Aspart (Prandial Insulin) | 44.8 |
| Biphasic Insulin Aspart 30 (Biphasic Insulin) | 31.9 |
Percentage of participants who required a second insulin formulation to be added to their treatment. This outcome offers evidence to the efficacy and durability of the insulin regimens. (NCT00184600)
Timeframe: Month 12
| Intervention | percentage of participants (Number) |
|---|---|
| Insulin Detemir (Basal Insulin) | 17.9 |
| Insulin Aspart (Prandial Insulin) | 4.2 |
| Biphasic Insulin Aspart 30 (Biphasic Insulin) | 8.9 |
Percentage of participants who required a second insulin formulation to be added to their treatment. This outcome offers evidence to the efficacy and durability of the insulin regimens. (NCT00184600)
Timeframe: Month 36
| Intervention | percentage of participants (Number) |
|---|---|
| Insulin Detemir (Basal Insulin) | 89 |
| Insulin Aspart (Prandial Insulin) | 82 |
| Biphasic Insulin Aspart 30 (Biphasic Insulin) | 88 |
The EuroQol Group 5-Dimension Self-Report Questionnaire score (EQ5D) is a standardised instrument for use as a measure of health outcome in medical research. Responses can be used to generate a single numerical value associated with a given health state. The scale of values is graded from -0.59 to 1.00, with lower scores indicating a poorer health status. A score of 0 represents no quality of life and scores less than 0 represent states perceived by the respondent to be worse than death. (NCT00184600)
Timeframe: Month 12
| Intervention | units on a scale (Mean) |
|---|---|
| Insulin Detemir (Basal Insulin) | 0.78 |
| Insulin Aspart (Prandial Insulin) | 0.76 |
| Biphasic Insulin Aspart 30 (Biphasic Insulin) | 0.76 |
The EuroQol Group 5-Dimension Self-Report Questionnaire score (EQ5D) is a standardised instrument for use as a measure of health outcome in medical research. Responses can be used to generate a single numerical value associated with a given health state. The scale of values is graded from -0.59 to 1.00, with lower scores indicating a poorer health status. A score of 0 represents no quality of life and scores less than 0 represent states perceived by the respondent to be worse than death. (NCT00184600)
Timeframe: Month 36
| Intervention | units on a scale (Mean) |
|---|---|
| Insulin Detemir (Basal Insulin) | 0.80 |
| Insulin Aspart (Prandial Insulin) | 0.77 |
| Biphasic Insulin Aspart 30 (Biphasic Insulin) | 0.76 |
For each visit and telephone contact, participants were asked to perform in advance three capillary glucose profiles (using blood glucose metre provided for the trial) obtained before breakfast and before the evening meal for participants in the biphasic and basal groups and before meals and two hours after meals and at bedtime in the prandial group. (NCT00184600)
Timeframe: Baseline, month 12
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| All timepoints excluding 3am | Fasting | Postprandial | 3am | |
| Biphasic Insulin Aspart 30 (Biphasic Insulin) | -59 | -45 | -68 | -52 |
| Insulin Aspart (Prandial Insulin) | -65 | -23 | -83 | -34 |
| Insulin Detemir (Basal Insulin) | -43 | -59 | -47 | -40 |
For each visit and telephone contact, participants were asked to perform in advance three capillary glucose profiles (using blood glucose metre provided for the trial) obtained before breakfast and before the evening meal for participants in the biphasic and basal groups and before meals and two hours after meals and at bedtime in the prandial group. (NCT00184600)
Timeframe: Baseline, month 36
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| All timepoints excluding 3am | Fasting | Postprandial | 3am | |
| Biphasic Insulin Aspart 30 (Biphasic Insulin) | -56 | -50 | -61 | -38 |
| Insulin Aspart (Prandial Insulin) | -67 | -49 | -85 | -27 |
| Insulin Detemir (Basal Insulin) | -58 | -47 | -67 | -45 |
HbA1c values offer evidence of the efficacy and durability of the insulin regimens. (NCT00184600)
Timeframe: Baseline, Month 12
| Intervention | percentage (%) of total haemoglobin (Mean) | |
|---|---|---|
| Baseline | Month 12 | |
| Biphasic Insulin Aspart 30 (Biphasic Insulin) | 8.63 | 7.33 |
| Insulin Aspart (Prandial Insulin) | 8.55 | 7.20 |
| Insulin Detemir (Basal Insulin) | 8.45 | 7.64 |
HbA1c values offer evidence of the efficacy and durability of the insulin regimens. (NCT00184600)
Timeframe: Baseline, Month 36
| Intervention | percentage (%) of total haemoglobin (Mean) | |
|---|---|---|
| Baseline | Month 36 | |
| Biphasic Insulin Aspart 30 (Biphasic Insulin) | 8.63 | 7.22 |
| Insulin Aspart (Prandial Insulin) | 8.55 | 7.04 |
| Insulin Detemir (Basal Insulin) | 8.45 | 7.11 |
Rate of hypoglycaemic events was calculated as the median number of events per participant per year, defined as grade 1 (symptoms only), 2 (minor) and 3 (major). Symptoms only if self-measured plasma glucose level of 3.1 mmol/L (56 mg/dL) or more. Minor (grade 2) if able to treat her/himself and plasma glucose was below 3.1 mmol/L (56 mg/dL). Major (grade 3) if unable to treat her/himself. Rates are reported for all participants and for the subset of participants who achieved target HbA1c below or equal to 6.5%. (NCT00184600)
Timeframe: Month 12
| Intervention | hypoglycaemic events/participant/year (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| All participants, Grade 1 | All participants, Grade 2 | All participants, Grade 3 | All participants, Grade 2 or 3 | Achieved HbA1c target, Grade 1, n=18, 50, 39 | Achieved HbA1c target, Grade 2, n=18, 50, 39 | Achieved HbA1c target, Grade 3, n=18, 50, 39 | Achieved HbA1c target, Grade 2 or 3, n=18, 50, 39 | |
| Biphasic Insulin Aspart 30 (Biphasic Insulin) | 5.0 | 3.9 | 0 | 3.9 | 5.4 | 4.0 | 0 | 4.0 |
| Insulin Aspart (Prandial Insulin) | 8.0 | 8.0 | 0 | 8.0 | 7.8 | 8.0 | 0 | 8.7 |
| Insulin Detemir (Basal Insulin) | 2.0 | 0 | 0 | 0 | 3.9 | 3.0 | 0 | 3.0 |
Rate of hypoglycaemic events was calculated as the median number of events per participant per year, defined as grade 1 (symptoms only), 2 (minor) and 3 (major). Symptoms only if self-measured plasma glucose level of 3.1 mmol/L (56 mg/dL) or more. Minor (grade 2) if able to treat her/himself and plasma glucose was below 3.1 mmol/L (56 mg/dL). Major (grade 3) if unable to treat her/himself. Rates are reported for all participants and for the subset of participants who achieved target HbA1c below or equal to 6.5%. (NCT00184600)
Timeframe: Month 36
| Intervention | hypoglycaemic events/participant/year (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| All participants, Grade 1 | All participants, Grade 2 | All participants, Grade 3 | All participants, Grade 2 or 3 | Achieved HbA1c target, Grade 1, n=73, 70, 55 | Achieved HbA1c target, Grade 2, n=73, 70, 55 | Achieved HbA1c target, Grade 3, n=73, 70, 55 | Achieved HbA1c target, Grade 2 or 3, n=73, 70, 55 | |
| Biphasic Insulin Aspart 30 (Biphasic Insulin) | 3.8 | 3.0 | 0 | 3.0 | 3.0 | 2.7 | 0 | 3.0 |
| Insulin Aspart (Prandial Insulin) | 5.7 | 5.5 | 0 | 5.7 | 5.7 | 5.3 | 0 | 5.5 |
| Insulin Detemir (Basal Insulin) | 2.7 | 1.7 | 0 | 1.7 | 3.0 | 2.0 | 0 | 2.0 |
Two participant counts are listed. The first is the percentage of total participants who achieved the target (HbA1c below or equal to 6.5%) at Month 12. The second is the percentage of subset of participants who achieved the target and did not have either minor or major hypoglycaemic episode within the four weeks prior to the month 12 exam. Minor hypoglycaemic episode is an episode in which the participant was able to treat her/himself and plasma glucose was below 3.1 mmol/L (56 mg/dL). Major hypoglycaemic episode is an episode in which the participant was unable to treat her/himself. (NCT00184600)
Timeframe: Month 12
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Total participants who achieved target | Subset who achieved target, n=18, 50, 39 | |
| Biphasic Insulin Aspart 30 (Biphasic Insulin) | 17.0 | 52.5 |
| Insulin Aspart (Prandial Insulin) | 23.9 | 43.9 |
| Insulin Detemir (Basal Insulin) | 8.1 | 78.9 |
Average number of episodes of hypoglycemia per 30 days per patient (NCT00135330)
Timeframe: 20 weeks
| Intervention | hypoglycemia events / 30 days / patient (Mean) |
|---|---|
| Exenatide | 0.391 |
| Exenatide Plus Rosiglitazone | 0.594 |
| Rosiglitazone | 0.853 |
Number of subjects experiencing hypoglycemia at any point during the study (NCT00135330)
Timeframe: 20 weeks
| Intervention | participants (Number) |
|---|---|
| Exenatide | 8 |
| Exenatide Plus Rosiglitazone | 9 |
| Rosiglitazone | 6 |
Change in insulin incremental area under the concentration-time curve (ASIiAUC) from baseline to week 20. ASIiAUC is a measure of beta-cell function. (NCT00135330)
Timeframe: 20 weeks
| Intervention | uIU-min/ml (Least Squares Mean) | |
|---|---|---|
| Baseline ASIiAUC | Change in ASIiAUC at week 20 | |
| Exenatide | 643.40 | 747.26 |
| Exenatide Plus Rosiglitazone | 686.41 | 194.68 |
| Rosiglitazone | 786.12 | -99.85 |
Ratio (value at endpoint divided by value at baseline) of AUC(15-180 min) for C-peptide (nmol-min/L) during a MCT from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | nmol-min/L (Geometric Mean) | |
|---|---|---|
| Baseline C-peptide during a MCT | Ratio(endpoint/baseline) of C-peptide during a MCT | |
| Exenatide | 319.77 | 0.908 |
| Exenatide Plus Rosiglitazone | 310.51 | 0.804 |
| Rosiglitazone | 325.65 | 0.854 |
Change in AUC(15-180 min) for glucose during a MCT baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mmol-min/L (Least Squares Mean) | |
|---|---|---|
| Baseline glucose AUC during MCT | Change in glucose AUC during MCT at week 20 | |
| Exenatide | 1782.86 | -560.12 |
| Exenatide Plus Rosiglitazone | 1799.68 | -635.24 |
| Rosiglitazone | 1741.87 | -425.59 |
Change in body fat mass form baseline to week 20, as assessed during an MCT (NCT00135330)
Timeframe: 20 weeks
| Intervention | kg (Least Squares Mean) | |
|---|---|---|
| Baseline body fat mass | Change in body fat mass at week 20 | |
| Exenatide | 32.05 | -2.76 |
| Exenatide Plus Rosiglitazone | 32.55 | -1.06 |
| Rosiglitazone | 30.54 | -1.99 |
Change in body weight from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | kg (Least Squares Mean) | |
|---|---|---|
| Baseline body weight | Change in body weight at week 20 | |
| Exenatide | 93.05 | -2.82 |
| Exenatide Plus Rosiglitazone | 93.76 | -1.21 |
| Rosiglitazone | 91.78 | 1.48 |
Change in fasting high-density lipoprotein (HDL) cholesterol from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mmol/L (Least Squares Mean) | |
|---|---|---|
| Baseline HDL | Change from baseline HDL at week 20 | |
| Exenatide | 1.13 | 0.022 |
| Exenatide Plus Rosiglitazone | 1.17 | 0.046 |
| Rosiglitazone | 1.17 | 0.055 |
Change in fasting insulin from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | uIU/ml (Geometric Mean) | |
|---|---|---|
| Baseline fasting insulin | Ratio (wk20/baseline)of fasting insulin | |
| Exenatide | 12.84 | 0.980 |
| Exenatide Plus Rosiglitazone | 10.96 | 0.599 |
| Rosiglitazone | 12.77 | 0.755 |
Change in fasting low-density lipoprotein (LDL) cholesterol from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mmol/L (Least Squares Mean) | |
|---|---|---|
| Baseline LDL | Change from baseline LDL at week 20 | |
| Exenatide | 2.59 | -0.049 |
| Exenatide Plus Rosiglitazone | 2.57 | 0.096 |
| Rosiglitazone | 2.71 | 0.334 |
Ratio (endpoint value divided by baseline value) for fasting proinsulin, comparing endpoint (week 20) to baseline (NCT00135330)
Timeframe: Week 20
| Intervention | pmol/L (Geometric Mean) | |
|---|---|---|
| Baseline fasting proinsulin | Ratio(wk20/baseline)of fasting proinsulin | |
| Exenatide | 4.32 | 0.663 |
| Exenatide Plus Rosiglitazone | 3.80 | 0.538 |
| Rosiglitazone | 3.56 | 0.623 |
Change in fasting serum glucose concentration from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mmol/L (Least Squares Mean) | |
|---|---|---|
| Baseline fasting serum glucose | Change fr baseline fasting serum glucose at wk 20 | |
| Exenatide | 8.42 | -1.46 |
| Exenatide Plus Rosiglitazone | 8.43 | -1.60 |
| Rosiglitazone | 8.48 | -1.80 |
Change in fasting total cholestrol from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mmol/L (Least Squares Mean) | |
|---|---|---|
| Baseline total cholesterol | Change fr baseline total cholesterol at week 20 | |
| Exenatide | 4.42 | -0.128 |
| Exenatide Plus Rosiglitazone | 4.41 | 0.258 |
| Rosiglitazone | 4.62 | 0.438 |
Ratio (endpint value divided by baseline value) of fasting triglycerides from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mmol/L (Geometric Mean) | |
|---|---|---|
| Baseline triglyceride | Ratio (endpoint/baseline) for triglycerides | |
| Exenatide | 1.56 | 0.861 |
| Exenatide Plus Rosiglitazone | 1.67 | 0.977 |
| Rosiglitazone | 1.76 | 0.992 |
Change in HbA1c from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | Percentage (Least Squares Mean) | |
|---|---|---|
| Baseline HbA1c | Change from baseline HbA1c at week 20 | |
| Exenatide | 7.79 | -0.908 |
| Exenatide Plus Rosiglitazone | 7.84 | -1.31 |
| Rosiglitazone | 7.92 | -0.968 |
Change in hip circumference form baseline to week 20 (NCT00135330)
Timeframe: 20 weeks
| Intervention | cm (Least Squares Mean) | |
|---|---|---|
| Baseline hip circumference | Change in hip circumference at week 20 | |
| Exenatide | 113.29 | -1.28 |
| Exenatide Plus Rosiglitazone | 112.12 | 0.147 |
| Rosiglitazone | 111.90 | 1.51 |
Change in incremental for postprandial C-peptide (mmol/L) during MCT from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mmol/L (Least Squares Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline C-peptide at 15 min | Change fr baseline C-peptide at 15 min at week 20 | Baseline C-peptide at 30 min | Change fr baseline C-peptide at 30 min at week 20 | Baseline C-peptide at 60 min | Change fr baseline C-peptide at 60 min at week 20 | Baseline C-peptide at 90 min | Change fr baseline C-peptide at 90 min at week 20 | Baseline C-peptide at 120 min | Change fr baseline C-peptide at 120 min at week 20 | Baseline C-peptide at 150 min | Change fr baseline C-peptide at 150 min at week 20 | Baseline C-peptide at 180 min | Change fr baseline C-peptide at 180 min at week 20 | |
| Exenatide | 0.238 | -0.006 | 0.521 | -0.071 | 0.818 | -0.148 | 0.895 | -0.185 | 0.817 | -0.259 | 0.843 | -0.251 | 0.610 | -0.075 |
| Exenatide Plus Rosiglitazone | 0.259 | 0.016 | 0.517 | -0.036 | 0.871 | -0.025 | 0.953 | -0.117 | 0.828 | -0.134 | 0.651 | -0.254 | 0.482 | -0.238 |
| Rosiglitazone | 0.206 | 0.087 | 0.560 | 0.099 | 0.881 | 0.054 | 1.03 | -0.052 | 0.972 | -0.016 | 0.813 | -0.093 | 0.619 | -0.092 |
Change in incremental for postprandial glucose (mmol/L) during a MCT from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mmol/L (Least Squares Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline glucose at 15 min | Change fr baseline glucose at 15 min at wk 20 | Baseline glucose at 30 min | Change fr baseline glucose at 30 min at wk 20 | Baseline glucose at 60 minutes | Change fr baseline glucose at 60 min at wk 20 | Baseline glucose at 90 minutes | Change fr baseline glucose at 90 min at wk 20 | Baseline glucose at 120 minutes | Change fr baseline glucose at 120 min at wk 20 | Baseline glucose at 150 minutes | Change fr baseline glucose at 150 min at wk 20 | Baseline glucose at 180 minutes | Change fr baseline glucose at 180 min at wk 20 | |
| Exenatide | 0.950 | -0.651 | 2.39 | -1.46 | 3.59 | -2.56 | 3.24 | -2.87 | 2.49 | -2.24 | 1.62 | -1.42 | 0.461 | -0.583 |
| Exenatide Plus Rosiglitazone | 1.12 | -0.286 | 2.54 | -1.06 | 3.88 | -2.46 | 3.36 | -2.91 | 2.24 | -2.52 | 1.14 | -1.95 | 0.036 | -0.995 |
| Rosiglitazone | 0.828 | 0.150 | 2.23 | -0.066 | 3.48 | -0.720 | 3.48 | -0.952 | 2.31 | -0.912 | 1.25 | -0.830 | 0.279 | -0.481 |
Change in incremental for postprandial insulin (mmol/L) during meal challenge test (MCT) from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mmol/L (Least Squares Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline insulin at 15 min | Change fr baseline insulin at 15 min at wk 20 | Baseline insulin at 30 min | Change fr baseline insulin at 30 min at wk 20 | Baseline insulin at 60 min | Change fr baseline insulin at 60 min at wk 20 | Baseline insulin at 90 min | Change fr baseline insulin at 90 min at wk 20 | Baseline insulin at 120 min | Change fr baseline insulin at 120 min at wk 20 | Baseline insulin at 150 min | Change fr baseline insulin at 150 min at wk 20 | Baseline insulin at 180 min | Change fr baseline insulin at 180 min at wk 20 | |
| Exenatide | 9.97 | -1.71 | 19.81 | -3.00 | 27.92 | -11.04 | 26.06 | -9.42 | 19.56 | -11.26 | 15.67 | -7.48 | 10.58 | 0.031 |
| Exenatide Plus Rosiglitazone | 8.09 | -1.84 | 14.79 | -2.63 | 27.67 | -7.47 | 21.85 | -9.27 | 17.52 | -8.69 | 12.74 | -8.13 | 8.18 | -5.26 |
| Rosiglitazone | 7.53 | -0.455 | 18.83 | -1.04 | 32.09 | -7.42 | 32.25 | -6.19 | 25.47 | -6.43 | 18.11 | -5.57 | 10.74 | -4.04 |
"Change in insulin AUC in the first stage(uIU-min/ml) from baseline to week 20. First stage represents the first 10 minutes after reaching a steady state during a hyperglycemic clamp test." (NCT00135330)
Timeframe: Week 20
| Intervention | uIU-min/ml (Least Squares Mean) | |
|---|---|---|
| Baseline insulin AUC | Change from baseline insulin AUC at week 20 | |
| Exenatide | 200.50 | 134.88 |
| Exenatide Plus Rosiglitazone | 136.84 | 32.12 |
| Rosiglitazone | 157.49 | -50.81 |
"Change in insulin iAUC in the first stage(uIU-min/ml) from baseline to week 20. First stage represents the first 10 minutes after reaching a steady state during a hyperglycemic clamp test." (NCT00135330)
Timeframe: Week 20
| Intervention | uIU-min/ml (Least Squares Mean) | |
|---|---|---|
| Baseline insulin iAUC | Change from baseline insulin iAUC at week 20 | |
| Exenatide | 5.98 | 99.08 |
| Exenatide Plus Rosiglitazone | -9.92 | 53.71 |
| Rosiglitazone | 23.09 | 11.51 |
Change of M-Value (mg/kg-min) during hyperinsulinemic euglycemic clamp test from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mg/kg-min (Least Squares Mean) | |
|---|---|---|
| M-Value at baseline | Change in M-Value from baseline at week 20 | |
| Exenatide | 3.89 | 0.477 |
| Exenatide Plus Rosiglitazone | 2.49 | 2.07 |
| Rosiglitazone | 4.02 | 1.42 |
Change in lean body mass from baseline to week 20, as assessed during an MCT (NCT00135330)
Timeframe: 20 weeks
| Intervention | kg (Least Squares Mean) | |
|---|---|---|
| Baseline lean body mass | Change in lean body mass at week 20 | |
| Exenatide | 64.62 | -2.99 |
| Exenatide Plus Rosiglitazone | 60.94 | 0.532 |
| Rosiglitazone | 61.09 | 1.23 |
Change in percent body fat from baseline to week 20, as assessed during an MCT (NCT00135330)
Timeframe: 20 weeks
| Intervention | percentage (Least Squares Mean) | |
|---|---|---|
| Baseline percent body fat | Change in percent body fat at week 20 | |
| Exenatide | 33.42 | -1.40 |
| Exenatide Plus Rosiglitazone | 34.07 | -0.347 |
| Rosiglitazone | 32.50 | -1.18 |
Change in waist circumference from baseline to week 20 (NCT00135330)
Timeframe: 20 weeks
| Intervention | cm (Least Squares Mean) | |
|---|---|---|
| Baseline waist circumference | Change in waist circumference at Week 20 | |
| Exenatide | 105.98 | -2.95 |
| Exenatide Plus Rosiglitazone | 106.85 | -2.38 |
| Rosiglitazone | 105.34 | -0.225 |
Change in waist-to-hip ratio (waist circumference divided by hip circumference) from baseline to week 20 (NCT00135330)
Timeframe: 20 weeks
| Intervention | ratio (cm/cm) (Least Squares Mean) | |
|---|---|---|
| Baseline waist-to-hip ratio | Change in waist-to-hip ratio at week 20 | |
| Exenatide | 0.939 | -0.016 |
| Exenatide Plus Rosiglitazone | 0.957 | -0.022 |
| Rosiglitazone | 0.943 | -0.016 |
"Pedal edema scores experienced by each patient throughout the study (1+ indicates a patient experienced a pedal edema score of 1 , 2, or 3; 2+ indicates a patient experienced a pedal edema score of 2 or 3, etc.)~Scale:~Slight pitting, no visible distortion, disappears rapidly~A somewhat deeper pit than in 1+, but again no readily detectable distortion, and it disappears in 10 - 15 seconds~The pit is noticeably deep and may last more than a minute; the dependent extremity looks fuller and swollen~The pit is very deep, lasts as long as 2 - 5 minutes, and the dependent extremity is grossly distorted" (NCT00135330)
Timeframe: 20 weeks
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| No edema | Edema score: 1+ | Edema score: 2+ | Edema score: 3+ | |
| Exenatide | 37 | 7 | 1 | 0 |
| Exenatide Plus Rosiglitazone | 34 | 11 | 3 | 0 |
| Rosiglitazone | 30 | 14 | 6 | 1 |
Ratio (value at endpoint divided by value at baseline) of AUC (15-180 min) for insulin (uIU-min/ml) during MCT. (NCT00135330)
Timeframe: Week 20
| Intervention | uIU-min/ml (Geometric Mean) | |
|---|---|---|
| Baseline AUC for insulin during MCT | Ratio(endpoint/baseline) of insulin AUC during MCT | |
| Exenatide | 5171.40 | 0.806 |
| Exenatide Plus Rosiglitazone | 4324.13 | 0.664 |
| Rosiglitazone | 5816.83 | 0.722 |
Change from baseline at Week 104 is defined as Week 104 minus Week 0. (NCT00094770)
Timeframe: Baseline and Week 104
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Sitagliptin 100 mg | -1.6 |
| Glipizide | 0.7 |
Change from baseline at Week 52 is defined as Week 52 minus Week 0. (NCT00094770)
Timeframe: Baseline and Week 52
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Sitagliptin 100 mg | -1.5 |
| Glipizide | 1.1 |
HbA1c is measured as percent. Thus, this change from baseline reflects the Week 104 HbA1c percent minus the Week 0 HbA1c percent. (NCT00094770)
Timeframe: Baseline and Week 104
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Sitagliptin 100 mg | -0.54 |
| Glipizide | -0.51 |
HbA1c is measured as percent. Thus, this change from baseline reflects the Week 52 HbA1c percent minus the Week 0 HbA1c percent. (NCT00094770)
Timeframe: Baseline and Week 52
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Sitagliptin 100 mg | -0.67 |
| Glipizide | -0.67 |
Participants with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs. (NCT00094770)
Timeframe: Baseline to Week 104
| Intervention | Participants (Number) |
|---|---|
| Sitagliptin 100 mg | 18 |
| Glipizide | 21 |
Number of participants who reported 1 or more episodes of the adverse experience of hypoglycemia. (NCT00094770)
Timeframe: Baseline to Week 104
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Participants with one or more Hypoglycemic AEs | Total number of Hypoglycemic episodes | Participants with no Hypoglycemic AEs | |
| Glipizide | 199 | 805 | 385 |
| Sitagliptin 100 mg | 31 | 57 | 557 |
Number of participants who reported 1 or more episodes of the adverse experience (AEs) of hypoglycemia. (NCT00094770)
Timeframe: Baseline to Week 52
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Participants with one or more Hypoglycemic AEs | Total number of Hypoglycemic episodes | Participants with no Hypoglycemic AEs | |
| Glipizide | 187 | 657 | 397 |
| Sitagliptin 100 mg | 29 | 50 | 559 |
An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. (NCT00094770)
Timeframe: Baseline to Week 104
| Intervention | Participants (Number) | |
|---|---|---|
| With CAES | Without CAES | |
| Glipizide | 480 | 104 |
| Sitagliptin 100 mg | 452 | 136 |
Participants with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs. (NCT00094770)
Timeframe: Baseline to Week 104
| Intervention | Participants (Number) | |
|---|---|---|
| With drug related CAEs | Without drug related CAEs | |
| Glipizide | 193 | 391 |
| Sitagliptin 100 mg | 97 | 491 |
A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. (NCT00094770)
Timeframe: Baseline to Week 104
| Intervention | Participants (Number) | |
|---|---|---|
| With LAEs | Without LAEs | |
| Glipizide | 74 | 510 |
| Sitagliptin 100 mg | 85 | 503 |
Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose. (NCT00094770)
Timeframe: Baseline to Week 104
| Intervention | Participants (Number) | |
|---|---|---|
| With serious CAEs | Without serious CAEs | |
| Glipizide | 73 | 511 |
| Sitagliptin 100 mg | 64 | 524 |
Serious LAEs are any LAEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose. (NCT00094770)
Timeframe: Baseline to Week 104
| Intervention | Participants (Number) | |
|---|---|---|
| With serious LAEs | Without serious LAEs | |
| Glipizide | 0 | 584 |
| Sitagliptin 100 mg | 0 | 588 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | kilograms (Least Squares Mean) |
|---|---|
| Olanzapine | 2.76 |
| Olanzapine + Amantadine | 2.40 |
| Olanzapine + Metformin | 0.65 |
The BPRS is an 18-item clinician-administered scale used to assess the degree of severity of a subject's general psychopathological symptoms. Each item is rated on a scale from 1 (symptom not present) to 7 (symptom extremely severe). The BPRS total score ranges from 18 to 126. (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 48.24 | -13.89 |
| Olanzapine + Amantadine | 45.90 | -9.90 |
| Olanzapine + Metformin | 47.00 | -9.72 |
Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 4.06 | -0.98 |
| Olanzapine + Amantadine | 4.03 | -0.72 |
| Olanzapine + Metformin | 4.00 | -0.79 |
The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 12.76 | -6.39 |
| Olanzapine + Amantadine | 14.22 | -4.12 |
| Olanzapine + Metformin | 15.40 | -4.36 |
To understand the drivers of weight gain as indicated by the correlation between weight changes and changes in the Eating Inventory (EI) and Food Craving Inventory (FCI). The EI is a 51-item inventory that measures dietary restraint, disinhibition, and perceived hunger. The FCI is a 28-item instrument measuring the frequency over the past month of general cravings and cravings for specific types of foods, namely: high fats, sweets, carbohydrates/starches, and fast-food fats. Correlations were computed on the combined treatment groups. (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | correlation (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| EI: Disinhibition | EI: Cognitive Restraint | EI: Hunger | FCI: Carbohydrates/Starches (N=186, N=141) | FCI: Fast Food Fats (N=188, N=140) | FCI: High Fats (N=186, N=138) | FCI: Sweets (N=187, N=140) | FCI: Total Score (N=184, N=137) | |
| 2 Weeks | -0.034 | -0.273 | -0.150 | 0.013 | -0.019 | 0.051 | 0.022 | 0.039 |
| 22 Weeks | 0.285 | -0.038 | 0.148 | -0.064 | 0.047 | 0.043 | -0.008 | -0.000 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 5.32 | 0.26 |
| Olanzapine + Amantadine | 5.25 | 0.10 |
| Olanzapine + Metformin | 5.28 | 0.01 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 1.25 | -0.00 |
| Olanzapine + Amantadine | 1.26 | -0.11 |
| Olanzapine + Metformin | 1.22 | -0.08 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 3.02 | 0.16 |
| Olanzapine + Amantadine | 3.06 | -0.04 |
| Olanzapine + Metformin | 2.91 | -0.02 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 5.01 | 0.36 |
| Olanzapine + Amantadine | 5.03 | 0.01 |
| Olanzapine + Metformin | 4.91 | -0.08 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimoles per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 1.58 | 0.33 |
| Olanzapine + Amantadine | 1.61 | 0.35 |
| Olanzapine + Metformin | 1.68 | 0.06 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | percent hemoglobin A1c (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 5.51 | 0.09 |
| Olanzapine + Amantadine | 5.48 | 0.10 |
| Olanzapine + Metformin | 5.53 | -0.03 |
Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | kg per meters squared (Mean) |
|---|---|
| 1 Metformin Alone | 36.7 |
| 2 Metformin + Rosliglitazone | 38.2 |
| 3 Metformin + Lifestyle Program | 35.3 |
Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | g/cm squared (Mean) |
|---|---|
| 1 Metformin Alone | 1.15 |
| 2 Metformin + Rosliglitazone | 1.15 |
| 3 Metformin + Lifestyle Program | 1.15 |
Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | kg (Mean) |
|---|---|
| 1 Metformin Alone | 36.1 |
| 2 Metformin + Rosliglitazone | 39.7 |
| 3 Metformin + Lifestyle Program | 32.2 |
Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | cm (Mean) |
|---|---|
| 1 Metformin Alone | 110.8 |
| 2 Metformin + Rosliglitazone | 114.0 |
| 3 Metformin + Lifestyle Program | 108.6 |
A diagnosis was made by an out-of-range value >=95th percentile or systolic >=130 or diastolic >=80 sustained over 6 months or on an anti-hypertensive medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 57 |
| 2 Metformin + Rosliglitazone | 53 |
| 3 Metformin + Lifestyle Program | 45 |
A diagnosis was made from out-of-range value >= 130 mg/dL sustained over 6 months or put on lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 18 |
| 2 Metformin + Rosliglitazone | 16 |
| 3 Metformin + Lifestyle Program | 15 |
A diagnosis was made by an out-of-range value >=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 20 |
| 2 Metformin + Rosliglitazone | 28 |
| 3 Metformin + Lifestyle Program | 22 |
Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | uU/mL divided by mg/dL (Median) |
|---|---|
| 1 Metformin Alone | .75 |
| 2 Metformin + Rosliglitazone | .83 |
| 3 Metformin + Lifestyle Program | .71 |
All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | mL/uU (Median) |
|---|---|
| 1 Metformin Alone | 0.037 |
| 2 Metformin + Rosiglitazone | 0.049 |
| 3 Metformin + Lifestyle Program | 0.039 |
Number of serious adverse events reported during the trial. Participant could have multiple episodes reported. (NCT00081328)
Timeframe: Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.
| Intervention | episodes of serious adverse event (Number) |
|---|---|
| 1 Metformin Alone | 42 |
| 2 Metformin + Rosiglitazone | 34 |
| 3 Metformin + Lifestyle Program | 58 |
Defined as A1c persistently >=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin) (NCT00081328)
Timeframe: Study duration - 2 years to 6.5 years of follow up from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Treatment failure | Did not fail treatment during trial | |
| 1 Metformin Alone | 120 | 112 |
| 2 Metformin + Rosliglitazone | 90 | 143 |
| 3 Metformin + Lifestyle Program | 109 | 125 |
Change in percent body fat (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of change (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentile (Mean) |
|---|---|
| Metformin | -1 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | insulin per kg (Mean) |
|---|---|
| Metformin | -0.1 |
| Oral Placebo | -0.0 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | centimeters (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Change in Systolic | Change in Diastolic | |
| Metformin | 0 | 0 |
| Oral Placebo | -0 | 0 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage (Mean) | |
|---|---|---|
| HbA1c | Change from Baseline to 26 Weeks | |
| Metformin | 9.0 | 0.2 |
| Oral Placebo | 8.9 | 0.2 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| HbA1c Decrease ≥0.5% | HbA1c Increase ≥0.5% | HbA1c <7.5% | |
| Metformin | 19 | 44 | 3 |
| Oral Placebo | 18 | 35 | 4 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mg/dL (Mean) | ||||
|---|---|---|---|---|---|
| Change in LDL | Change in VLDL | Change in HDL | Change in Triglycerides | Change in Total Cholesterol | |
| Metformin | -6 | -0 | -0 | 4 | -5 |
| Oral Placebo | 2 | 1 | -1 | 6 | 3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
56 reviews available for metformin and Weight Gain
| Article | Year |
|---|---|
Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology.
Topics: Adult; Antipsychotic Agents; Humans; Metformin; Psychotic Disorders; Weight Gain | 2022 |
Should antidiabetic medicines be considered to reduce cardiometabolic risk in patients with serious mental illness?
Topics: Antipsychotic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Re | 2022 |
Pharmacological interventions for prevention of weight gain in people with schizophrenia.
Topics: Antipsychotic Agents; Betahistine; Famotidine; Fluoxetine; Humans; Melatonin; Metformin; Nausea; Niz | 2022 |
Short-term neonatal outcomes in women with gestational diabetes treated using metformin versus insulin: a systematic review and meta-analysis of randomized controlled trials.
Topics: Birth Weight; Diabetes, Gestational; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Infant, Newb | 2023 |
[Prevention and treatment of antipsychotic induced weight gain].
Topics: Antipsychotic Agents; Aripiprazole; Humans; Metformin; Topiramate; Weight Gain | 2023 |
Time course and dose effect of metformin on weight in patients with different disease states.
Topics: Antipsychotic Agents; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Huma | 2020 |
Minimizing weight gain for patients taking antipsychotic medications: The potential role for early use of metformin.
Topics: Antipsychotic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Hypoglycemic Agents; | 2017 |
Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis.
Topics: Adult; Cohort Studies; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemi | 2018 |
Combination of Metformin and Lifestyle Intervention for Antipsychotic-Related Weight Gain: A Meta-Analysis of Randomized Controlled Trials.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Combined Modality Therapy; Drug-Related Side Effects | 2019 |
Prevention of Excessive Gestational Weight Gain and Postpartum Weight Retention.
Topics: Adult; Anti-Obesity Agents; Diet, Healthy; Diet, Reducing; Evidence-Based Medicine; Exercise; Female | 2018 |
Hypothalamic AMPK and energy balance.
Topics: Adipose Tissue, Brown; Adipose Tissue, White; AMP-Activated Protein Kinases; Animals; Anti-Obesity A | 2018 |
Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis.
Topics: Adolescent; Antipsychotic Agents; Child; Humans; Hypoglycemic Agents; Mental Disorders; Metformin; W | 2018 |
Myths about Insulin Resistance: Tribute to Gerald Reaven.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; History, 20th Century; History, 21st Century; Humans; Hy | 2019 |
A "glucose eater" drug as a therapeutic agent in psychiatry.
Topics: Alzheimer Disease; Animals; Antipsychotic Agents; Depressive Disorder, Major; Diabetes Mellitus, Typ | 2013 |
[Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus].
Topics: Contraindications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Comb | 2013 |
Placental dysfunction in obese women and antenatal surveillance strategies.
Topics: Diabetes, Gestational; Female; Fetal Development; Humans; Hypoglycemic Agents; Inflammation; Metform | 2015 |
Effect comparison of metformin with insulin treatment for gestational diabetes: a meta-analysis based on RCTs.
Topics: Birth Weight; Diabetes, Gestational; Female; Gestational Age; Humans; Insulin; Metformin; Pre-Eclamp | 2015 |
Novel strategies in the management of polycystic ovary syndrome.
Topics: Adult; Clomiphene; Contraceptives, Oral, Combined; Female; Fertility Agents, Female; Fertilization i | 2015 |
Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials.
Topics: Antipsychotic Agents; Humans; Hypoglycemic Agents; Metabolic Diseases; Metformin; Randomized Control | 2015 |
Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme.
Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Exenatide; Female; Glucagon-Like Peptides; | 2016 |
A review of the evidence for the use of metformin in the treatment of metabolic syndrome caused by antipsychotics.
Topics: Adult; Antipsychotic Agents; Combined Modality Therapy; England; Evidence-Based Medicine; Humans; Li | 2015 |
Major malformation risk, pregnancy outcomes, and neurodevelopmental outcomes associated with metformin use during pregnancy.
Topics: Abnormalities, Drug-Induced; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Infan | 2016 |
Novel approaches to the treatment of hyperglycaemia in type 2 diabetes mellitus.
Topics: Bariatric Surgery; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hyperg | 2016 |
Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes | 2016 |
Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis.
Topics: Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Clozapine; Fasting; Humans; Hypog | 2016 |
Treatment of Pediatric Type 2 Diabetes.
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Pept | 2016 |
Metformin - a potentially effective drug for gestational diabetes mellitus: a systematic review and meta-analysis.
Topics: Birth Weight; Diabetes, Gestational; Female; Gestational Age; Glycated Hemoglobin; Humans; Hypoglyce | 2017 |
Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Double-Blind Method; Humans; Metformin; Psychotic Disorders; Schizophrenia; We | 2016 |
Metabolic risks in older adults receiving second-generation antipsychotic medication.
Topics: Affective Disorders, Psychotic; Aged; Aged, 80 and over; Antipsychotic Agents; Cardiovascular Diseas | 2009 |
Management of atypical antipsychotic drug-induced weight gain: focus on metformin.
Topics: Adolescent; Adult; Antipsychotic Agents; Child; Clinical Trials as Topic; Double-Blind Method; Femal | 2009 |
Diabetes medications and body weight.
Topics: Abdominal Fat; Benzamides; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipepti | 2009 |
Advances in oral therapy for type 2 diabetes.
Topics: Acarbose; Administration, Oral; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; | 2000 |
Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies.
Topics: Antipsychotic Agents; Appetite Depressants; Blood Glucose; Body Weight; Double-Blind Method; Humans; | 2009 |
Can metformin or rosiglitazone reduce metabolic side effects associated with atypical antipsychotics?
Topics: Antipsychotic Agents; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Randomized Control | 2009 |
Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis.
Topics: Adult; Antipsychotic Agents; Child; Humans; Hypoglycemic Agents; Metformin; Racial Groups; Weight Ga | 2011 |
Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions.
Topics: Antipsychotic Agents; Cardiovascular Diseases; Glucose Metabolism Disorders; Guidelines as Topic; Hu | 2010 |
Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.
Topics: Anti-Obesity Agents; Antipsychotic Agents; Fructose; Humans; Hypoglycemic Agents; Metformin; Obesity | 2010 |
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hyp | 2010 |
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hyp | 2010 |
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hyp | 2010 |
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hyp | 2010 |
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hyp | 2010 |
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hyp | 2010 |
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hyp | 2010 |
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hyp | 2010 |
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hyp | 2010 |
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hyp | 2010 |
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hyp | 2010 |
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hyp | 2010 |
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hyp | 2010 |
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hyp | 2010 |
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hyp | 2010 |
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hyp | 2010 |
Metabolic syndrome with the atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Cardiovascular Diseases; Clozapine; Humans; Metabolic Syndrom | 2010 |
What to add in with metformin in type 2 diabetes?
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Fractures, Bone; Gluc | 2011 |
Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Body Mass Index; Humans; Hyp | 2011 |
Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials.
Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Glycated He | 2011 |
A systematic review of metformin to limit weight-gain with atypical antipsychotics.
Topics: Antipsychotic Agents; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; | 2011 |
Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Ag | 2011 |
Efficacy of metformin for prevention of weight gain in psychiatric populations: a review.
Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agen | 2012 |
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; | 2012 |
Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses.
Topics: Bias; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemogl | 2012 |
Options for pharmacological management of obesity in patients treated with atypical antipsychotics.
Topics: Amantadine; Antipsychotic Agents; Cimetidine; Cyclobutanes; Fluoxetine; Fructose; Humans; Lactones; | 2002 |
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
Topics: Blood Volume; Clinical Trials as Topic; Comorbidity; Contraindications; Diabetes Mellitus, Type 2; D | 2003 |
Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combinatio | 2005 |
[Development of body weight during antidiabetic treatment].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Energy Metabolism; Humans; Hypoglycemic Agents | 2006 |
Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; H | 2008 |
An overview of obesity in children with psychiatric disorders taking atypical antipsychotics.
Topics: Adolescent; Antipsychotic Agents; Appetite Depressants; Child; Child, Preschool; Cognitive Behaviora | 2008 |
Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobi | 2008 |
Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
Topics: Administration, Oral; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combinatio | 2008 |
[Combination treatment with insulin and metformin in type 2 diabetes. Improves glycemic control and prevents weight gain].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; In | 1999 |
93 trials available for metformin and Weight Gain
| Article | Year |
|---|---|
Metformin action over gut microbiota is related to weight and glycemic control in gestational diabetes mellitus: A randomized trial.
Topics: Adult; Body Mass Index; Diabetes, Gestational; Female; Gastrointestinal Microbiome; Glycemic Control | 2022 |
Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled Trial of Metformin for Antipsychotic-Induced Weight Gain in Patients with First-Episode Psychosis: A Pilot Study.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Humans; Hypoglycemic Agents; Metformin | 2021 |
Gestational weight gain in women with type 2 diabetes and perinatal outcomes: A secondary analysis of the metformin in women with type 2 diabetes in pregnancy (MiTy) trial.
Topics: Birth Weight; Body Mass Index; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Gestational | 2022 |
Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin.
Topics: Diabetes, Gestational; Female; Humans; Hypothyroidism; Metformin; Pilot Projects; Polycystic Ovary S | 2022 |
Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin.
Topics: Diabetes, Gestational; Female; Humans; Hypothyroidism; Metformin; Pilot Projects; Polycystic Ovary S | 2022 |
Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin.
Topics: Diabetes, Gestational; Female; Humans; Hypothyroidism; Metformin; Pilot Projects; Polycystic Ovary S | 2022 |
Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin.
Topics: Diabetes, Gestational; Female; Humans; Hypothyroidism; Metformin; Pilot Projects; Polycystic Ovary S | 2022 |
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
Topics: Administration, Oral; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Glycated H | 2022 |
A randomised placebo-controlled trial of the effectiveness of early metformin in addition to usual care in the reduction of gestational diabetes mellitus effects (EMERGE): study protocol.
Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes, Gestational; Female; Galactose; Gestat | 2022 |
Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gastrointestinal Microbiome; Gl | 2023 |
Effects of half-dose spiomet treatment in girls with early puberty and accelerated bone maturation: a multicenter, randomized, placebo-controlled study protocol.
Topics: Adiponectin; Female; Humans; Hypoglycemic Agents; Metformin; Multicenter Studies as Topic; Polycysti | 2023 |
Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study).
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; D | 2020 |
Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial.
Topics: Antipsychotic Agents; Double-Blind Method; Humans; Life Style; Melia; Metformin; Multicenter Studies | 2021 |
Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
Topics: Anti-Obesity Agents; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Combinations; D | 2018 |
Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A post hoc analysis of a randomized placebo-controlled 4.3-year trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Diabetes | 2018 |
CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine.
Topics: Antipsychotic Agents; Body Mass Index; Body Weight; Clozapine; Diabetes Mellitus, Type 2; Double-Bli | 2018 |
A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral anti
Topics: Aged; Biphasic Insulins; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemo | 2018 |
Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr
Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Female; | 2019 |
Pharmacogenetics of Metformin for Medication-Induced Weight Gain in Autism Spectrum Disorder.
Topics: Adolescent; Ataxia Telangiectasia Mutated Proteins; Autism Spectrum Disorder; Child; Double-Blind Me | 2019 |
Determinants of weight gain in the action to control cardiovascular risk in diabetes trial.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Male; Metfo | 2013 |
Randomized trial of metformin vs insulin in the management of gestational diabetes.
Topics: Blood Glucose; Brazil; Diabetes, Gestational; Female; Gestational Age; Humans; Hypoglycemic Agents; | 2013 |
Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitor | 2013 |
Vildagliptin more effectively achieves a composite endpoint of HbA₁c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment.
Topics: Adamantane; Aged; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metf | 2013 |
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dose-Response Relationship, Drug; Double-Blind Method; | 2013 |
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dose-Response Relationship, Drug; Double-Blind Method; | 2013 |
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dose-Response Relationship, Drug; Double-Blind Method; | 2013 |
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dose-Response Relationship, Drug; Double-Blind Method; | 2013 |
Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Dr | 2013 |
Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Dr | 2013 |
Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Dr | 2013 |
Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Dr | 2013 |
[Efficacy and safety of vildagliptin as a second-line therapy vs other oral antidiabetic agents in patients with type 2 diabetes: Czech results within the worldwide prospective cohort EDGE study].
Topics: Adamantane; Adult; Aged; Cohort Studies; Czech Republic; Diabetes Mellitus, Type 2; Drug Therapy, Co | 2013 |
Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blin | 2014 |
Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combinatio | 2014 |
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method | 2014 |
Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndrome.
Topics: Abdominal Fat; Absorptiometry, Photon; Adiponectin; Adiposity; Adolescent; Adult; Body Mass Index; C | 2014 |
Metformin induces a prompt decrease in LH-stimulated testosterone response in women with PCOS independent of its insulin-sensitizing effects.
Topics: Adrenal Cortex; Adult; Body Mass Index; Double-Blind Method; Female; Follow-Up Studies; Humans; Hype | 2014 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country: a randomized control trial.
Topics: Adult; Blood Glucose; Developing Countries; Diabetes, Gestational; Drug Therapy, Combination; Female | 2015 |
Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglyc | 2015 |
Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy.
Topics: Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Gestational Age; Hu | 2015 |
Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy.
Topics: Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Gestational Age; Hu | 2015 |
Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy.
Topics: Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Gestational Age; Hu | 2015 |
Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy.
Topics: Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Gestational Age; Hu | 2015 |
METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN.
Topics: Adipose Tissue; Adult; Aging; Body Fat Distribution; Climacteric; Double-Blind Method; Drug Combinat | 2016 |
Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Weight; Double-Blind Method; Dyslipidemias; Female; | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug | 2016 |
A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Double-Blind Method; Drug | 2016 |
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Topics: Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; I | 2016 |
Prediction of excessive weight gain in insulin treated patients with type 2 diabetes.
Topics: Aged; Biphasic Insulins; Blood Glucose; Chi-Square Distribution; Diabetes Mellitus, Type 2; Drug The | 2017 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study.
Topics: Acarbose; Aged; Albumins; Albuminuria; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Drug Th | 2016 |
Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes.
Topics: Aged; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, C | 2008 |
A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents.
Topics: Antipsychotic Agents; Child; Double-Blind Method; Humans; Hypoglycemic Agents; Metformin; Risperidon | 2008 |
Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combinati | 2008 |
Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome.
Topics: Adult; Aged; Anthropometry; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Reducing; Fe | 2009 |
Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dr | 2009 |
Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dr | 2009 |
Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dr | 2009 |
Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dr | 2009 |
Metformin therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Female; Humans; Hypoglycemic Agents; Insulin; Ins | 2010 |
Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptid | 2009 |
Metformin for weight control in pediatric patients on atypical antipsychotic medication.
Topics: Adolescent; Antipsychotic Agents; Blood Glucose; Body Mass Index; Child; Female; Humans; Hypoglycemi | 2009 |
Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Body Mass Index | 2009 |
Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dr | 2009 |
Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).
Topics: Adult; Aged; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic | 2010 |
Three-year efficacy of complex insulin regimens in type 2 diabetes.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combina | 2009 |
Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination | 2009 |
Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucose Clamp Techniq | 2010 |
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.
Topics: Adamantane; Adolescent; Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Dr | 2010 |
Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; In | 2010 |
Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Gl | 2011 |
Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.
Topics: Adolescent; Adult; Aged; Algorithms; Amantadine; Antipsychotic Agents; Benzodiazepines; Clinical Pro | 2012 |
Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Body Weight; Brain-Derived Neurotrophic Factor; Cell | 2012 |
Metformin monotherapy in youth with recent onset type 2 diabetes: experience from the prerandomization run-in phase of the TODAY study.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Female; Glycated Hemog | 2012 |
Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Double-Blind Method; Femal | 2012 |
Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus.
Topics: Adult; Birth Weight; Blood Glucose; Diabetes, Gestational; Female; Glucose Tolerance Test; Glyburide | 2012 |
Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study.
Topics: Adolescent; Adult; Amenorrhea; Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Do | 2012 |
Metformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial.
Topics: Adult; Birth Weight; Blood Glucose; Diabetes, Gestational; Drug Therapy, Combination; Female; Fetal | 2012 |
Metformin's effect on first-year weight gain: a follow-up study.
Topics: Adult; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Infant; Infant, | 2012 |
Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial.
Topics: Adolescent; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Glucose Tolerance Test; Gl | 2003 |
Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.
Topics: Administration, Oral; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combinatio | 2003 |
Improved glycemic control without weight gain using triple therapy in type 2 diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ethnicity; Female; | 2004 |
Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hy | 2005 |
Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Circadian Rhythm; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Ad | 2005 |
Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial.
Topics: Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Hemo | 2005 |
Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.
Topics: Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Diabetes Mellitus, Typ | 2006 |
Glycaemic control without weight gain in insulin requiring type 2 diabetes: 1-year results of the GAME regimen.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; F | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Blood Glucose; Body Mass Index; Child; Diabetes Melli | 2006 |
Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fem | 2007 |
Weight gain in type 2 diabetes mellitus.
Topics: Adipose Tissue; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 2007 |
Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study.
Topics: Adolescent; Body Mass Index; Child; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; | 2007 |
A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin.
Topics: Adult; Aged; Aged, 80 and over; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; | 2007 |
Safety and efficacy of repaglinide in combination with metformin and bedtime NPH insulin as an insulin treatment regimen in type 2 diabetes.
Topics: Aged; Blood Glucose; Blood Pressure; Body Mass Index; Carbamates; Diabetes Mellitus, Type 2; Drug Ad | 2008 |
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
Topics: Administration, Oral; Aged; Blood Glucose; Data Interpretation, Statistical; Diabetes Mellitus, Type | 2007 |
Weight changes in type 2 diabetes and the impact of gender.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycat | 2008 |
Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial
Topics: Biomarkers; Biphasic Insulins; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2007 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis.
Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Glycated Hemoglobin; Glycemic Index; Humans; Hypoglyce | 2008 |
Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Drug | 2008 |
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Topics: Adult; Antipsychotic Agents; Appetite Depressants; Benzodiazepines; Body Mass Index; Chronic Disease | 2008 |
The UK Prospective Diabetes Study. UK Prospective Diabetes Study Group.
Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hype | 1996 |
Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial.
Topics: Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LD | 1998 |
Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial.
Topics: Albuminuria; Blood Glucose; Blood Pressure; C-Peptide; Diabetes Mellitus, Type 2; Drug Administratio | 1999 |
Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 1999 |
[Combination treatment with insulin and metformin in type 2 diabetes. Improves glycemic control and prevents weight gain].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; In | 1999 |
108 other studies available for metformin and Weight Gain
| Article | Year |
|---|---|
Metformin prevents airway hyperreactivity in rats with dietary obesity.
Topics: Animals; Asthma; Bronchial Hyperreactivity; Bronchoconstriction; Bronchoconstrictor Agents; Diet, Hi | 2021 |
Protective Effects of Individual and Combined Low Dose Beta-Carotene and Metformin Treatments against High-Fat Diet-Induced Responses in Mice.
Topics: Adipocytes; Adipose Tissue; Adiposity; Animals; beta Carotene; Blood Glucose; Cell Size; Diet, High- | 2021 |
Effectiveness and safety of basal insulin therapy in type 2 diabetes mellitus patients with or without metformin observed in a national cohort in China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; China; Diabetes Mellitus, Type 2; Female; Glycated Hemog | 2022 |
Metabolic programming in the offspring after gestational overfeeding in the mother: toward neonatal rescuing with metformin in a swine model.
Topics: Adipose Tissue; Animals; Female; Fructosamine; Humans; Metformin; Mothers; Overnutrition; Swine; Wei | 2022 |
Combined Topiramate and Metformin Pharmacotherapy for Second-Generation Antipsychotic-Induced Weight Gain in Pediatric Bipolar Disorder and Aggression.
Topics: Aggression; Antipsychotic Agents; Bipolar Disorder; Child; Humans; Metformin; Topiramate; Weight Gai | 2022 |
Weight gain in pregnancy: can metformin steady the scales?
Topics: Birth Weight; Diabetes Mellitus, Type 2; Female; Humans; Infant, Newborn; Metformin; Pregnancy; Preg | 2022 |
Metformin for the prevention of clozapine-induced weight gain: A retrospective naturalistic cohort study.
Topics: Adult; Antipsychotic Agents; Clozapine; Cohort Studies; Humans; Male; Metformin; Retrospective Studi | 2022 |
Metformin in pregnancy and risk of abnormal growth outcomes at birth: a register-based cohort study.
Topics: Child; Cohort Studies; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Infant, Newborn; In | 2022 |
Metformin in pregnancy and risk of abnormal growth outcomes at birth: a register-based cohort study.
Topics: Child; Cohort Studies; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Infant, Newborn; In | 2022 |
Metformin in pregnancy and risk of abnormal growth outcomes at birth: a register-based cohort study.
Topics: Child; Cohort Studies; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Infant, Newborn; In | 2022 |
Metformin in pregnancy and risk of abnormal growth outcomes at birth: a register-based cohort study.
Topics: Child; Cohort Studies; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Infant, Newborn; In | 2022 |
Metabolic and Metabolomic Effects of Metformin in Murine Model of Pulmonary Adenoma Formation.
Topics: Adenoma; Animals; Disease Models, Animal; Lung Neoplasms; Metformin; Mice; Weight Gain | 2023 |
Free leptin index, excessive weight gain, and metformin treatment during pregnancy in polycystic ovary syndrome: What about inflammation?
Topics: Female; Humans; Hypoglycemic Agents; Leptin; Metformin; Polycystic Ovary Syndrome; Pregnancy; Weight | 2023 |
Salsalate and/or metformin therapy confer beneficial metabolic effects in olanzapine treated female mice.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Female; Glucose; Humans; Lipids; Metformin; Mice; Ol | 2023 |
Metformin and Dipeptidyl Peptidase-4 Inhibitor Differentially Modulate the Intestinal Microbiota and Plasma Metabolome of Metabolically Dysfunctional Mice.
Topics: Animals; Blood Glucose; Cholesterol; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Gastrointes | 2020 |
Combination of honey with metformin enhances glucose metabolism and ameliorates hepatic and nephritic dysfunction in STZ-induced diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Honey; | 2019 |
Real-world Evaluation of glycemic control and hypoglycemic Events among type 2 Diabetes mellitus study (REEDS): a multicentre, cross-sectional study in Thailand.
Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycemic Control; Hum | 2020 |
Metabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: a preliminary study.
Topics: Adolescent; Adult; Blood Glucose; Contraceptives, Oral, Combined; Female; Glycated Hemoglobin; Human | 2020 |
Early metformin treatment improves pancreatic function and prevents metabolic dysfunction in early overfeeding male rats at adulthood.
Topics: Adipose Tissue, White; Animals; Animals, Newborn; Blood Glucose; Body Composition; Body Weight; Fema | 2020 |
Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats.
Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents; Blood Glucose; Cytokines; Disease Models, Animal; | 2021 |
Metformin combined with insulin in women with gestational diabetes mellitus: a propensity score-matched study.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Drug Therapy, Combination; Female; Humans; Hypoglycemic | 2021 |
Instrumental Variable Methods for Continuous Outcomes That Accommodate Nonignorable Missing Baseline Values.
Topics: Bias; Body Mass Index; Computer Simulation; Confounding Factors, Epidemiologic; Data Interpretation, | 2017 |
Metformin for antipsychotic-induced weight gain: Statistical curiosities.
Topics: Antipsychotic Agents; Exploratory Behavior; Humans; Hypoglycemic Agents; Metformin; Schizophrenia; W | 2017 |
Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Female; Humans; Hypoglycemic Agen | 2017 |
Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States.
Topics: Blood Pressure; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Combinations; Glycated Hemogl | 2017 |
Developing a metformin prescribing tool for use in adults with mental illness to reduce medication-related weight gain and cardiovascular risk.
Topics: Antipsychotic Agents; Cardiovascular Diseases; Humans; Mental Disorders; Metformin; Obesity; Risk Fa | 2017 |
Metformin protects against retinal cell death in diabetic mice.
Topics: Animals; Blood Glucose; Cell Death; Cells, Cultured; Diabetes Mellitus, Experimental; Humans; Hypogl | 2017 |
Antipsychotic-Induced Weight Gain and Metformin.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Humans; Metformin; Overweight; Weight Ga | 2017 |
Metformin prescription in psychiatry.
Topics: Adult; Cardiovascular Diseases; Humans; Metformin; Psychiatry; Risk Factors; Weight Gain | 2018 |
Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model.
Topics: Acyltransferases; Administration, Oral; Animals; Carcinogenesis; Carcinoma, Pancreatic Ductal; Chemo | 2018 |
Metformin for Antipsychotic-Related Metabolic Syndrome in Children: Fact or Fiction?
Topics: Antipsychotic Agents; Child; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Weight Gain | 2018 |
Mobility for All?
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Double-Blind Method; Humans; Metf | 2018 |
Dr. Handen et al. Reply.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Humans; Metformin; Overweight; We | 2018 |
Drs. Walkup and Cottingham Reply.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Humans; Metformin; Overweight; Weight Ga | 2018 |
Comparative risk of new-onset diabetes following commencement of antipsychotics in New Zealand: a population-based clustered multiple baseline time series design.
Topics: Adult; Antipsychotic Agents; Cluster Analysis; Diabetes Mellitus, Type 2; Female; Humans; Hypnotics | 2019 |
Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long?
Topics: Antipsychotic Agents; Female; Humans; Male; Metabolic Diseases; Metformin; Obesity; Psychotic Disord | 2013 |
[Poor prognostic value of weight change during chemotherapy in non-metastatic breast cancer patients: causes, mechanisms involved and preventive strategies].
Topics: Adiposity; Antineoplastic Agents; Breast Neoplasms; Energy Metabolism; Exercise; Female; Humans; Hyp | 2013 |
Metformin and Alzheimer's disease risk.
Topics: Antipsychotic Agents; Female; Humans; Male; Metabolic Diseases; Metformin; Obesity; Psychotic Disord | 2014 |
Response to Rosenfeld.
Topics: Antipsychotic Agents; Female; Humans; Male; Metabolic Diseases; Metformin; Obesity; Psychotic Disord | 2014 |
Metformin and berberine prevent olanzapine-induced weight gain in rats.
Topics: Adipose Tissue, White; Animals; Antipyretics; Benzodiazepines; Berberine; Eating; Female; Ion Channe | 2014 |
Metformin for weight loss in schizophrenia: safe but not a panacea.
Topics: Antipsychotic Agents; Female; Humans; Male; Metabolic Diseases; Metformin; Obesity; Psychotic Disord | 2014 |
Advanced onset of puberty after metformin therapy in swine with thrifty genotype.
Topics: Adiposity; Age Factors; Animals; Biomarkers; Blood Glucose; Diet, High-Fat; Disease Models, Animal; | 2014 |
Economic implications of weight change in patients with type 2 diabetes mellitus.
Topics: Body Weight; Cost Savings; Diabetes Mellitus, Type 2; Female; Health Care Costs; Humans; Hypoglycemi | 2014 |
Metformin for weight loss and control in patients with mood disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Dibenzothiazepines; Female; Humans; Hypoglycemic | 2014 |
Observational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement.
Topics: Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Me | 2015 |
Effect of bariatric surgery combined with medical therapy versus intensive medical therapy or calorie restriction and weight loss on glycemic control in Zucker diabetic fatty rats.
Topics: Age Factors; Animals; Behavior, Animal; Biomarkers; Blood Glucose; Caloric Restriction; Combined Mod | 2015 |
Metformin in an Adolescent with Significant Weight Gain.
Topics: Adolescent; Aggression; Antipsychotic Agents; Autism Spectrum Disorder; Humans; Hypoglycemic Agents; | 2015 |
Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Double-Blind Method; Femal | 2015 |
How much is too much? Outcomes in patients using high-dose insulin glargine.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Huma | 2016 |
Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes.
Topics: Aged; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fem | 2016 |
Pancreatitis associated with metformin used for management of clozapine-related weight gain.
Topics: Adolescent; Antipsychotic Agents; Clozapine; Disease Management; Humans; Male; Metformin; Pancreatit | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes.
Topics: Birth Weight; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Metformin; Obesity; Pregnancy; | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes.
Topics: Birth Weight; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Metformin; Obesity; Pregnancy; | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes.
Topics: Birth Weight; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Metformin; Obesity; Pregnancy; | 2016 |
Metformin-Induced Type 1 Hypersensitivity in a Child with Antipsychotic-Induced Weight Gain.
Topics: Antipsychotic Agents; Bipolar Disorder; Child; Drug Hypersensitivity; Humans; Hypersensitivity, Imme | 2017 |
Metformin reduces weight gain in overweight/obese adolescents with type 1 diabetes.
Topics: Adolescent; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Metformin; Obesity; Weight Gain | 2016 |
Metformin as a Possible Intervention for Cardiometabolic Risks in Pediatric Subjects Exposed to Antipsychotic Drugs.
Topics: Adolescent; Antipsychotic Agents; Blood Glucose; Child; Humans; Lipids; Metformin; Psychotic Disorde | 2016 |
Use of Metformin for Cardiometabolic Risks in Psychiatric Practice: Need-to-Know Safety Issues.
Topics: Acidosis, Lactic; Antipsychotic Agents; Cohort Studies; Diabetes Mellitus, Type 2; Gastrointestinal | 2016 |
Strategies to control antipsychotic-induced weight gain.
Topics: Anti-Obesity Agents; Antipsychotic Agents; Awareness; Body Weight; Bupropion; Clinical Competence; F | 2008 |
Use of metformin to control clozapine-associated weight gain in an adolescent with schizoaffective disorder.
Topics: Adolescent; Antipsychotic Agents; Clozapine; Female; Humans; Hypoglycemic Agents; Metformin; Psychot | 2010 |
Metformin provides weight reduction for hospitalized patients receiving polypharmacy.
Topics: Adult; Antipsychotic Agents; Female; Hospitalization; Humans; Male; Metformin; Middle Aged; Overweig | 2010 |
Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice.
Topics: Animals; Blood Glucose; Body Weight; Dietary Fats; Energy Intake; Glucagon-Like Peptide 1; Glucose I | 2010 |
Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet.
Topics: Animals; Diet; Dietary Carbohydrates; Dietary Fats; Gluconeogenesis; Hypoglycemic Agents; Insulin; I | 2010 |
Adding noninsulin antidiabetic drugs to metformin therapy for type 2 diabetes.
Topics: Algorithms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Weight Gain | 2010 |
Effects of metformin on rosiglitazone-induced cardiac hypertrophy in mice.
Topics: Animals; Body Weight; Cardiomegaly; Drug Therapy, Combination; Eating; Male; Metformin; Mice; Mice, | 2010 |
Countering side effects.
Topics: Antipsychotic Agents; Body Weight; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Psych | 2010 |
Pronounced weight gain in insulin-treated patients with type 2 diabetes mellitus is associated with an unfavourable cardiometabolic risk profile.
Topics: Aged; Body Fat Distribution; Body Weight; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes | 2010 |
Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes.
Topics: Aged; Biphasic Insulins; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Fasting; Femal | 2011 |
Electroconvulsive therapy for the treatment of refractory mania.
Topics: Antipsychotic Agents; Bipolar Disorder; Electroconvulsive Therapy; Female; Follow-Up Studies; Humans | 2011 |
Adverse effect of pioglitazone in military personnel and their families: a preliminary report.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Edema; Family; Female; Humans; Hypoglycemic Agents; Incidenc | 2009 |
Which oral agent to use when metformin is no longer effective?
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Tolerance; | 2011 |
Metformin: an effective attenuator of risperidone-induced insulin resistance hyperglycemia and dyslipidemia in rats.
Topics: Animals; Antipsychotic Agents; Blood Glucose; Disease Models, Animal; Dyslipidemias; Glyburide; Huma | 2011 |
Insulin management of type 2 diabetes mellitus.
Topics: Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug | 2011 |
Options for intensifying diabetes treatment.
Topics: Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Health Status | 2011 |
Metabolic syndrome and mental illness. Weight gain and other unhealthy attributes increase risk of diabetes and heart disease.
Topics: Antipsychotic Agents; Blood Glucose; Combined Modality Therapy; Coronary Disease; Diabetes Mellitus, | 2011 |
The impact of initiating biphasic human insulin 30 therapy in type 2 diabetes patients after failure of oral antidiabetes drugs.
Topics: Aged; Biphasic Insulins; Blood Glucose; China; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Fem | 2012 |
Pregnancy management of women with pregestational diabetes.
Topics: Congenital Abnormalities; Counseling; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Me | 2011 |
Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico.
Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Drug Combinations; Edema; Female; Foll | 2012 |
Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea.
Topics: Adult; Aged; Cross-Sectional Studies; Denmark; Diabetes Mellitus, Type 2; Female; Health Knowledge, | 2012 |
Considering metformin in cardiometabolic protection in psychosis.
Topics: Antipsychotic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agent | 2012 |
Metformin as a treatment for antipsychotic drug side effects: special focus on women with schizophrenia.
Topics: Amenorrhea; Antipsychotic Agents; Female; Humans; Hypoglycemic Agents; Metformin; Schizophrenia; Wei | 2012 |
Response letter. Effects of linagliptin.
Topics: Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Humans; Hypoglycemic Agents; Linagliptin | 2012 |
Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Admin | 2013 |
Metformin use as an adjunct to insulin treatment.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; Hypoglycemic Age | 2003 |
Prevention of weight gain in type 2 diabetes requiring insulin treatment.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Com | 2004 |
Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats.
Topics: Animals; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Eating; Glucose Intolerance; Male; Metfo | 2004 |
[Effects of rosiglitazone and metformin on insulin resistance in high-fat diet rats].
Topics: Animals; Blood Glucose; Dietary Fats; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metfor | 2004 |
Identification of potential caloric restriction mimetics by microarray profiling.
Topics: Animals; Caloric Restriction; Energy Intake; Gene Expression Profiling; Gene Expression Regulation; | 2005 |
Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
Topics: Acarbose; Administration, Oral; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gl | 2005 |
Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes.
Topics: Administration, Oral; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination | 2006 |
Low insulin-like growth factor-II levels predict weight gain in normal weight subjects with type 2 diabetes.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin; | 2006 |
Stability of body weight in type 2 diabetes.
Topics: Adult; Aged; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Humans; Insulin; Male; Metform | 2006 |
Phentermine, sibutramine and metformin could be used for the prevention and treatment of steroid-induced weight gain.
Topics: Adrenergic Agents; Appetite Depressants; Cyclobutanes; Humans; Hypoglycemic Agents; Metformin; Phent | 2007 |
Weight gain and insulin requirement in type 2 diabetic patients during the first year after initiating insulin therapy dependent on baseline BMI.
Topics: Aged; Body Mass Index; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combin | 2006 |
Thiazolidinediones for initial treatment of type 2 diabetes?
Topics: Algorithms; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Metformin; Rosiglitaz | 2006 |
Gaining: pediatric patients and use of atypical antipsychotics.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Autistic Disorder; Body Mass Index; Child; Dia | 2006 |
Weight changes following the initiation of new anti-hyperglycaemic therapies.
Topics: Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic | 2007 |
The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Metformin; Pioglita | 2007 |
[New data on hypoglycemia risk and beta cell function].
Topics: C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Gluc | 2007 |
Exenatide: new drug. Type 2 diabetes for some overweight patients.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptid | 2007 |
Antipsychotic-induced weight gain in patients with schizophrenia.
Topics: Antipsychotic Agents; Exercise; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Like Growth | 2008 |
Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth.
Topics: Algorithms; Animals; Carcinoma, Lewis Lung; Cell Proliferation; Diet, Atherogenic; Drug Evaluation, | 2008 |
Metformin and brown adipose tissue thermogenetic activity in genetically obese Zucker rats.
Topics: Adipose Tissue, Brown; Animals; Blood Glucose; Body Temperature Regulation; Carrier Proteins; Eating | 1993 |
Differential regulation of uncoupling proteins by chronic treatments with beta 3-adrenergic agonist BRL 35135 and metformin in obese fa/fa Zucker rats.
Topics: Adipose Tissue; Adrenergic beta-Agonists; Analysis of Variance; Animals; Carrier Proteins; Eating; E | 1998 |
Diabetes control without weight gain.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformi | 1999 |
Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes mellitus.
Topics: Aged; Basal Metabolism; Diabetes Mellitus, Type 2; Eating; Humans; Hypoglycemic Agents; Metformin; M | 1999 |
Metformin: a useful adjunct to insulin therapy?
Topics: Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, Combina | 2000 |
A simple therapeutic combination for type 2 diabetes.
Topics: Administration, Oral; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Diet, | 2000 |
Mechanisms of dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in obese Zucker rats.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Adipose Tissue; Adrenal Glands; Adrenalectomy; Analysis of Va | 2000 |
Effect of metformin on nitric oxide synthase in genetically obese (ob/ob) mice.
Topics: Adipose Tissue, Brown; Animals; Blood Glucose; Blotting, Western; Dose-Response Relationship, Drug; | 2001 |
Metformin restores responses to insulin but not to growth hormone in Sprague-Dawley rats.
Topics: Adipose Tissue; Animals; Biological Transport; Body Composition; Exercise Test; Fatty Acids; Glucose | 2002 |